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ABSTRACT
CHARACTERIZATION OF METASTASIS-ASSOCIATED CELL SURFACE
GLYCOPROTEINS IN PROSTATE CANCER
Lifang Yang
Eastern Virginia Medical School and Old Dominion University, 2010
Director: Dr. O. John Semmes
Prostate cancer (PCa) is a major health problem in males in the United States. Its
lethality is mostly attributed to the primary tumor metastasizing to distant sites that are
highly resistant to conventional therapies. Serum Prostate Specific Antigen (PSA) is the
only protein biomarker used in clinic for prediction of prostate cancer recurrence
following local therapies. Nonetheless, PSA lacks the ability to predict the behavior of
an individual tumor in an individual patient. Therefore, development of reliable
biomarkers for detection of metastatic potential in primary tumors, as well as discovery
of new therapeutic targets, is in a great need for improved disease survival and
management. Tumor metastasis is a multistep process involving extravasation of a
cancer cell subsequent invasion and expression at a site distal to the primary tumors. Cell
surface glycoproteins play pivotal roles as recognition molecules in a range of cell
communication and adhesion events. Aberrant cell surface glycosylation has been
reported in various cancers including PCa, and strongly correlated with prognosis and
metastasis. However, the staggering complexity of glycans renders their analysis
extraordinarily difficult. This research project aims to develop a mass spectrometrybased glycoproteomic approach for the selective isolation and identification of cell
surface glycoproteins from cellular samples, and apply this technology to the discovery
of new glycoprotein biomarkers which are indicative of prostate cancer progression and
metastasis. To this end, cell surface glycosylation patterns were characterized by lectin

flow cytometry and lectin cytochemistry on a human syngeneic PCa cell metastatic
model, PC3 and its two variants with different metastatic potentials. It was found that
metastatic potentials of PC3 variants were inversely correlated with cell surface oc2-6
sialic acid levels. Targeted to cell surface sialoglycoproteins, a new glycoproteomic
approach was successfully developed, which combined selective metabolic labeling of
cell surface sialyl glycans, chemically probing the labeled sugar with a biotin tag, affinity
purification of sialylated proteins, SDS-PAGE separation, and subsequent LC-MS/MS
for protein identification. Application of this methodology in our prostate cancer model
system resulted in unique identification of a total of 80 putative cell surface
sialoglycoproteins differentally expressed between PC3 variants. After prioritization of
the candidate biomarkers, one cell-based prioritized biomarker CUB-domain-containing
protein 1 (CDCP1) was verified in prostate cancer cell lines and clinical samples,
including tissues and body fluids, by immunoassays. Results indicated that expression
of CDCP1 protein is dysregulated in prostate cancer and it has potential utility as a
therapeutic target and a diagnostic marker for PCa progression. Overall, the data from
this research project provided the proof-of-principle evidence for our targeted
glycoproteomic approach, which we believe will help expedite the discovery of new
cancer biomarkers and therapeutic targets in diseases and delineation of signal
transduction pathways on a global scale.
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CHAPTER I
INTRODUCTION

1.1 Prostate Cancer Pathogenesis and Biomarker
1.1.1 Incidence and mortality
Prostate cancer (PCa) accounts for 9.7% of malignant tumors in men and is the most
commonly diagnosed cancer among males in the Western world i. The highest PCa
incidence rates (>100.0 per 100.000/year) are found in North America and the lowest in
Asia . The American Cancer Society estimates there are 217,730 newly diagnosed cases
and 32,050 deaths due to PCa in 2010 3. Incidence of PCa increases with age more
rapidly than any other cancer. Autopsy studies have shown invasive carcinomas in 8% of
men in their 20s rising to 80% for men in their 70s 4. Based on National Cancer Institute
(NCI)'s Surveillance and Epidemiology and End Result (SEER) program statistics
review, the average annual age-adjusted incidence rate in the United States has
experienced 2.6% and 16.5% growth from 1975-1988 and 1988-1992, respectively.
This dramatic increase in the late 1980s reflects improvements in detection and diagnosis
through widespread use of prostate-specific antigen (PSA) testing, which received initial
U.S. Food and Drug Administration approval in 1986. Since the early 1990s, PCa
incidence has been declining (Fig. 1). From 2003-2007, the age-adjusted incidence

The model journal for this dissertation is Nature Biotechnology
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Figure 1 Annual age-adjusted prostate cancer incidence and mortality rate among
males, US, 1975 to 2007. Figure was generated from Surveillance, Epidemiology, and
End Result (SEER) program website (www.seer.cancer.gov). incidence source:
SEER 9 areas (Connecticut, Iowa, Hawaii, New Mexico, Utah, Atlanta, Detroit,
Settles, San Francisco). Mortality source: US Mortality Files, National Center for
Health Statistics, CDC. Rates are age-adjusted to 2000 US-standard population.
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rate was 156.9 per 100,000 men per year. The mean age at PCa diagnosis is 67 years,
and 91% of the cases are diagnosed after 54 years and less than 1% before 45 years 5.
PCa incidence also differs for different racial and ethnic populations. The rate is highest
in Blacks and lowest in Asians. Black Americans have the highest PCa incidence in the
world and are considered at high risk for the disease 6. In the United States, PCa is the
second most frequent cause of cancer-related death in men. Overall, annual age-adjusted
mortality remains relatively stable in last thirty years although the rate has declined
slightly since the early 1990s (Fig. 1). The age-adjusted death rate was 24.7 per 100,000
men per year and the median age at death was 80 years of age during 2003-2007 period 5 .
1.1.2 Etiology and risk factors

Despite the high prevalence of PCa, the pathogenesis of PCa remains unclear. Most
experts believe the etiology of prostate cancer is multi-factorial, with advancing age, diet,
race, and family history most often implicated . After age and ethnic background, the
strongest epidemiological risk factor for PCa is a positive family history. 5-10% of PCa
are reported to be hereditary or familial. A man with first degree relatives (father,
brother, or son) who have had prostate cancer is two to three times more likely to develop
Q

the disease himself and generally associated with early onset . Several genes such as
RNaseL, E1AC2, MSR1, BRCA2 have been identified as candidate susceptibility genes 9.
But epidemiologic evidence suggests that familial PCa is agenetically heterogeneous
disease and many gene loci rather than a specific major susceptibility gene predispose to
familial PCa 10. Moreover, gene-environment interactions may play a crucial role in PCa
development especially for these genes with low-penetrance and polymorphisms n .
Recent studies have indicated that chronic inflammation and atrophy are very important

4

in PCa pathogenesis 12. In particular, there is growing evidence that asymptomatic
chronic prostatic inflammation, defined as category IV prostatitis, is prevalent in cases of
PCa

. Several investigators have proposed a causal link between inflammation and PCa

, but currently no firm statement on causality can be made. Dietary factors such as
animal fat consumption and calcium from dairy foods are associated with increased risk
of PCa, whereas anti-oxidative nutrients like selenium, vitamin E and tomato-based
products containing lycopene probably protects against PCa 14. The elevated insulin-like
growth factor (IGF) has been proposed to represent a link between western lifestyle or
obesity and PCa 15, however, a contradictory association was also reported 16. Androgens
are well known to regulate prostate growth and function and may also speed tumor
growth, but no definite link between increased circulating androgen levels and PCa has
been found 17. The etiology of PCa is thus poorly understood compared to other common
human cancers.

1.1.3 Pathological characteristics and natural history

The prostate gland is located just beneath the bladder and in front of the rectum. It
contains three major glandular regions-the peripheral zone, the central zone, and the
transition zone. Each glandular zone has specific architectural and stromal features. But
in all zones, both ducts and acini are lined by androgen-dependent glandular PSAsecreting cells. Beneath it, there is a proliferative compartment of androgen-independent
basal cells, which are recognized by their location, morphology and expression of high
molecular weight cytokeratins and p63 as opposed to luminal cells. Endocrine-paracrine
cells are irregularly distributed in the gland 18. Most prostate adenocarcinomas arise in
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the peripheral zone, and are characterized by multi-focality and morphological and
molecular heterogeneity, typically lacking basal cells 7 ' 19 ' 20 . There are two types of
prostatic intraepithelial neoplasia (PIN) one of which is considerate to be a forerunner of
cancer. The first is low grade (LGPIN) which is not associated with PCa. The other,
high grade (HGPIN) predicts risk of subsequent cancer 21 ' 22 . One characteristic of
HGPIN is the retention of the basal cell layer which harbors over-proliferative phenotype.
One study discovered that HGPIN co-exists with PCa in 85% of prostate surgery
specimens, and that PIN may appear as soon as ten years before cancerous cells develop
23

. The prostate lesions, named proliferative inflammatory atrophy (PIA), are usually

located in the periphery of the gland near the prostate carcinoma, have been proposed as
precursors for PIN or carcinoma 4, but the hypothesis presently remains controversial 25.
The natural history of PCa is highly variable 26. Some tumors simply do not
continue to grow or only grow at an extremely slow rate and never form metastases.
Autopsies of men who died of unrelated causes have demonstrated that latent PCa is
present in about 70% of men in their 60s ' . However, the majority of PCa grows and
expands around the urethra, causing urinary problems similar to benign prostatic
hypertrophy (BPH). When the cancer is still confined to the prostate itself, it is called a
9R

"localized disease"

. By the time the tumor is large enough to cause symptoms, it has

often spread beyond its capsule. PCa may invade surrounding fat and tissue, the seminal
vesicles, and/or the neck of the bladder. The cancer cells may invade lymph nodes in the
pelvic region. Later, PCa can spread to the bones, primarily those in the lower spine,
pelvis, and femur. Other organs such as the liver, brain, or lungs can also be metastatic
sites

. Once the cancer has spread distantly from the prostate, it is difficult to
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effectively treat and completely cure. If the cancer spreads without intervention, or if
treatment has failed, PCa can ultimately result in death.

1.1.4 Diagnosis and treatment
Two standard screening examinations, digital rectal examination (DRE) and serum
prostate-specific antigen (PSA), are the first step in diagnosing prostate cancer, no matter
symptoms are present or not. If a man's PSA level is elevated and/or his digital rectal
exam is abnormal, ultrasound directed needle biopsy and histological examination are
usually performed

. The widespread use of PSA monitoring for early detection has

greatly changed the way PCa is diagnosed . The increase of PCa detected due to
increased screening examinations has revealed problems with PSA, such as lacking
specificity and without lower limit to completely exclude PCa , and cause some
dilemmas in clinical practice. For example, there has been an increasingly large number
of men with elevated PSA and an initial set of negative biopsies. The negative result
does not exclude the presence of cancer. A high percentage of these men require repeat
biopsies. However, the threshold level of PSA that should indicate biopsy, the optimal
number of biopsy cores for detecting PCa in prostate biopsy, and when to stop biopsying
remains controversial33. The absence of clear guidelines in this field can delay diagnosis
and treatment of PCa patients, as well as cause cancer-free men anxiety and side effects.
For patients who have been diagnosed with PCa, various diagnostic imaging tests such as
MRI, CT, and PET are the options to determine the extent of the tumor in the prostate
and whether cancer cells have spread to surrounding tissues or other parts of the body 34 .
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Treatment for PCa depends on many factors: the patient's age, the risk of the
disease, the presence of other medical conditions, and the patient's overall health. To
date, there are five major treatment options for patients with PCa: watchful waiting,
radical prostatectomy, radiotherapy (external and internal radiation), hormone therapy,
and chemotherapy

' . For localized PCa, radical prostatectomy is standard treatment

for patients with a life expectancy >10 years, whereas radiotherapy is an alternative. The
randomized studies comparing these two therapies suggest that they provide similar rates
of cancer control at 10 years, and that except for the youngest patients, choice of therapy
should be based on toxicity and quality of life

. Patients with a life expectancy <10

years and low-moderate grade tumors may be offered "watchful waiting", in which
patients are under active surveillance38. For locally advanced PCa, combined
radiotherapy and neoadjuvant total androgen blockade (LH-RH agonist plus antiandrogen) is the preferred treatment. The role of radical prostatectomy in this population
has been debated 39 ' 40 . Patients with metastatic disease are treated with individual or
combined hormonal therapies, chemotherapy (docetaxel), radiotherapy, surgical
treatments, and antiresorptive medications 29.

1.1.5 Prognosis and risk stratification
PCa is a markedly heterogeneous disease with considerable variation in clinical
course ranging from asymptomatic disease to a rapidly progressing fatal malignancy.
Sophisticated risk assessment is required in clinic. Reliable methods to identify high-risk
patients are essential to help clinicians make therapeutic decisions to achieve maximal
cancer control. Currently, three preoperative clinicopathologic parameters are used to
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assess PCa risk. They are clinical tumor stage, biopsy grade and volume parameters, and
preoperative serum PSA 41.
PCa is staged anatomically. Stage I (A) corresponds to clinically inapparent tumors
usually found microscopically. Stage II (B) refers to a palpable tumor confined with the
prostate. Stage III (C) indicates that cancer extends outside of the capsule of prostate, but
only barely. Stage IV (D) signifies involvement of cancer to lymph nodes or distant
tissue 29. Since 1992, the consensus TNM staging (Table 1) has gained general
acceptance and has replaced the old A-B-C-D system 42. The stage level is an important
prognostic factor in PCa. In particular, seminal vesicle invasion and regional lymph node
involvement are inversely associated with survival. Also, capsular penetration is
associated with increased risk of recurrence 22 ' 4I . However, the prognostic role of
substaging in organ-confined disease is less informative 43.
PCa is also staged pathologically using the Gleason system, which is the method of
predicting a prognosis based on the histological appearance of cells obtained from either
a needle biopsy or a prostatectomy. Small samples of prostate cancer cells are reviewed
under the microscope and assigned a pattern number from 1 to 5. Patterns 1 and 2
correspond to well-differentiated cancers. Pattern 3 indicates a moderately differentiated
cancer, and pattern 4 and 5 correspond to poorly differentiated or anaplastic lesions 29.
The advantage of Gleason grading over other grading system is that it accounts for the
remarkable heterogeneity of PCa. It records two predominant patterns and adds them
together to give a Gleason score range from 2 to 10. If only one pattern is present, that
pattern number is doubled to obtain the Gleason sum score (for example 4+4=8). The
99

higher the score, the more aggressive the cancer

. In many multivariate analyses, the

Gleason score proves to be an independent predictor of both pathologic tumor stage and
time to biochemical recurrence 44_46. Gleason score is commonly stratified as: score 2-A
(well differentiated); 5-6 (moderately differentiated); 7 (moderately to poorly
differentiated); and 8-10 (poorly differentiated). Score 7 tumors can further be
subclassified into 3+4 or 4+3, depending on which grade is most prevalent in the cores 22'
1

. This type of Gleason score classification and subclassification has been validated to

predict postoperative outcomes 47 ' 48 . However, the Gleason grading system has been
hampered by poor reproducibility 49 ' 50 . Intra- and inter-pathologist variations of
interpretation are common, reported in up to 64% of cases 51. Another limitation of
Gleason score system is poorly correlation of scores from needle biopsies with Gleason
scores of specimens obtained surgically during prostatectomies. Discordance rates of
43% to 46%), with upgrading in 35% of cases, have been reported 52.
Tumor volume is associated with adverse pathologic findings (high grade,
extracapsular extension, seminal vesicle involvement, positive margins, lymph node
metastasis, and ultimate disease progression) after a radical prostatectomy53. The
prognostic impact of tumor volume however, is variable, largely depending how to
quantitatively measure tumor volume 54. Several studies report the percentage of the
prostate involved by the tumor and maximum tumor diameter to be an independent
predictor of recurrence 55 ' 56 . In needle biopsies, tumor volume as measured by number of
positive cores or the percentage of positive cores, is also associated with recurrence or
progression after surgery or radiation therapy 57 . Tumor volume probably has little
prognostic independence once the Gleason score and pathological stage are known 22.
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Table 1 TNM staging system of prostate cancer
T = Tumors that is:
Tx: Cannot evaluate the tumor
TO: No evidence of primary tumor
Tl: Tumor present, but undetectable using DRE or imaging
Tla: Incidental in the resected specimen (<5% tissue involvement)
Tib: Incidental in the resected specimen (>5% tissue involvement)
Tic: Found by biopsy with rising PSA
T2: Tumor palpable and localized tumor
T2a: Half or less than half of one lobe involved
T2b: More than half of one lobe, but not both involved
T2c*: Both lobes involved
T3: Extended to the capsule, but not beyond prostate
T3a: Extracapsular involvement (unilateral, bilateral)
T3b: Seminal vesicle involvement
T4: Fixed or invading adjacent organs (such as bladder or rectum)
N = Lymph node metastasis in:
Nx: Cannot evaluate the regional lymph nodes
NO: No spread to the regional lymph nodes
Nl: Spread to the regional lymph nodes
M = Distant metastasis
Mx: Cannot evaluate distant metastasis
MO: No distant metastasis
Ml: Distant metastasis
Mia: Metastasis to lymph nodes beyond the regional ones
Mlb: Metastasis to bone tissue
Mlc: Metastasis to other organs (regardless of bone involvement)
DRE = digital rectal examination; PSA = prostate-specific antigen.
Data are from the AJCC 6th edition (2002) and UICC 6th edition.
* "T2c" implies a tumor which is palpable in both lobes of the prostate. Tumors which are found
to be bilateral on biopsy only but which are not palpable bilaterally should not be staged as T2c.
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Despite limitations as a screening tool, PSA testing may still supply valuable clues
to the risk of tumor recurrence and treatment response. Numerous studies have
confirmed elevated serum PSA was associated with larger tumor volume, higher clinical
stage, and Gleason grade 58. PSA seems to be a strong predictor of aggressive PCa. A
Malmo Preventive Medicine study with 21,277 men participating showed that PSA level
at age 44-50 was highly predictive of advanced prostate cancer diagnosed up to 25 years
later, with advanced cancer defined as T3, T4 or metastasis at diagnosis. But the
prognostic accuracy decreased with age 27 ' 59 . Preoperative PSA is also a sensitive
indicator of recurrence after radical prostatectomy. In a large study with a cohort of 1582
men who underwent radical prostatectomies, lower preoperative serum PSA was reported
to be associated with a decreased incidence of positive surgical margins, extracapsular
disease, seminal vesicle invasion and lymph node involvement. Multivariate analysis
suggested that only serum PSA levels and the biopsy Gleason score predicted time to
recurrence

. However, contrasting results are reported. Stanley's group has shown PSA

values may only presage pathologic Gleason scores if PSA values are either extremely
high or low, and less reliable as a prognosticator when PSA level was between 2 and 9
ng/mL

' . These results support a previous study in which no clinically useful

relationship was found between preoperative PSA and biochemical progression in large
volume cancers

. Therefore, preoperative PSA seems insufficient to allow useful

predictions for individual patients based on PSA as a single marker. Predictions can be
improved by PSA derivatives such as PSA doubling time (PSADT) and PSA velocity
(PSAV), as they have demonstrated the significant relationship with PCa aggressiveness
4 66

" . However, the use of these indications in the pretreatment setting is more
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controversial, and none of the measures has been shown to increase diagnostic and
77 fn

prognostic accuracy better than a simple PSA test ' .
Recognition of the limitations of above single prognostic factors has led to the
development of multivariable tools that incorporate preoperative clinicopathologic factors
in an array in an attempt to better predict pathological tumor features and treatment
outcome. Current diagnosis employs a mix of biopsy Gleason score, clinical tumor stage
and preoperative PSA levels ' . Currently, the most commonly used stratification
system was developed by D'Amico et al. which divides patients into low, intermediate,
and high risk (Table 2) 47. This tool has been validated for use in men treated with
radical prostatectomy and radical radiotherapy 47 ' 6 . Other combined prognostic tools
include Partin Tables, and statistical model nomograms, which have different predictive
significances and limitations, and their universal application still needs to be validated '
68

1.1.6 Current challenges in clinical PCa management
The introduction of prostate-specific antigen (PSA) into the paradigm of early
detection, as well as a lower PSA threshold (in the range of 2.5-3.0 ng/mL rather than
traditional 4.0 ng/mL) used in clinic for recommending prostate biopsy, have resulted in
profound changes in stage and grade of PCa. As expected due to increased PSA
screenings, stage has migrated towards more localized, and curable diseases (Tlc-T2a) 70.
Results from the SEER database also showed that the percentage of PCa patients with
metastatic disease at the time of diagnosis dropped from 16% in the 1980s to 4% in 2003
71

. Unexpectedly, grade has shifted heavily toward moderate differentiation (Gleason 5-
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Table 2 D'Amico et al. risk stratification for clinically localized prostate cancer
PCa Risk

Serum PSA (ng/mL)

Gleason Score

Clinical Stage

Low risk

<=10

<=6

Tic, T2a

Intermediate
risk

10-20

7

T2b

High risk

> 20

8-10

T2c, T3

PSA = prostate-specific antigen

The risk stratification scheme, developed by D'Amico et al. is currently in widespread
use for prognostic assessment of clinically localized prostate cancer. Patients are divided
into three risk groups (low, intermediate, or high) of occult micrometastases and relapse
by the combination of three preoperative clinicopathologic factors: biopsy Gleason score,
serum PSA, and clinical stage. When there is a conflict in three parameters, the worse
factor wins and determines the risk category assignment. For example, a patient with a
low Gleason Score of 6 combined with a PSA of 25 ng/mL is considered high risk. Table
adapted from D'Amico et al. J Urol. (1998).
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7), whereas rates of poorly (Gleason 8-10) and well-differentiated (Gleason 2-4) disease
70

have remained relatively stable

. According to D'Amico's risk categories, most

diagnoses of PCa belong to the low-risk group, the proportion of which increased from
79

30% in 1990 to 45% in 2000

. The low-risk tumors, however, can be either indolent or

aggressive. There is currently no means that allow urologist/oncologist to differentiate
the minority of men with potentially lethal cancer from a large proportion of those whose
PCa pose no threat to life or health. The net result is an unfortunate trend to overdiagnosis and over-treatment of clinically insignificant PCa 73 . This can create the
potential for patient's mental burden and the morbidity and mortality associated with
aggressive local therapies. On the other side, patients with potential aggressive disease
may omit adjuvant intervention and miss a crucial opportunity to be cured. There is a
significant need for an improved risk-stratification system that incorporates novel
biomarkers to better determine the risk of recurrence and allow patients to make more
informed decisions about treatment.
For patients with significant disease, the major challenge is the prediction of clinical
progression and survival after defined local therapy. It is reported that about 25% of men
with PCa ultimately will experience subsequent recurrent disease after radical
prostatectomy within 15 years. A portion of these men will go on to experience clinically
expressed extracapsular disease, with as many as two-thirds having evidence of bone
involvement29. Monitoring of post-treatment PSA provides a means of detecting
recurrent disease long before the tumor is detected by other means such as imaging or
symptoms. Increasing PSA levels after treatment, also called 'biochemical recurrence",
generally indicates the presence of tumor cells. However, It is noteworthy that PSA
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recurrence merely represents a surrogate endpoint marker 74 , as only 34% of these
patients develop distant metastases after a median follow up of 8 years 75. In line with
this, many patients will experience a post-treatment PSA elevation that confers no
prognostic information, referred to PSA only progression 7 ' 74 . In addition, there is
considerable debate on the best criteria for defining biochemical recurrence. No single
PSA value is invariably associated with clinical metastasis or cancer-specific survival27'
. Moreover, PCa can recur in the absence of a PSA increase or detectable PSA level '
. Hence, biochemical failure after local therapy does not perform well in this field, and
there is an equally urgent need for new biomarkers which can serve as surrogate end
points for clinical recurrences or cancer specific survival.
The first choice to manage distant metastatic disease is hormonal modulation. But
nearly all cancers will eventually acquire androgen independence, becoming refractory to
androgen deprivation therapy (ADT). The median survival of a patient after developing
hormone-refractory prostate cancer (HRPC) is approximately 12 months, and few
palliative treatment options are available which have shown benefit at this stage 29. PSA
tests are frequently used to monitor the effects of the treatment in men with HRPC.
However, PSA level in patients with such an advanced stage is only moderately
associated with survival, and PSA can't accurately reflect the treatment response 27 ' 79 .
Currently the greatest need for stage IV patients is to find more accurate makers of
response as well as develop novel agents to prolong survival.

In summary, PCa is a major public health issue in the United State. The
development of PSA for PCa detection and prognostication has revolutionized the
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management of this disease. Nevertheless, the limitations of PSA, as described above,
underscore the necessity to find more accurate diagnostic and prognostic biomarkers that
can predict the natural history of the disease, assess recurrent risk, and facilitate
stratification of patients to different treatment protocols aimed at improving survival
outcome.

1.2 Protein Glycosylation
Covalent attachment of carbohydrates to proteins is one of the most common and
versatile post-translational modifications with more than 50% of eukaryotic proteins
thought to be glycosylated 80. Protein glycosylation is prevalent in membrane and
secreted proteins where they play a decisive role in cellular recognition events involved
in cell adhesion, cell-to-cell communication, and receptor-ligand interactions " .
Glycans also critically influence the physicochemical properties of proteins that impact
protein folding, solubility, and turnover 84 ' 85 . Hence, glycans expand the biological
information carried by proteins. Glycans also confer glycoproteins the nature of
complexity which arises from both the structural diversity and elaborate bio synthetic
processes.
The glycans associated with human proteins are composed of various combinations
of seven monosaccharide units

. The monosaccharide units are glucose (Glc), mannose

(Man), galatose (Gal), fucose (Fuc), N-acetylgalactosamine (GalNAc), Nacetylgluctosamine (GlcNAc) and sialic acid (SA). Free monosaccharides can exist in an
open form, but in nature they are usually found as five or six sided ring structures. For
carbohydrates in a cyclic form, the configuration is given as a or P anomers.
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Monosaccharides are commonly joined together to form di-, tri-, oligo-, and
polysaccharides by linking the anomeric carbon atom of one monosaccharide to any
hydroxyl group on another monosaccharide. This reaction determines the type of linkage
(a- or P-bond), which is essential for enzyme recognition

. Furthermore, bonds can be

made between the different carbon atoms of the two monosaccharides, for example,
carbon 1 of one monosaccharide and carbon 3 of the adjacent monosaccharide, denoted
as (1—»3). In addition, the monosaccharides can form both linear and branching chains.
Therefore, a combination of the number and sequences of monomeric units, their linkage,
a number of conformations, as well as occurrence of branch points means there are
theoretically astonishingly large number of different structures possible. Although not all
possible oligosaccharides are observed in nature, glycan structures are still extremely
varied and complex. Moreover, glycan structures can be modified by diverse
substitutions including sulfation, phosphorylation, methylation, and acetylation , which
also contribute to the structural diversity.
The point of attachment of the sugar chain to the polypeptide is another level of
complexity. Glycosylation can occur at different amino acid residues in the protein
sequence. Several types of glycosylation are known: (i) the N-linked glycans which
attached to the amide group of asparagine residues in a consensus Asn-X-Ser/Thr
sequence (X can be any amino acid except proline) via an N-acetylglucosamine
(GlcNAc) residue; (ii) the O-lined glycans where the sugar is commonly attached to the
hydroxyl group on serine/threonine residues or rarely to other amino acids, e.g. tyrosine,
hydroxyproline and hydroxylysine. (iii) glycosylphosphatidylinositol anchors which are
attached to the carboxyl terminus of some membrane-associated proteins; (iv) C-
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glycosylation that occurs on tryptophan residues in certain membrane-associated and
on

secreted proteins

; (v) S-linked glycosylation where the sugar is attached through a

sulfur atom on cysteine or methionine 90. The most common and widely studied forms
are N-linked and O-linked glycosylation. Fluctuations can occur in both the occupancy
rate of O- and N-linked sites on a protein and in the substructures of carbohydrates
attached to a specific site. The former, referred to macroheterogeneity, results from the
fact that not all potential glycosylation sites are actually glycosylated. The later, called
microheterogeneity, is normally a range of glycan structures associated with each site.
These phenomena are a consequence of the competitive action of diverse enzymes during
biosynthesis

.

Glycan structural diversity requires a finely tuned glycosylation process to
accomplish. N-linked glycosylation is a highly specific cotranslational reaction which
occurs during protein synthesis before the protein is folded into its final conformation.
When the nascent protein enters the endoplasmic reticulum (ER), a block of core
precursor sugars (Glc3Man9GlcNAc2), which is a highly conserved evolutionary process
in ER, is transferred to the amino group in the asparagine side chain by the
oligosaccharyltransferase complex 91. The glycan is later processed by stepwise
trimming and stepwise addition of new monosaccaride residues by a number of enzymes
in the ER and Golgi, generating the three main classes of N-glycans found in mature
glycoproteins with a common conserved pentasaccharide core MansGlcNAc2 (Fig. 2A).
The three main classes of glycans are: (i) High mannose - only mannose residues are
attached to the core structure, (ii) Complex N-glycans - characterized by the
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Figure 2 The subclasses and oligosaccharide structures of N- and O-linked
glycoproteins. (A) The representative three types of N-linked oligosaccharides. Nglycans are attached to the protein backbone by linkage to asparagine in the
consensus sequence Asn-Xaa-Ser/Thr. They share a universal pentasaccharide core
sequence Man3GlcNAc2, and are classified into three types: (1) high mannose, in
which only mannose residues are attached to the core; (2) complex, in which various
antennae are attached to the core; and (3) hybrid, in which only mannose residues
are attached to the Manal-6 arm of the core and one or two antennae are on the
Manal-3 arm. (B) The representative four types of O-glycan cores. The O-glycans
are commonly attached to the protein via serine or threonine residues. The most
basic O-glycan core structures are observed linked to a single Gal residue, however
it can be extended by lactosamine repeats, fucosylation and sialylation with different
linkages. In both figure, directionality is from nonreducing end at the top to the
reducing end at the bottom with the arrows indicating the extension at the
nonreducing end. Linkages between monosaccharides contain the anomeric
configuration of the monosaccharide (a, alpha and (3, beta). Glycan symbol
nomenclature is indicated in the low panel. In the case of complex JV-linked glycans,
the common terminal motifs attached to Gal are shown in a dotted box. Adapted
from Raman, R. et al. Nat Methods 2, 817 (2005).
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presence of variable numbers of antennae as well as N-acetyllactosamine (LacNAc,
Gaipi-3/4GlcNAc) in their antennal region. They can be further capped by fucose and
sialic acid residues to form a variety of oligosaccharide structures. These N-glycans
constitute the most abundant class of mammalian oligosaccharide, (iii) Hybrid N-glycans
- containing both a mannose residue and N-acetyllactosamine attached to the trimannosyl
chitobiose core, sharing structural features of the high mannose type and complex type .
The presence or absence of an oc-fucosyl residue on the core mannose of three types of Nglycans further adds to the structural diversity of the oligosaccharides.
In contrast to N-glycans, the biosynthesis of O-glycans is a post-translational event
that takes place in Golgi after protein N-glycosylation, folding and oligomerization.
Because there is no clear consensus sequence analogous for O-glycans, the synthesis is
simpler than for N-glycans. An example of the process is the most prevalent form mucintype of O-glycosylation. Generally, the process involves sequential single
monosaccharide transfer steps. The first step is normally the transfer of Nacetylgalactosamine (GalNAc) to Ser/Thr residues of the protein backbone, by the action
of specific polypeptide GalNAc transferases (ppGalNAcTs). To date, more than 24
ppGalNAcTs have been described, with differential tissue expression and overlapping but
different specificities 87 ' 93 . Subsequent addition of galactose (Gal) and/ or GlcNAc by
specific transferases leads to the formation of the common O-glycan core structures (Fig.
2B). There are at least eight core structures, four of which are particularly widespread in
human

. The basic core structures can be further extended and terminated by the

transfer of lactosamine repeats, sialic acid and fucose residues to give a heterogeneous
range of glycans. Besides GalNAc, single GlcNAc can also be attached to Ser/Thr
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residues to ubiquitously modify cytoplasmic and nuclear O-linked glycoproteins. OGlcNAcylation has been found to be as abundant and dynamic as phosphorylation to
regulate cellular signal transduction 94.
Carbohydrates are constructed stochastically by a complicated pathway. Unlike
genes and protein, carbohydrates are generated through non-template-driven biosynthesis
and regulated by multiple factors, including metabolic levels of sugar nucleotides,
competitive expression and localization of glycosylation enzymes (glycosyltransferases,
glycosylhydrolases), and protein-trafficking mechanisms 88'95. Due to these features,
glycans are expressed in a cell type-specific fashion and subjected to alterations under
different physiological and pathological settings.

1.3 Altered Cell surface Glycosylation and Cancer
During malignant transformation and cancer progression, tumor cells express a
unique repertoire of glycosylation patterns. The common types of aberrant
glycosylaytion associated with cancer are: (i) hypo, hyper or newly glycosylated protein
glycosylation sites; (ii) change in the glycan biosynthetic machinery including
upregulation of fucosyltransferase (FucTs), sialyltransferases (SiaTs), Nacetylglucosaminyltransferase V (GnTV) which is involved in the elaboration of highly
branched N-linked glycans 96; (iii) increased levels of fucosylation 97; (iv) alterations in
sialylation 98 ' 99 ; (v) addition of polylactosamine units 10°; (vi) increased (31-6 GlcNAc
branching in N-linked structures 101'102; (vii) truncated glycoforms such as terminal Nacetylgalactosamine (GalNAc) 103, or Tn and STn antigens 104 in O-linked structures;
(viii) inappropriate synthesis of blood group related carbohydrate antigens such as histo-
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blood group A/B antigens 105'106, or Lewis antigens (i.e. sialyl-Lex, sialy-Lea, and Le y ) 107 '
108

in either N-linked or O-linked structures. Among these changes, altered sialylation of

tumor cell surface glycoconjugates is most often correlated with a metastatic tumor
phenotype. Changes have been reported reflecting the amount, type, distribution, and
bonding of sialic acids to adjacent molecules 6 ' 109 . Several reports showed a positive
correlation between the levels of cell surface sialylation and the metastatic ability of
various experimental tumors 110 > m . For instance, an increase in the amount of Nacetylneuraminic acid (Neu5 Ac) on glycan chains has been reported in colorectal cancers
and associated with the metastatic spread of colon cancer cells

. However, the

correlation between cell surface sialyaltion and metastatic potentials of tumor cells is not
absolute. Sometimes the distribution of sialic acid on specific N- or O-linked
i n

oligosaccharides
monosaccharide

M

or alterations in the attachment of sialic acid to its neighboring
, rather than the total quantity of sialic acid, may affect the metastatic

properties of these cells. For example, Neu5Ac is usually attached to adjacent
monosaccharides via an a2->3 or an a2-»6 bond. However, the attachment in an a2-»8
bond results in the structure called polysialic acids, which are at an increased levels in
lung cancer I14 and breast cancer 115 and are associated with pancreatic tumor cell
invasion 116. Moreover, altered sialylation can also results from other glycosylation
changes. One example is increased pi-6 branching can increase the number of Gal(314GlcNAc structures that can be sialylated, leading to a total increase in cell surface
sialylation I17. Therefore, alternation in cell surface sialylation is a complex and dynamic
process.
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Alterations of the carbohydrate structures have important clinical and functional
relevance. Clinicopathological studies showed that high expression of some glycosyl
epitopes promotes invasion and metastasis, leading to a shorter 5-10 year survival rate for
patients, whereas expression of the glycosyl epitopes suppress tumor progression, leading
to higher postoperative survival rates 118. The concept of glycosylation-dependent
promotion or inhibition of tumor progression has been further supported by the data from
human tumor cell lines and experimental animal studies 119'120. Modification of surface
carbohydrate expression by specific strategies such as glycosylation inhibition, enzymatic
treatment, gene transfection, and gene knockout mice, brings direct evidence that cell
surface carbohydrates are very important in the regulation of metastatic behavior of
tumor cells, as detailed below.
Metastasis is defined as the growth of a cancerous cell in an environment
noncontiguous with its tissue of origin I21. It is a complex process occurring in a stepwise fashion (Fig. 3). At the beginning, individual primary tumor cells gain the capacity
to degrade and migrate through the basement membrane and extracellular matrix (ECM).
Then the tumor cells access and intravasate into the local vasculature, interacting with
host cells such as endothelial cells, platelets, and leukocytes. After traveling around the
body, tumor cells lodge in the small vessels of distant organs and exit from the circulation
by extravasation. Eventually tumor cells survive and proliferate at the secondary sites to
100

become a pathological metastasis

. The mechanisms of each event are functionally

maintained by a combination of defined molecules involved in the process, each of which
is affected directly or indirectly by glycosylation 123. Particularly tumor cell proliferation,
invasion, and extravasation of metastatic cascade are of high relevance in glycobiology.
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Figure 3 The process of tumor metastasis. Metastasis is a complex and multiple-stage
process. (A) Tumor proliferation at the origin site is crucial at early stages of
progression. (B) During invasion, tumor cells gain the capacity to degrade, and migrate
through, basement membranes and extracellular matrix. (C) Tumor cells access the
local vasculatures and intravasate into the bloodstream or lymphatic glands, where
they aggregate with host cells such as platelets and lymphocytes and eventually lodge
in the small vessels of distant organs. (D) During extravasation, tumor cells adhere to
capillary wall and escape from the blood vessel. (E) In the distal organ, tumor cells
proliferate to form micrometastases. (F) Once new angiogenesis is set up, tumor cells
are able to form pathological macrometastases. Adapted from Alberts, B. et al.
Molecular Biology of the Cell, 4th ed., New York: Garland, 1325 (2002).
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Tumor proliferation is very important in the early stages of progression and after
metastasis. A broad spectrum of glycans affects tumor proliferation. For example, many
studies indicate that N-glycans of many growth factor receptors regulates signal
transduction by modulating receptor functions

102 m

' . N-glycosylation of the epidermal

growth factor receptor (EGFR) is required for receptor dimerization and transforming
activity

. Treating U251 glioma and BXPC3 pancreatic adenocarcinoma cells with N-

glycosylation inhibitor tunicamycin can disrupt EGFR signaling and enhance
radiosensitivity

. Similarly, O-lined glycans and mucins play a role in tumor cell

proliferation. Mucins are glycoproteins that contain numerous O-glycans in clustered
domains along the core protein. Most tumor cells express mucins as transmembrane
proteins on the cell surface or as secreted proteins I27. MUC4 is reported to be involved
in the pathogenesis of pancreatic cancer and aberrantly expressed in many other epithelial
carcinomas

'

. MUC4 contains an EGF-like domain on its extracellular part, which

can directly interact with ErbB2 initiating phosphorylation of the receptor tyrosine kinase
in the absence of typical ErbB2 ligands. Therefore, MUC4 can modulate HER2/ErbB2
signaling and is a determinant of therapeutic outcome of Herceptin-based therapy for
patients with breast cancer 130. High expression of another mucin family member MUC1
has been also implicated in many solid tumors including prostate cancer 131'132. Recent
investigation suggests that MUC1 can be associated with intracellular signal molecules
such as Ras and [3-catenin to regulate tumor cell growth
During invasion, tumor cells detach from each other, invade, and migrate through
the neighboring tissues. This requires the coordinated remodeling of cell surface
adhesion molecules and secretion of degradative enzymes (proteases and glycosidase).
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Glycans are involved in each of these stages

. The presentation of cancer-related

glycans generally reduces cell-cell adhesion and promotes migration. Studies show
structural modification of N-glycans on N-cadherin with increased branched structures by
enzyme GnTV, led to decreased cell-cell adhesion, promoting tumor cell detachment and
invasion. However, small interfering RNA-directed knockdown of GnTV in HT1080
fibrosarcoma cells resulted in enhanced N-cadherin-mediated cell-cell adhesion as well as
decreased cell migration and invasion 134. Expression of sialylated glycans is also
reported to promote dissociation of tumor cells. Transfection of breast cancer cells with
enzyme ST6Gal-I, which is responsible for sialic acid capping of terminal galactose
residues on N-linked glycans, increased cell migration and reduced cell to cell adhesion.
In contrast, transfection with antisense ST6Gal-I RNA enhances homotypic cell-cell
adhesion. Enhanced expression of sialic acid is also found on the O-linked sugars such as
sialyl Tn antigen (STn), which is commonly overexpressed in the mucin-rich surfaces of
cancer cells. Transfection of breast cancer cells with cDNA that encodes the human
sialyltransferase responsible for STn biosynthesis (ST6GalNAc-I) reduced cell to cell
interaction and increased the migration potential of transfected cells. Besides altered cell
to cell interaction, local ECM remodeling is essential for tumor cell invasion. Integrins
represent a very important class of cell surface adhesion receptors mediating attachment
to ECM protein ligands, such as fibronectin and laminin. Numerous integrin biological
processes including expression, heterodimerization, ligand binding, and downstream
signaling, are modulated by glycosylation 96 ' 135 . For instance, sialylation led to integrin
activation, increased adhesion to ECM ligands, and augmented migration and invasion of
colon cancer cell lines in vitro

. In addition to sialylation, integrins are also modified

by GnTV, and as a result, carry high level of pi,6-branched structures

. Increased

GnTV expression disrupts the ability of integrins to cluster on the tumor cell membrane,
which in turn, reduces the formation of tumor cell focal adhesion and increases tumor
motility and invasion. Similarly, in vivo, spontaneous mammary tumors, which
developed in a GnTV-deficient mouse model, exhibited decreased growth, metastasis,
and signaling downstream of the focal adhesion kinase
Like invasion, extravasation requires a series of steps. After entry into the
vasculature, tumor cells, stimulated by some blood-borne factors, aggregate with
activated platelets, and/or leukocytes to form microvascular occlusions in the small
vessels of distant organs, initiating extravasation

123

. The molecular mechanisms by

which cancer cells traverse the vasculature is thought to occur through "hematapoietic
mimicry", an identical traffic control axis used by hematopoietic progenitor cells (HPC)
into bone marrow and lymphocytes homing to sites of inflammation. This shear stressdependent process begins with rolling on endothelia cells, which leads to tethering and
integrin-dependent stable adhesion. The first step of extravasation, rolling of tumor cells
along the endothelium, is regulated by glycosylation 96. Rolling is mediated by the
adhesion of selectins to carbohydrate ligands on the surface of tumor cells. The selectin
family consists of three members each exhibiting differential expression patterns.
Endothelial cells display E-selectin, platelets express P-selectin, and leukocytes present
L-selectin 139. It is thought that tethering and rolling of tumor cells occurs through
selectin-mediated interaction between malignant cells and the endothelium. However,
interactions between malignant cells and host cells, such as circulating platelets and
leukocytes, are also indicated to participate in tumor cell extravasation 140. Carbohydrate
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ligands for selectins typically consist of clustered arrangements of oligosaccharides that
bear sialic acid, fucose, and sulfate, predominantly present at the outmost layer of Olinked glycans

. One class of carbohydrate ligands are Lewis type blood group

antigens, sialyl Lewis X (sLex) and sialyl Lewis A (sLeA). Tumor cells frequently
overexpress sLe x and sLeA bearing glycoforms of cell surface molecules such as
glycoprotein CD44, CEA, PCLP, MCAM, and glycolipids 141. The presence of these
ligands corrects with metastatic formation and patient survival for several types of
cancers 142. Recent experimental animal studies confirmed a clinical correlation is a
reflection of a causal relationship. Mice lacking L-selectin, P-selectin, or both, exhibit
greater resistance to the metastasis of colon carcinoma cells 143. The expression pattern
of E-selectin also governs metastasis. In a mouse model in which E-selectin was
overexpressed in the liver, melanoma cells expressing E-selectin ligands formed liver
metastasis but not tumor cells lacking E-selectin ligands 144.

In summary, altered glycosylation is a universal feature of malignant transformation
and tumor progression. The highly selective glycosylation changes have the greatest
functional consequences in the metastatic cascade. Exploiting these differences would
likely afford excellent opportunities to identify sensitive and specific cancer biomarkers,
as well as uncover potential new cancer therapeutic targets.

1.4 Glycoproteomics in Cancer Biomarker Discovery
Cancer related changes in glycosylation can lead to biomarker discoveries. In fact,
many of the clinical tests currently used to diagnose and manage the treatment of cancer

have exploited changes in glycosylation that accompany the disease process. Table 3
lists some of the FDA approved cancer biomarkers that are glycosylated. These include
many glycoproteins, such as carcinoembryonic antigen (CEA), commonly used as a
marker of colon cancer 145; cancer antigen 125 (CA-125), frequently used to diagnose
ovarian cancer

; a-fetaprotein (AFP), usually used in screening and diagnosing liver

cancer 147; and PSA, a marker for prostate cancer as described earlier. Other clinically
useful cancer biomarkers directly detect glycan epitopes. One of the examples is CA19-9
which binds to sialy-Lea and commonly used for diagnosing and monitoring pancreatic
1 AQ

cancer

. Despite the fact that these serum biomarkers remain the diagnostic gold

standard in clinic, their diagnostic value is more frequently questioned, due to poor
sensitivity and specificity of the assays 27'145'147"149. Alternatively, researchers have
found capitalizing upon changes in cancer-related glycoforms affords the possibility of
increasing diagnostic sensitivity and specificity. The separation of serum AFP by lectin
LCA highlights this point. Based on the binding capacity of AFP towards LCA, AFP has
three different glycoforms with different diagnostic function: AFP-L1, AFP-L2 and AFPL3. While AFP-L1, known as the non-LCA-binding fraction, is the most abundant
isoform of AFP in serum of patients with benign liver disease, chronic hepatitis and liver
cirrhosis; AFP-L2 has intermediate affinity to LCA and is present in maternal serum
during pregnancy and frequently derived from yolk sac tumors. AFP-L3 or the LCAreactive AFP glycoform, carrying an additional a 1-6 fucose residue, appears to be
produced by cancer cells. It is the major glycoform in serum of HCC patients and a
marker for biologic malignancy of HCC 147. Overall, detection of these glycoprotein
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Table 3 Some of the FDA-approved cancer glycobiomarkers
Biomarker

Assay type

Source

Cancer type
Nonseminomatous
testicular

Clinical use

oc-Fetoprotein

Glycoprotein

Serum

Human chorionic
gonadotropin^

Glycoprotein

Serum

Testicular

Staging

CA19-9

Carbohydrate

Serum

Pancreatic

Monitoring

CA125

Glycoprotein

Serum

Ovarian

Monitoring

CEA

Protein

Serum

Colon

Monitoring

Epidermal growth factor
receptor

Protein

Colon

Colon

Therapy selection

KIT

Protein (IHC)

Tissue

Gastrointestinal
stromal tumor

Diagnosis/Therapy
selection

Thyroglobulin

Protein

Serum

Thyroid

Monitoring

PSA

Protein

Serum

Prostate

Screening/
Monitoring/Diagnosis

CA15-3

Glycoprotein

Serum

Breast

Monitoring

CA27-29

Glycoprotein

Serum

Breast

Monitoring

Tissue,
Serum

Breast

Prognosis/Tj erapy
selection/Monitoring

Fibrin/FDP

Protein
(IHC),
Protein
Protein

Urine

Bladder

Monitoring

BTA

Protein

Urine

Bladder

Monitoring

CEA and HMW-mucin

Protein

Urine

Bladder

Monitoring

HER2/NEU

Staging

BTA, bladder tumor-associated antigen; CA, cancer antigen; CEA, carcinoembryonic antigen;
FDP, fibrin degradation protein; IHC, immunohistochemistry; PSA, prostate-specific antigen
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glycoform changes is nearly all at the cytological and histological levels, as shown with
lectins and glycoreactive antibodies, the availability of which is limited. Thus, sensitive,
fast, and robust analytical methodologies are required to identify cancer-specific
glycobiomarkers.
The complex and heterogeneous nature of carbohydrate structure and synthesis has
constrained the pace of glycosylation study. Traditional analytical techniques including
capillary electrophoresis, gel filtration, high-pressure liquid chromatography, and thin
layer chromatography are time consuming and most have only been applied to a single
glycoprotein 150. With recent advances in proteomics, chemical biology, and mass
spectrometric instrumentation, glycoproteomics is rapidly emerging as a critical sub-field
of proteomics. Mass spectrometry (MS), due to its high sensitivity and versatility, has
been a state-of-art technology in glycoproteomics. While the knowledge of the mass of a
glycoprotein or glycan provides initial information regarding composition, the
fragmentation ions of glycopeptides and glycans can determine structural sequence
directly. There are two basic levels of glycoproteomics analysis by MS: (1) examination
of the glycoproteome (glycoproteomics), which includes identification of glycoproteins
and mapping glycosylation sites; (2) survey of the glycome (glycomics), which is
on

concerned characterizing glycan repertoires released from glycoproteins .
Protein biomarker discovery is a complex and challenging task. Five conceptual
phases of biomarker development have been proposed: preclinical exploratory (I),
clinical assay and validation (II), retrospective longitudinal repository studies (III),
prospective screening studies (IV) and cancer control studies (V) 151 . The conventional
pipeline for the preclinical exploratory phase involves four essential stages: initial

discovery of differentially abundant proteins; prioritization of qualified candidates;
candidate verification; assay development and pre-clinical validation

. MS-based

glycoproteomics is now playing a principle role in the initial phase of discovering cancerrelated glycobiomarkers. Glycoprotein enrichment techniques, coupled with and highresolution MS have greatly increased the analytical sensitivity to reach the depth of
glycobiomarker coverage in complex samples such as plasma, serum, other bodily fluids,
tissue lysate or cell line homogenates 153. In addition, with the current drive towards
larger panels of multiplexed biomarkers, candidate-based quantitative glycoproteomics
platforms, such as multiple reaction monitoring (MRM), have been introduced recently
154,155 Y ^ n £ w q uam: jtative MS approaches perform full biomarker discovery,
quantification, and verification on the same technology platform, allowing targeted
detection of glycoprotein candidates in complex samples in a multiplexed fashion.
Furthermore, the new approaches have greatly enhanced both the specificity and
sensitivity to the point of rivaling immunoassay for some analytes, providing a
complementary tool for glycoprotein biomarker verification in addition to antibody based
approaches 156. It is clear that glycoproteomics is playing an increasingly important role
in biomarker discovery.

1.5 MS-based Glycoproteomics Approaches
A comprehensive analysis of glycosylation in a complex biological sample requires
a concerted approach. Technology platforms incorporating MS for glycobiomarker
discovery typically consists of glycoprotein or glycopeptide enrichment, multidimensional protein or peptide separation, tandem MS analysis and bioinformatic data
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interpretation (Fig. 4)

. A bottom-up approach (the analytes introduced into the mass

spectrometer are peptides) is the most mature and most widely used approach in
proteomics, most glycoproteomics workflows adapt it into the platform. Proteolytic
digestion can be performed before or after enrichment step, with different rationales for
each strategy. Major advantages of the former, enrichment at glycopetide level, include a
lower possibility of nonspecific protein-protein interactions, a particular concern about
glycoprotein capture efficiency

157

. In contrast, enrichment at glycoprotein level can

increase the sequence coverage from multiple peptides, which in turn facilitates
glycoprotein identification

. The separation procedures for glycoproteins or

glycopeptides closely parallel the methodologies of mainstream proteomics. For
glycoproteins, various fractional approaches, such as gel electrophoresis, multiple forms
of chromatography (size exclusion, hydrophobic interaction, ion exchange, affinity
chromatography), and chemical immobilization can be applied, depending on the specific
workflow. For glycopetides, multidimentional liquid chromatography (LC) and capillary
electrophoresis (CE) favor their separation 92 ' 159 . It is notable that the reliable analysis of
MS data in glycoproteomic studies largely relies on available bioinformatics tools and
glyco-related databases. The well-built proteomics softwares and databases allow the
fully automatic assignment of fragment spectra of unknown peptides. Once protein
sequence is identified, glycosylation status of the targeted proteins can be annotated by
UniProt Knowledgebase (UniProtKB) database. The high-throughput tools for glycan
characterization are evolving, and there are several software platforms such as
GlycoMod, Cartoonist, GlycoPep DB, Peptoonist, and GlycoMiner that aid in the
identification of glycans

. Bioinformatic tools for direct glycopeptide analysis,
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Figure 4 The workflows of mass spectrometry-based glycoproteomic analysis. The
pipeline parallels the mainstream of proteomic analysis, typically consisting of four
steps: glycoprotein or glycopeptide enrichment, glycoprotein or glycopeptide
separation, tandem mass spectrometric analysis, and bioinformatic data
interpretation. After enrichment step, the workflow can split into three directions:
intact glycoprotein or glycopetide analysis, glycan analysis and deglycosylated
protein analysis. Adapted from Pan, S. et al. Mol Cell Proteomics. (2010).
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however, are still primitive and require manual assignment and interpretation of the
spectra. Data evaluation is therefore the bottleneck in this field. Looking back to the
glycoproteomic pipelines, however, the key stages developed in recent years are the
isolation of glycoproteins/glycopeptides and MS analysis of glycoproteomes.

1.5.1 Enrichment of glycoproteomes
Most mass spectrometers can only analyze samples in which the concentrations of
protein cover three to four orders of magnitude, whereas the protein concentrations of
biological samples span up to 10 to 12 orders of magnitude 160 ' I61 . Naturally occurring
glycoproteins are often present at low levels

. In a complex protein digest, the signal

intensities of glycopeptides are relatively low since the extensive microheterogeneity of
the carbohydrate gives rise to different glycoforms, each present at a low concentration in
the total peptide pool 159 . Moreover, glycopeptide signals generated by MS are often
suppressed in the presence of other peptides, especially when the glycans are terminated
with a negatively charged sialic acid moiety 159'162. Therefore, it is essential to enrich
glycoproteins present in complex biological samples prior to MS analysis. Two main
specific approaches for glycoprotein/glycopeptide enrichment have been widely applied:
lectin affinity based enrichment methods and chemical-based methods.

1.5.1.1 Lectin affinity chromatography
Lectins are a class of proteins isolated from plants, fungi, bacteria, and animals that
have a unique affinity towards carbohydrates

. Lectin affinity enrichment is based on

the specific and reversible binding interaction between a lectin and a distinct glycan
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structure attached on a glycoprotein/glycopeptide. A variety of lectins can selectively
bind to different oligosaccharide moieties. For example, concanavalin A (ConA) binds to
high mannose, hybrid and biantennary complex-type N-glycans; wheat germ agglutinin
(WGA) binds to N-acetyl-glucosamine and sialic acid; PNA is specific to T-antigen
found commonly in O-glycans, and jacalin (JAC) specifically recognizes galactosyl
(P—*1,3) N-acetylgalactosamine and O-linked glycans 164. Lectin affinity enrichment has
been applied to enrich glycoproteins/glycopeptides with specific glycan attachment from
plasma, serum, urine, tissue and other biological samples of human and mice through
affinity chromatography and other methods

. The typical lectin affinity

chromatography protocol involves immobilization of lectins onto appropriate matrices
such as agarose, silica or magnetic beads in a number of chromatographic formats
including tubes, columns and microfluidic channels 165'166, whereby protein sample or
trypsin-digested peptides are loaded by gravity-flow mode or low-pressure pumps. The
unbound material is removed by washing the column while the captured
glycoproteins/glycopetides are displaced from the column by elution buffer and identified
by MS/MS 92 ' 96 . Multiple lectin species with distinct specificities can also be used in
combination or in series to achieve a comprehensive enrichment of
glycoproteins/glycopetides from complex biological mixtures 167'168. For instance, our
group analyzed human plasma glycoproteins captured by various lectins and found a
difference between sera from subjects with benign prostatic hyperplasia and prostate
cancer or between sera from hepatocellular carcinoma patients and control subjects 169.
Likewise, Hancock and co-workers developed a multilectin affinity column which
combines ConA, WGA and Jacalin to perform a comparative glycoproteome analysis of
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sera from breast cancer patients and normal controls. The authors identified 813
glycoproteins in the serum samples including low-abundance components such as
neuropilin-1 and pregnancy zone protein, and a number of proteins associated with lipid
transport and cell growth were detected of changes in expression 167. In related work,
Qiu and Regnier utilized an extended strategy called serial lectin affinity chromatography
(SLAC) for fractionation and comparison of glycan site heterogeneity on glycoproteins
derived from human serum through a series of different lectins with precisely elucidated
binding specificities

170

. To date, most of the work using lectin affinity for targeted

glycoprotein enrichment has been limited to N-glycosylation because the binding
specificity of lectin for O-glycosylation is less satisfactory. To overcome such caveat,
efforts have been made using serial lectin columns of Con A and JAC in tandem to
remove N-glycosylated species from a complex mixture with Con A before Jacalin
selection, which greatly improves O-glycopeptide selection specificity and allow the
171

identification of a broad variety of O-glycosylated proteins from human serum
Lectin-based affinity selection has successfully purified glycoproteins/glycopeptides with
specific structures and identified some cancer biomarker candidates. Numerous
advantages of the lectin affinity approach including its simplicity, cost-effectiveness, and
capability of discrimination of glycan structures among different proteins and different
glycoforms of the same protein. The weakness of this method does exist, such as the low
binding affinity between oligosaccharides and most lectins (the affinity constant Ka in the
low micromolar range), broad binding specificity for certain lectins, and the fact that the
binding capacities of lectins are affected by the tertiary structure of glycoconjugate.
These disadvantages could result in some of the proteins/peptides captured by the lectins
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actually have no designated sugar and linkage that is ascribed to lectin affinity. In this
case, further validation of the oligosacchride structure of candidate proteins by other
methods will be required.

1.5.1.2 Chemical-based Methods
Alternative approach for glycosylation characterization stems from the exploitation
of glycan chemical reactivity. Two similar approaches, including hyarazide and boronic
1 79

acid chemistry, capitalize on the c/s-diols present in monosaccharides
Aebersold and colleagues et ah first described the use of hydrazide chemistry for the
17^

N-linked glycoproteome examination

. In this scheme, carbohydrate cz's-diols are

converted to aldehydes by sodium periodate treatment, which sequentially react with the
immobilized hydrazide groups. Bound glycoproteins are trypsin-digested in situ, and
nonglycosylated /unbound peptides are removed by washing. Covalently coupled Nlinked glycoproteins are then released by PNGaseF treatment and analyzed by LCMS/MS. Using this approach, the author identified 145 glycopeptides from 57 unique
proteins. The same technique was applied to examine the changes in the N-linked
glycoproteome profile of sera from cancer-bearing and genetically identical normal mice
174

'. As a result, glycoproteome profiles of mouse sera from mice with cancer formed a

distinct cluster from the profiles of normal mice as examined by unsupervised
hierarchical clustering. Interestingly, when the entire proteome was examined, clustering
analysis did not distinguish cancerous from non-cancerous sera samples, indicating the
potential of glycoproteomics for cancer biomarker discovery. To date, hydrazide-based
glycoprotein enrichment has been applied to various biological samples including cell
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lines, body fluids, and tissues 175. For example, Soltermann et al. used the method to
capture the glycoproteins from malignant pleural effusions of patients with lung cancer
and controls

. They were able to analyze the glycoproteins with low protein abundance

([xg/mL to ng/mL) and identified several proteins associated with tumor progression or
metastasis, e.g. CD44, CD166, CA-125, and lysosome-associated membrane glycoprotein
2 (LAMP-2). In 2007 the Aebersold group published a revised version of this method
that captured glycopeptides rather than intact glycoproteins, resulting in a claim of an
improved glycopeptide recovery (>90%)

I77

. Later the same group further modified the

protocol by substituting hydrazide functionalized beads with biotinylated hydrazide, and
i no

employing streptavidin beads to capture extracellular N-glycoproteins on live cells
By integrating of quantitative proteomic workflows such as stable isotope labeling by
amino acids in cell culture (SILAC), the group demonstrated the ability to monitor
abundant changes of the cell surface glycoproteome between related cell types and upon
perturbation of a specific cell type. The main advantage of hydrazide approaches is the
high specificity. The method simplifies the peptide mixture by only isolating and
analyzing on average one to two deglycosylated peptides from each glycoprotein. This
character also raised issues such as low sequence coverage and potential false
identification for glycoprotein. Another drawback of hydrazide methods is limited to
only the isolation of broad classes of N-linked glycoproteins/glycopeptides regardless of
the glycan structure, therefore, lacking the specificity and selectivity required for analysis
of cancer-related glycosylation changes.
Recent studies have compared lectin affinity and hydrazide chemistry methods for
performance and efficiency in isolating glycoproteins/glycopeptides from a complex
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biological sample

" . The two methods are complementary in enriching glycoproteins

due to their different mechanisms and the structural and complexity of a specific protein.
When both methods were applied, it significantly improves the coverage of the
glycoproteome, resulting in an increased number of glycoproteins identified.
The second chemical-based method takes advantage of the principle that
heterocyclic boronic diesters formed by the reaction of geminal diol groups in glycans
with boronic acid are stable under basic conditions. Using this method, Sparbier et al.
recently showed boronic-acid-functionalized magnetic beads could be used to capture
low-abundance glycoproteins from human serum 182. In addition, Xu et al. synthesized a
novel diboronic acid functionalized mesoporous silica (FDU-12-GA) and successfully
applied it for specific glycopeptide enrichment183.

1.5.2 MS Analysis of Glycoproteomes
Central to all glycoproteomic strategies is the MS analysis of glycopeptides
generated by the digestion of glycoproteins. The complete analysis of glycosylation
includes the determination of the peptide sequence, the carbohydrate structure (sequence,
branching points, and heterogeneity), and the sites of attachment to the protein backbone.
However, it is technically challenging to simultaneously perform such comprehensive
analysis in a complex biological sample. First, compared to peptides, glycans exhibit
poorer ionization efficiencies. Second, glycosidic bonds are highly labile under
conventional fragmentation condition so that different instrument parameters are required
for peptide backbone and glycan analysis 160. For example, quadrupole-TOF MS/MS has
been widely used for analysis of N-glycopeptides. With low collision-induced
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dissociation (CID) fragmentation energy, B-type and Y-type fragmentation ions of the
glycan moiety prevails and information on the composition and sequence of
carbohydrates is predominantly achieved (Fig. 5A). At higher collision energy, glycan
ions are hardly observed any more. Instead, a series of y- and b-type peptide ions
dominate the MS/MS spectra (Fig. 5B) 184 . Third, mixed fragmentation ion spectra from
the peptide backbone, the carbohydrate group and the combinations of both, complicates
the interpretation and may be sometimes misleading 153. As a standard setup, most
workflows employ deglycosylation before MS analysis and splits glycosylation study into
two directions: glycan analysis and peptide analysis (Fig. 4). To define the total glycan
repertoire of the samples, specific released glycan populations are derivatised,
fractionated, and analyzed by MS, as described below. For peptide analysis, a standard
proteomic pipeline is applied.

1.5.2.1 Glycan release from the glycoproteins/glycopeptides
Glycans can be released from glycoprotein/glycopeptide by using enzymatic and
chemical methods I 5 9 ' m . Each procedure has certain advantages and disadvantages.
Enzymatic release is straightforward, but depending on the substrate specificity not all
types of glycans are liberated. Chemical methods, can suffer from several limitations,
such as low specificity, destruction of non-carbohydrate substituents and polypetide
backbone, and modifications of the amino acid residues. Hence, some glycosylation
information (extent and sites) is lost.
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Figure 5 The nomenclature of peptide and glycan fragment ions from a tandem
mass spectrum. (A) Peptide fragmentation notation. Fragments will only be
detected if they carry at least one charge. If this charge is retained on the N
terminal fragment, the ion is classed as either a, b or c. If the charge is retained on
the C terminal, the ion type is either x, y or z. A subscript indicates the number of
residues in the fragment. (B) Glycan fragmentation nomenclature. In this
nomenclature, ions retaining the charge on the non-reducing terminus are named
A, B and C, and the ions retaining charge on the reducing terminus are X, Y and
Z. A and X correspond to cross-ring cleavages, whereas B, C, Y and Z correspond
to glycosidic cleavages. Subscript numbers denote the cleavage position, starting
at the reducing terminus for the X, Y and Z ions, and at the non-reducing terminus
for the others. In the case of ring cleavages, superscript numbers are given to show
the cleaved bonds. Adapted from Morelle, W. et al. Nat Protocols 2, 1585 (2007).
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Intact N-glycans are usually released using enzymatic methods. Several enzymes
are commercially available. The most popular is peptide N-glycosidase F (PNGase F),
which cleaves the linkage between the core GlcNAc and the asparagine residues of all
classes of N-glycans, with the exception of N-glycans containing a (al-»3)-linked fucose
attached to the core GlcNAc residue 185. PNGase A, an enzyme found in almond
emulsion, is sensitive to such PNGase F-resistant glycans

. Two other enzymes for N-

glycans cleave the glycosidic bond between the two GlcNAc residues within the
chitobiose core, differ in their substrate specificities: endoglycosidase D (endo D)
releases all classes of N-glycans, while endo H selectively cleaves oligomannose- and
hybrid-type structures .
Since O-glycans lack a common core and may contain extended sugar chains, the
enzymes are quite limited for their release. So far, only one enzyme, endo-a-Nacetylgalactosaminidase (O-glycanase) targeted to the core 1 O-glycan structure, has
been described

. Most assays rely on chemical methods, such as
1 88

trifluoromethansulfonic acid, hydrazinolysis, P-elimination, and periodate oxidation
Among these, P-elimination has been widely adopted. Reductive P-elimination uses
NaOH to cleave the glycosidic bond and NaBFLj to reduce the free reducing end of the
released glycan to an alditol form

189

. This procedure has even been applied to

glycoproteins separated on SDS-PAGE or blotted to PVDF membranes 190. However, the
degradation of glycan at the high pH remains a problem. Another drawback is the
reduction conversion prevents downstream glycan labeling and derivatization. A newly
introduced method is ammonia-based non-reductive p-elimination. This method avoids
these drawbacks and becomes the favored choice of many glycan analysis

191 192

'

.
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1.5.2.2 Mapping glycosylation sites
In nature, not all potential glycosylation sites are actually occupied, and this
characteristic (carbohydrate macroheterogeneity) also correlates the disease states
Since direct intact glycopeptide analysis is difficult, one way around this problem is to
remove the sugar chains and concomitantly incorporate a MS-amenable tag at the
glycosylation sites. This strategy is particularly suitable for mapping N-glycosylation
sites because PNGase F not only cleaves all types of N-glycans, but also possesses
additional amidase activity during this process. Therefore, PNGaseF converts asparagine
to aspartic acid during the cleavage reaction. This results in a 1-Da mass shift detectable
by high resolution mass spectrometers
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. Stable isotope labeling with 18 0 during

deglycosylation can further enhance the precise of site identification

I94

. The study of

Kaji et al. represents one of the earliest efforts to apply this strategy to glycosylation
analysis 195. The approach, termed isotope-coded glycosylation-site-specific tagging
(IGOT), involves the capture of glycopeptides by lectin affinity chromatograph, followed
1&

by PNGase F mediated incorporation of

O into the N-glycosylation site and LC-

MS/MS analysis. Using IGOT, Kaji et al. identified 250 glycoproteins containing 400
unique N-glycosylation sites. In a similar manner, Lewandrowski et al. coupled
glycopeptides enrichment by lectin affinity chromatography and hydrazide beads with
PNGase F deglycosylation to elucidate N-glycosylation sites on human platelet proteins
. Over 70 glycosylation sites from 41 unique proteins were identified, and the majority
had not been found in previous studies.
Deglycosylation can also be used to determine O-glycosylation sites. A method,
called BEMAD- |3-elimination followed by Michael addition with dithiothreitol (DTT) or
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biotin pentylamine (BAP) yielded a unique tag on O-GlcNAc sites, allowing for
enrichment via affinity chromatography as well as O-GlcNAc site identification by LCMS/MS

. Three previously known and three new O-GlcNAc sites on Synapsin 1 were

identified by this strategy. Vosseller et al. used BEMAD in a quantitative manner, where
two samples were compared by using deuterated (d6) DTT for one sample and unlabled
(dO) DTT for anther sample 198. Combining thiol chromatography and LC-MS/MS, the
team could identify the BEMAD-labeled peptides, determine the sites of modification,
and perform comparative quantitation of large number of O-GlcNAc proteins in one
study. However, BEMAD is not specific for O-GlcNAc glycosylation. Any
modification of serines and threonines that is susceptible to ^-elimination, such as Ophosphorylation and O-sulfation, may be targeted by this method 197. Therefore, extra
experiments are required to distinguish between O-glycosylation and other types of
modification.

1.5.2.3 Glycomics Methods
Various MS techniques can be employed to decipher glycan structures. Matrixassisted laser desorption ionization time-of-flight (MALDI-TOF) and electrospray
inonization (ESI) are the two major inonization techniques used for glycan analysis.
MALDI-MS, usually with a time-of-flight (TOF) analyzer, can be used for
monosacchride composition analysis, in which predominantly singly charged ions are
formed with very little fragmentation

159

. The major advantage of MALDI-TOF-MS is

the relative simplicity of instrumentation, the speed of analysis, the high mass range and
the robustness towards low concentrations of contaminants. Together with automated
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sample spotting, MALDI-TOF provides a valuable tool for high-throughout glycan
profiling

199

. However, this type of analysis only provides a snapshot of the most likely

structures to be present, but does not allow the assignment of defined carbohydrate
structures. ESI-MS is also applied to analysis of glycan mixtures. The advantage of ESIMS over MALDI-MS is that ESI-MS can be coupled with glycan separation column
online to enhance the detection sensitivity. But ESI-MS usually generates doubly or
triply charged ions, thus leading to high complex mass spectra when heterogeneous
09

mixtures of glycans are analyzed .
Monosaccharide sequence, branching, and linkages can be determined through
fragmentation. With CID function, ESI-MS/MS, and MALDI-TOF/TOF are currently
the most frequently used methods, and both can be performed in the positive or in the
negative ion mode

. In general, glycans show two types of fragmentation: cleavage of

the glycosidic bonds between the sugar rings and cleavage within the rings, so-called
cross-ring cleavages (Fig. 5B). Glycosidic cleavage ions provide information on
carbohydrate sequence and branching as well as non-carbohydrate substitutes, whereas
the cross-ring cleavage ions are usually weak and may be used to define linkage 159.
Recently, MSn-based analytical methods and new fragmentation technologies have been
introduced to enhance the identification of structural isomers 200'201 . In the case of MS"
in iron trap, sequential fragmentation of glycan was found to result in cross-ring
cleavages that are highly informative in the determination of linkage position and
000

anomeric configuration identification
Fragmentation analysis may be performed with underivatized or derivatized
oligosaccharides. To ensure the highest sensitivity and to facilitate unambiguous
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sequencing in MS/MS experiments, glycans are usually derivatized by permethylation, by
methylesterification of sialic acids, or by reducing-end tagging before MS analysis
Permethylation, which generates methyl derivatives for each free OH and NH group and
esterifies the carboxy group in the sialyl residues, often prevails in glycomic analysis
(especially in MALDI-MS analysis) with some benefits. First, the addition of methyl
groups stabilizes sialylated structures and enhances overall sensitivity. Second, the
hydrophobic nature of methylated glycans facilitates their separation from salts and other
impurities that may affect the MS analysis. Third, the fragmentation of methylated
glycans is more predictable than that of their native counterparts, leading to accurate
structural assignments 204. A recent multi-institutional study by the Human Proteome
Organization revealed that MALDI-TOF-MS of permethylated N-glycans is consistent
and comparable to HPLC analysis of reductive animation derivatives for quantitation '
205

1.5.2.4 Site-specific glycosylation analysis
One of the disadvantages of glycoproteomic analysis involving glycan release is that
this strategy does not allow site-specific glycosylation profiling. For this purpose, the
direct analysis of the intact glycopeptides is required. As described earlier, CID ESIMS/MS, the most frequently employed technique, prefers to detect fragmentation ions of
the glycan moiety other than that of peptide. This limitation can be overcome by using
modern high-speed tandem MS (or MSn) technologies. So far, a variety of instruments
with MS" capacity have been introduced, including ESI based ion trap (IT), quadrupole
ion trap (QIT), Fourier transform ion cyclotron resonance (FT-ICR), ion trap/time-of-
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flight (IT/TOF) and quadrupole/time-of-flight (Q/TOF); MALDI based Q/TOF,
quadrupole ion trap/time-offlight (QIT/TOF) and tandem time-of-flight (TOF/TOF) mass
spectrometers 153. However, different instruments require pronounced distinct
fragmentation conditions, and provide different structural information for glycopeptides.
For instance, ESI-IT-MS, which allows repetitive ion isolation / CID fragmentation
cycles, has been recently shown to characterize both peptide and glycan in a single
measurement184. In this approach, the glycan fragment ions are collected at the first
cycle (MS2 stage), and peptide fragment ions carrying a single sugar are selected and
subjected to a second ion isolation/fragmentation, providing information on the peptide
sequence and glycosylation site. This technology has successfully applied to determine
the three glycosylation sites and the glycoform structures in Thy-1, a GPI-anchorred
protein, and determined the structures of neutral and sialylated N-glycans attached to
chicken egg yolk glycopeptides 201'206.
The invention of new fragmentation technologies of electron capture dissociation
(ECD) in FT-ICR-MS, can also facilitate the single amino acid localization of labile
modifications

. ECD produces cleavage specifically at N-aC backbone of the peptide

leaving the modification intact on the peptide backbone, thus allowing unambiguous
assignment of glycosylation sites in N- or O-glycopeptides

160

. In quadrupole ion traps, a

similar type of fragmentation method to ECD, electon transfer dissociation (ETD), has
been recently introduced 208. ETD uses the same principle as ECD and can generate the
cleavage of peptide backbone while preserving labile modifications. Together ECD/ETD
with CID complementary information can be thus obtained. Hogan et al. demonstrate the
power of combination of CID and ETD in a 3D-quadrupole IT for the structural
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characterization of a tryptic N-glycopeptide 209. CID experiments on the multiply
protonated glycopeptide ions yielded, almost exclusively, cleavage at glycosidic bonds
and therefore glycan structure information. ETD reactions resulted in cleavage of the
peptide backbone with no loss of the glycan structure. Although the application of this
complementary multistage fragmentation technique has been limited to model
glycopeptides, it holds promise for complete chemical structural determination of
glycopeptides in complex biological mixtures.

1.5.3 Concluding remarks
In the past decade, MS in combination with modern enrichment methodologies has
become one of the most powerful and versatile techniques for glycosylation analysis.
There are different strategies for characterization of glycosylation at the levels of intact
proteins, glycopeptides, and free glycans. Therefore, MS-based glycoproteome analysis
is a multidimensional task. There is no universal method for rapid and reliable
interrogation of the global glycoproteome. Research goals must dictate the best method
or combination of methods for analysis. Sometimes other non-MS-based approaches
such as HPLC glycan analysis, exoglycosidase digestion and chemical treatment are
necessary for full structural elucidation of glycoproteome.
Looking to the future, we envision that a large-scale, automatic, quantitative
glycoproteomic analysis of complex biological samples is on the way, with the continued
evolution in mass spectrometry, enrichment approach, separation technology and
bioinformatics. There is no doubt that glycoproteomics is gaining momentum in
biomarker research and clinical studies.
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CHAPTER II
DISSERTATION RATIONALE AND SUMMARY OF AIMS

The objective of this research project is to develop a mass spectrometry-based
glycoproteomic approach for the selective isolation and identification of cell-surface
glycoproteins from cellular samples. This technology is applicable in the discovery of
new glycoprotein biomarkers which are indicative of prostate cancer progression and
metastasis.
Prostate cancer is the most prevalent cancer and second leading cause of cancer
deaths in men in the USA. Its lethality is mostly attributed to the primary tumor
metastasizing to distant sites. Cancer metastasis involves a series of sequential steps
consisting of tumor invasion at the site of origin, followed by intravasation, survival in
the bloodstream or lymphatic glands, arrest in a distal organ, extravasation, and finally
growth and angiogenesis in the distal organ. The steps requiring interactions between
tumor cells and the surrounding microenvironment are tightly regulated by cell surface
mechanisms. Most membrane and secretory proteins are glycosylated. Glycans not only
affect properties of the proteins but also regulate diverse biological functions through
particular protein-carbohydrate interaction. At the cell surface, sugar moieties of
glycoproteins contribute to molecular recognition events involved in cancer metastasis.
Aberrant glycosylation of cell-surface glycoproteins have been repeatedly reported in a
wide variety of cancers, including prostate cancer, and are strongly correlated with cancer
prognosis, metastasis, and the organ specificity of metastasis. It is possible that a portion
of these alternatively glycosylated molecules can reach the bloodstream and serve as
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early sentinels that enable cancer detection. In fact, many of the oldest and most widely
used clinical cancer biomarkers are based on glycoproteins or glycans. It is clear that
glycoproteins become important targets for the development of cancer biomarkers. With
recent advances in carbohydrate chemistry, analytical technologies, and mass
spectrometric instrumentation, glycoproteomics is rapidly emerging as a sub-field of
proteomics with high biological and clinical relevance. By focusing on the glycoprotein
subproteome, glycoproteomic analysis greatly reduces sample complexity, which
significantly increases the detection sensitivity for low abundant proteins. Therefore,
the central hypothesis of this dissertation is that cell-surface glycoproteins with
aberrant glycosylation, mediating the key events during prostate cancer metastasis,
can be indentified using mass spectrometry-based glycoproteomics. An improved
understanding of metastasis-associated cell-surface glycoproteins may not only provide
diagnostic and prognostic indicators, but also enable the discovery of new therapeutic
targets for prostate cancer. The central hypothesis will be tested and our overall research
objective will be achieved by addressing the following specific aims:
Aim I. Characterization of cell-surface lectin-binding patterns associated with metastasis
in human prostate cancer cells. This aim entails:
A. Optimization of lectin staining protocols to cultured live cells. This includes
finding the suitable cell dissociation methods which preserve both cell viability and cellsurface carbohydrates, and determining optimal staining conditions that allows the
reliable quantitation of lectin binding.
B. A syngeneic PCa cell line model, which consists of human prostate cancer cell line
PC3 and its two syngeneic variants with different metastatic potentials, will be profiled

52
by flow cytometry using a panel of lectins with different carbohydrate specificities to
delineate the carbohydrate contents on their surface and identify different glycosylation
patterns associated with metastasis.
C. The cells described above will be stained by lectin cytochemistry and observed
under confocal microscopy to evaluate the distribution of the existing sugars.

Aim II. Targeted identification of metastasis-associated cell surface sialoglycoproteins in
prostate cancer cell lines. This aim entails:
A. Development of a targeted glycoproteomic methodology which combines advanced
carbohydrate labeling technologies with high performance mass spectrometry to
selectively identify cell-surface glycoproteins.
B. Examining the sensitivity and specificity of cell-surface carbohydrate labeling by
flow cytometry and confocal microscopy.
C. Optimization of carbohydrate labeling protocol in order to maximize carbohydrate
labeling performance and maintain cell viability.
D. Evaluating the efficiency of glycoprotein capture and enrichment by our targeted
glycoproteomic approach using in-blot streptavidin detection and ID-PAGE. The
efficiency will be assessed by comparing the number and intensity of protein bands
before versus after enrichment and labeling vs control groups.
E. Application of the optimized glycoproteomic approach to our prostate cancer cell
line model system and analysis of the recovered glycoproteins by LC-MS/MS in an
attempt to identify panels of cell-surface glycoproteins as potential PCa metastatic
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biomarkers. The identified proteins will be analyzed by bioinformation tools for their
subcellular location and glycosylation status.
F. Evaluating the utility of this methodology for glycoprotein isolation and
identification from a mass spectrometric perspective. It will be completed by comparing
glycoproteins identified by our targeted glycoproteomic with those from total cell lysate
proteome as well as other publications.
G. Functionally mapping differentially expressed glycoproteins between PC3 variants.
Analysis will be performed by Ingenuity Pathway Analysis software across glycoprotein
biomarker lists to prioritize biomarker candidates based on key biological characteristics
and to shed light on mechanisms linking potential biomarkers to prostate cancer
metastasis.

Aim III. Verification of expression of cell-based biomarkers in clinical samples. This
aim entails:
A. Confirming the differential expression of glycoproteins identified in Aim II in our
cell line models using available antibodies. We will employ several methods for analysis
glycoproteins in cell lines. Initially, we will perform Western blot analysis on
glycoprotein enriched fractions and whole cell lysates to determine their expression
differences. Next, we propose to extend analysis of whole cell lysates to other prostate
cancer cell line model systems. We will also examine candidate expression by antibodybased flow cytometry and confocal microscopy.
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B. Characterization of glycosylation status of biomarkers in prostate cancer cells. The
specific glycosidases and glycosylation inhibitors will be employed to investigate the
carbohydrate residues on the biomarkers.
C. Verification of expression of biomarkers in clinical samples. Using a cohort of
prostate cancer patient samples including tissues and Expression Prostate Secretion (EPS)
urines with different risk factors but no extra-prostatic disease at the time of their
prostatectomy, the clinical utility of biomarkers and their expression will be compared by
immunohistochemistry/immunocytochemistry and/or Western blot techniques.
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CHAPTER III
AIM I: CHARACTERIZATION OF CELL SURFACE LECTIN-BINDING
PATTERNS ASSOCIATED WITH METASTASIS IN HUMAN PROSTATE
CANCER CELLS

3.1 Introduction '
Prostate cancer is the most prevalent cancer and second leading cause of cancer
deaths in men in the USA 3 . It affects men after middle age, and accounts for
approximately 30% of all male malignancies . In nature PCa is pathologically and
clinically heterogeneous ranging from indolent, low grade disease to aggressive high
grade disease which frequently metastasizes. Its prognosis rate varies greatly for patients
with different clinical stages and pathological grades. Despite early detection through
testing for serum PSA and the efficacy of surgery and radiation therapy for treating
clinically localized PCa, about 30% of men with PCa will experience relapse and develop
a PSA recurrence within 10 years after radical prostatectomy 210. Metastatic PCa claimed
•

the lives of 28,660 American men in 2008

911

. PCa metastasis has organ tropism.

Bubendorf et al. examined metastatic patterns of PCa from a postmortem study of 1,589
patients and reported hematogeneous metastases were present in 35% patients, with the
most frequent locations being bone (90%), lung (46%), liver (25%), pleura (21%), and
adrenals (13%) 212 . The mechanisms responsible for this phenomenon remain largely
undefined. Most advanced or metastatic PCa show an initial response to androgenablation therapy in up to 80% of cases 213, but ultimately it progresses to hormone
refractory prostate cancer (HRPC) after 18-24 months 214. At this stage, despite castrate
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levels of testosterone, the tumor will become independent of androgens resulting in death
within a few years from diagnosis. Moreover, choices of therapeutic regimens for late
stage patients are very limited and the major goal of the treatments is just to improve the
quality of life. Eventually, these patients die 215 ' 216 .
The clinical fate of PCa patients is ultimately determined by the primary tumor's
malignant potential, which is controlled by many factors: (i) apoptotic susceptibility of
tumor cells; (ii) matrix-destroying protease activity; (iii) adhesion of tumor cells to target
cells, particularly to platelets, leukocytes, and microvascular endothelia cells; (iv) the
ability to extravasate into the target organ parenchyma; (v) the capacity to evoke
angiogenesis in tumor cell surroundings; (vi) cross-talks with the host microenvironment
1X1

. The underlined mechanisms of each determinant are functionally maintained by a

combination of molecules, each of which can be affected directly or indirectly by N- or
O-linked glycosylation

. Glycosylation is critical in determining a protein's stability,

conformation, folding, and binding affinity for other molecules 85. Moreover, glycsns per
se are adhesion molecules directly involved in cell recognition events through proteincarbohydrate and carbohydrate-carbohydrate interactions

. In mammals, most secreted

and membrane proteins are glycosylated. Given their important location and interactive
roles in biological and pathological processes, aberrant cell surface glycosylation,
including altered sialylation and fucosylation, polylactosaminylation, higher-ordered Nlinked branching, and truncated O-linked glycans, is often observed in a variety of
tumors, and are strongly correlated with cancer prognosis, metastasis, and the organ
specificity of metastasis ' 10°. Nevertheless, the expression of cell surface carbohydrates
is cell-type specific and developmentally regulated by the activity of glycosyltransferases
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'. Examining the relationship between cell surface oligosaccharide structures and

metastatic phenotype variants within a defined tumor-cell population has been mostly
done in breast cancer

" . In PCa, the exact nature of glycosylation changes

accompanying metastasis is ill defined. Characterizing such patterns is thus critical both
to understanding their role in PCa progression as well as to provide diagnostic tools and
therapeutic targets to help clinical PCa management.
Specific carbohydrate-binding ligands such as lectins have proven to be invaluable
994

tools for the analysis of complex glycoconjugates

. These proteins, derived from non99S

immune origin, recognize and bind to specific carbohydrate structural epitopes

. In

most previous studies, lectins were tagged with a fluorophore or enzyme and used for
histochemical analysis of formalin-fixed paraffin embedded (FFPE) tissues 226. Although
such analysis is very powerful, it does suffer from some limitations. First, histological
processing of tissues can render carbohydrates inaccessible due to protein denaturation
and glycolipid losses 226. Second, visual assessment of such stained samples is subjective
and probably with considerable error, particularly for complex samples with
79^

heterogeneous staining patterns

. Third, the quantitation across multiple areas of
99"i

tissues is difficult and fairly lengthy

. In contrast, lectin flow cytometry offers several

advantages. It can perform on a large number of live cells, and the extent of lectin
binding can be expressed in a defined quantitative fashion within a short period.
In Aim I we refined and optimized a lectin staining protocol for prostate cultured
cells with emphasis on compatibility with flow cytometic analysis. We then applied this
approach to delineate the carbohydrate alterations on a human syngeneic metastatic PCa
cell line model by using a battery of lectins with defined specificities. Additionally, we
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evaluated the distribution of the existing sugars over PCa cell surface with lectin
cytochemistry.

3.2 Materials and Methods
Materials — Dulbecco's modified Eagle media (DMEM), RPMI 1640 medium,
penicillin, streptomycin, and fetal bovine serum (FBS) were from Invitrogen (Carlsbad,
CA, USA). Antibiotics-antimycotic, propidium iodide, nonenzymatic dissociation buffer,
fluorescein conjugated streptavidin (streptavidin-FITC), 4-12% NuPAGE® Bis-Tris gels,
and lithium dodecyl sulfate (LDS) buffer were from Invitrogen. Halt™ protease inhibitor
cocktail was from Pierce (Rockford, IL, USA). Cell proliferation reagent WST-1 {4-[3(4-iodophenyl)-2-(4-nitrophenul)-2H-5-tetrazolio]-l,3-benzene disulfonate} was from
Roche (Indianapolis, IN, USA). Prestained protein standard was from Bio-Rad
(Hercules, CA, USA). Murine anti-a-tublin mAb was provided by Sigma (St Louis, MO,
USA). Murine anti-androgen receptor mAb was from BD PharMingen (San Diego, CA,
USA). Rabbit anti-PSA polyclonal antibody was from Dako (Carpinteria, CA, USA).
IRDye 700 or IRDye 800 conjugated secondary reagents were from Li-COR Biosciences
(Lincoln, PA, USA). All chemicals were of analytic grade and were purchased from
Sigma.

Lectins — Seven biotin- or FITC-conjugated lectins were purchased from EY
Laboratories (San Mateo, CA, USA) or Vector Laboratories (Burlingame, CA, USA).
Common name, abbreviation, source, and normal sugar specificity were as follows:
anguilla anguilla lectin (AAA) from Fresh water eel: fucose in an (a-1,6) linkage;
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concanavalin A agglutinin (ConA) from jack bean seeds: oc-mannose/ a-glucose; Helix
pomatia lectin (HPA) from Edible snail: N-acetyl-galactosamine (GalNAc); Umax flavus
lectin (LFA) from Garden slug: sialic acid; maackia amurensis lectin (MAL) from
Maackia amurensis seeds: sialic acid in an (a-2,3) linkage; sambucus nigra lectin (SNA)
from elderberry bark: sialic acid in an (a-2,6) linkage; wheat germ agglutinin (WGA)
from Triticum vulgaris: sialyloligosaccharide/N-acetyl-glucosamine (GlcNAc).

Cell Lines — PC3-N2 and PC3-ML2, two sublines of PC3 prostate cancer cells
(originally obtained from a skeletal metastasis in a patient with primary prostate
adenocarcinoma) were kindly provided to us by Dr. Stearns' group at Drexel University.
The N2 and ML2 cell lines have been developed on the basis of their invasiveness in
vitro and metastatic potential in vivo. Both cells were tumorigenic when injected
subcutaneously in SCID mice. However, N2 cells were unable to migrate through a
Matrigel-coated membrane in vitro as well as induce metastases following tail vein
injections in SCID mice, whereas ML2 cells were highly invasive in vitro and induced
skeletal metastases in more than 80% of cases 227. Human prostate bone metastasis PC3,
prostate carcinoma lymph node metastasis LNCaP, and prostate carcinoma brain
metastasis DU145, and HPV-18 immortalized prostate epithelial cell line RWPE-1 were
obtained from the American Type Culture Collection (ATCC). PC3 and its sublines were
routinely cultured in growth medium (DMEM medium, 10% FBS, 1% Antibioticantimycotic) at 37°C in a humidified atmosphere containing 5% carbon dioxide. DU145
and LNCaP cells were cultured in the growth medium and passaged according to the
manufacturer's instructions.
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Cell Proliferation Assay — Cells were seeded into 96-well microplates under 200 |j.l/well
complete medium. At the indicated time point, WST-1 reagent was added to 10% per
well and incubated for 2h at 37°C in 5% CO2. The absorbance was measured at 450 nm
by ELISA reader (ELx800, Bio-Tek Instruments, Winooski, VT, USA).

Flow Cytometric Assessment of Lectin Binding— Cells were grown in 150-mm dishes to
90% confluence and detached by nonenzyme dissociation buffer at 37°C. After washing,
0.5 xlO6 cell suspension was incubated with lectins in appropriate buffers and at
optimized concentrations for 30min at 4°C. Then cells were washed three times with
PBS/TBS and resuspended in 0.5 ml PBS/TBS. Before subjected to flow cytometry, they
were counterstained with 1 fig/ml PI for a minimum of 20 min at 4°C. For biotin-labeled
lectins, streptavidin-FITC staining was applied (4°C, 30 min) before PI staining. A flow
cytometer (FACScalibur, BD Biosciences, San Jose, CA) equipped with 488 nm
excitation source was used for data collection. The fluorescent signal of FITC and PI was
recorded in FL1 (525 nm band pass) and FL2 (585 nm band pass), respectively. Control
samples including unstained cells, lectin-stained cells only and Pi-stained only from each
cell line, were prepared for flow cytometric compensation setting. Flowjo software (Tree
Star Inc., Ashland, OR, USA) were employed for data analysis. To address the
specificity of lectin binding, the inhibitory sugar was preincubated with lectin overnight
and mixture was used for lectin staining.
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Lectin Cytochemistric Analysis — Cells were seeded onto 6-well plates containing glass
coverslips and cultured in growth medium up to 80% confluence. After rinsing with ice
cold PBS/TBS three times, cells were incubated with lectins in appropriate buffers and at
indicated concentrations for 30 min at room temperature in dark. Then cells were fixed
with 2% paraformaldehyde (PFA) in PBS/TBS for 12 min at room temperature. For
biotin-labeled lectins, streptavidin-FITC staining was applied for 30 min at 4°C. Finally
coverslips were mounted to the slides with VectorShield medium (Vector Labs,
Burlingame, CA, USA), and sealed with nail polish. Fluorescent images were examined
and captured under a confocal microscope (Carl Zeiss, Thornwood, NY, USA).

Western Blot Analysis — Whole cell lysates were collected in the M-PER lysis buffer
containing lx protease inhibitor cocktail. Protein concentration was measured by the
BCA protein assay. Protein samples (20 ug each) were separated by electrophoresis
through 4-12% SDS-PAGE and then transferred to Immobilon-FL PVDF membranes
(Millipor, Billerica, MA, USA). Prestained protein standard was used to assess transfer
efficiency and to determine the size of blotted proteins. Membranes were blocked in
LiCor blocking buffer (Rockland Immunochemicals, Gilbertsville, PA, USA) diluted
with PBS (1:1), and then incubated with anti-PSA primary antibodies (1:1000) or antiandrogen receptor (1:3,000) overnight at 4°C. Following extensive washing, membranes
were incubated with species-specific IRDye700 or 800-conjugated secondary antibodies
(goat anti-rabbit, 1:15,000; goat anti-rabbit, 1:15,000) for 1 h at room temperature, and
visualized with a LiCor Odyssey infrared imager (LiCor, Lincoln, NE, USA). Consistent
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protein loading was determined by reprobing membranes stripped in Restore Western
blot stripping buffer with anti-a-tubulin antibody (1:4,000).

3.3 Results
3.3.1 The properties of prostate cancer PC3 cells and its sublines
To study cell surface glycosylation changes accompanying metastasis, we need a
suitable model which accurately recreates the histopathological metastatic process
observed in humans. Clinically, the lethal phenotypes of human PCa are characterized by
their progression to HRPC and their propensity to form osseous metastases. Here we
employed a syngeneic PCa cell line model which consists of two sublines derived from
the widely used PCa PC3 cell line. PC3, originated from a patient bone lesion, is an
androgen-independent cell line. PC3-N2 (non-metastatic) and PC3-ML2 (metastatic) was
previously selected for their ability to both invade in vitro and generate skeletal
metastases in SCID mice in vivo

. To better support our following experiments, we first

tested two basic characteristics of PC3 variants: proliferation and androgen dependence.
Proliferation of PC3, N2, and ML2 cells was assessed using the cell proliferation reagent
WST-1 (Fig. 6A). Compared to parent PC3 cells, N2 cells grow slower and ML2 faster.
Immunoblot analysis of total cell lysates shows that these cells don't express androgen
receptor and androgen-regulated gene products such as PSA, therefore verifying that they
are androgen-independent cell lines (Fig. 6B).

3.3.2 Optimization of cell dissociation methods
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Figure 6 The properties of prostate cancer PC3 cell line and its sublines. (A) WST1 assessment of cell proliferation of PC3, N2 and ML2 cells. (B) Western blot
analysis of AR and PSA expression in PC3, N2, and ML2 total cell lysates.
Androgen-dependent cell line LNCaP and androgen refractory cell line DU145,
were included as positive and negative controls, a-tublin was used as a loading
control.
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Since PC3 cells and its sublines are adherent cells, and traditional cell dissociation
method, trypsinization, cleaves or strips some cell surface glycoproteins, we need to find
the best method to dislodge the cells from the plastic flask surface. Five cell detachment
methods (Fig. 7) were compared on ML2 cells. They are enzyme preparation, trypsinEDTA; mechanical disruption, gentle scraping; and three nonenzymatic reagents,
commercial dissociation buffer, EDTA only, and sodium citrate only. The following
three parameters were concerned: (1) cell dissociation efficiency; (2) cell viability; (3)
cell surface carbohydrate retention. As expected, trypsinization lifted cells very
efficiently with only 5-10 min incubation. In contrast, nonenzymatic reagents needed 2030 min and gentle tapping of the flask to take effect. Cells removed by these three
preparations resulted in some cell clumping, but all formed a single cell suspension after
repeated pipetting. The integrity conservation of the dissociated cells was compared by
flow cytometric analysis (Fig. 7A). Scraping pronouncedly changed cell light scatter
properties with more than 50% cell debris generated, while other methods could keep cell
physically intact. To assess cell viability, we incubated the dissociated cells with
propidium idodide (PI) and discriminated viable cells by flow cytometric analysis. As
shown in Figure 7B, trypsinization led to minimal cell death (about 9.5%) whereas cell
scraping damaged cells the most (>50% cell death). Three nonenzymatic preparations
resulted in different cell viability rate, and commercial buffer had the advantage over
EDTA and sodium citrate both in terms of percentage of the main population (intact
cells) and the total population (all detached events, including debris). These results
agreed with trypan blue exclusion counts shortly after dissociation (data not shown). For
cell surface carbohydrate retention, we used four FITC- or biotin-labeled lectins specific
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Figure 7 Flow cytometric assessment of different cell dissociation methods. (A) Cell
light scatter properties of ML2 cells dissociated by different methods. A polygon
delimits the main population of intact cells, whereas events outsides of main
population consist of aggregated cells and cellular debris. Number indicates main
population as a percentage of total events. (B) Cell viability within the main
population. Positive PI staining indicates dead cells. Numbers indicate percentages of
live (PI-) cells within main population. (C) Effect of dissociation methods on
carbohydrate retention. ML2 cells were dissociated by different methods, incubated
with FITC- or biotin-conjugated lectins (LFA, SNA, MAL, WGA), followed by
streptavidin-FITC (only for biotin-lectins), and analyzed by flow cytometry. PI
staining was used to gate live cells. Histogram for each lectin is shown by red line and
nonspecific staining (unstained cells) is overlaid in grey line for comparison.
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for sialic acid to measure cell surface carbohydrate levels on living cells. Flow cytometry
data revealed a homogenous fluorescent staining for all examined lectins on cell surface.
Scraping compromised most cell surface carbohydrates and trypsin selectively ate up
some sugars such as WGA (Fig. 7C). Sodium citrate also exhibited poor carbohydrate
retention. Conversely, commercial dissociation buffer preserved all carbohydrates best
followed by EDTA procedure.
On the basis of above results, we concluded that the commercial dissociation buffer
provides the best balance of dissociation efficiency, viability, and cell surface
carbohydrate retention. The reagent will be used for the following experiments in this
study.

3.3.3 Optimization of lectin staining protocols
Because of their extensive availability and the wide spectrum of carbohydrates that
may be specifically bound, lectins have become essential reagents for glycosylation
analysis. They bind non-covalently to carbohydrate residues and can be used in the same
types of application as monoclonal antibodies. However, lectin binding has different
characteristics. For example, some lectins at high concentration can induce apoptosis,
resulting in global changes of cell surface glycosylation 228. In addition, some lectins
require divalent cations (Ca2+ and Mg2+) to take effect while the binding of other lectins
990

may be interfered by phosphate ions

. On the other side, cell surface glycans are
910

expressed in a cell type and lineage-specific manner

. Therefore, when applying lectin

staining to cultured live cells, we need to work out a lectin binding protocol that allows
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the reproducible determination of carbohydrate moiety profiles, as well as reliable
quantitation of lectin binding.
A blocking reagent contains a high concentration of immunoglobulin and is often
used in immunostaining to minimize the non-specific antibody-base staining. But for
lectin staining, how to decrease the non-specific binding is largely unknown. Here we
compared three different blocking buffers with respect to their preservation of cell
viability and SNA binding to non-malignant prostate RWPE-1 epithelium cells (Fig. 8).
Although blocking buffers either with 1% FBS or 1% BSA can effectively protect the cell
death arisen from the high concentrations of SNA (Fig. 8B), they also significantly
decreased cell surface fluorescent signals (Fig. 8A). It is not surprising since serum
contains a lot glycoconjugates which can competitively inhibit lectin binding. BSA is not
a glycoprotein, but it is often contaminated by serum glycoproteins during its commercial
preparations.
Next we investigated the effect of two different buffers, PBS and TBS containing
9+

9-4-

divalent cations Mg and Ca , on lectin binding and cell death. As shown in Figure
9A, the addition of divalent cations induced RWPE-1 cell death as well as loss of MAL
binding. Similar results have been obtained for lectins SNA, WGA, and AAA. There is
no obvious change for ConA regarding binding signal and cell death between the two
buffers (Fig. 9B). Since an improvement in binding was not gained in most cases, the
addition of divalent cations is not recommended for most lectins.
As cell surface glycosylation is involved into cell-cell contact, the cell confluence
status may influence the expression level of carbohydrate. Figure 10 summarized the
relationship of SNA binding and the degree of PC3 cell confluence. In general, cells with
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low confluence showed lower fluorescent intensity than cells with higher confluence.
However, the intensity was no different after cells reached 60% confluence.
Some lectins such as SNA, WGA and ConA are potential inducers of apoptosis
The optimal concentration of these lectins which can best distinguish positive from
negative cell population and cause minimum cell death was determined. Figure 11
showed the example of SNA dose curve. The short incubation of PC3 cells (30 min at
4°C) with a series of diluted SNA generated a dose-dependent increase in fluorescent
signal; however, it also produced dose-dependent cell agglutination and cell death.
Balance of the signal intensity and cell death, SNA at 10 ug/ml was chosen for the
subsequent flow cytometric experiments. By contrast, some lectins such as LFA had
minimal cytotoxic effects on cells (Fig. 12). So the optimal concentrations for these
lectins (100 ug/ml for LFA) were based on their best capacity to tell positive population.
The same procedures were performed to optimize conditions for other lectins used in this
study, and their optimal working concentrations and buffers were indicated in Table 4.
Lastly, we examined the specificity of lectin binding by their hapten sugars. Five
free sugars were chosen to for the examined lectins: lactose (SNA, MAL), GlcNAc
(WGA), fucose (AAA), GalNAc (HPA), and mannose (ConA). Representative
histograms of the various blocking experiments can be seen in Figure 13. Preincubation
of lectin with their corresponding competitive sugars exclusively blocked or reduced
lectin binding (p<0.05, range 1.4-74.4 fold), confirming the binding specificity of these
lectins. However, the degree of reduction was various. For instance, 0.2 M GalNAc
almost completely reduced the fluorescence to the auto fluorescence level while the same
concentration of lactose only decreased 28% MAL binding. The differences underscore
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Table 4 Lectins and the optimized protocol for flow cytometric analysis
Concentration
100

Inhibitory
Sugars
0.2MNANA

PBS

10

0.2M Lactose

MAL/MAA ct2-3 sialic acid

PBS

100

0.2M Lactose

WGA

PBS

20

0.2M GlcNAc

AAA

sialyloligosaccharide,
GlcNAc
ot-fucose

PBS

100

0.2M Fucose

HPA

GalNAc

TBS+CaCl2

100

0.2M GalNAc

ConA

<x-Man> a-Glc

TBS+CaCl2

20

0.2M Mannose

Lectin

Carbohydrate Affinity

LFA

Sialic acid

Staining
buffer
TBS+CaCl2

SNA

a2-6 sialic acid

LFA, Limax Flavus Agglutinin; SNA, Sambucus Nigra Agglutinin; MAL, Maakia Amurensis
Lectin; WGA, Wheat Germ Agglutinin; AAA, Anguilla Anguilla Agglutinin; HPA, Helix
Pomatia Agglutinin; ConA, Concanavalin A. NANA, N-acetyl neuraminic acid; GlcNAc,Nacetyl-D-glucosamine; GalNAc, N-acetyl-D-galactosamine. Glc, D-glucose; TBS, Tris buffered
saline; PBS, phosphate buffered saline.
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the application of optimal concentrations as well as binding conditions of inhibitory
sugars.

3.3.4 Flow cytometric assessment of lectin-binding profiles
Having established an optimized lectin staining protocol (Table 4), we next
compared the cell surface glycosylation profiles among PC3 and its metastatic variants by
lectin flow cytometric analysis. Mean fluorescent intensity (MFI) of living cells (PI-)
was used to quantitate lectin binding. The results of cell-binding assays for each of the
three cell lines on the panel of 7 lectins are shown in Figure 14. In general, control
unstained samples emitted very low levels of fluorescence (MFI average: PC3 6.63; N2
4.91; ML2 6.54). Four lectins (SNA, MAL, ConA, and WGA) showed very strong
binding compared to control samples (p<0.05). The MFI for the remaining lectins was
low, but still significantly different (p<0.05) from control value. Among cell lines,
distinct binding between N2 and ML2 cells was observed for sialic acid. N2 cells
showed higher binding than ML2 cells for SNA (2.14 fold, p<0.05) which recognizes a26 linked sialic acid, and for WGA (1.25 fold) which has the carbohydrate specificity for
sialyloligosaccharide/ GlcNAc. In terms of MAL which binds preferentially to a2-3
linked sialic acid, ML2 cells showed a little higher binding (1.2 fold) than N2 cells, but
the difference was not significant. Neither was those detected between cell lines for other
lectins.

3.3.5. Carbohydrate analysis using lectincytochemistry
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Figure 14 Cell surface carbohydrate profile analysis by lectin flow cytometry. PC3,
N2, and ML2 cells were stained with seven lectins with different carbohydrate
specificities under the optimal experiment conditions, and analyzed by flow
cytometry. PI staining was used to gate live cells. Mean fluorescence intensity (MFI)
of each lectin binding for three PCa cell lines was compared. Error bars represent the
standard deviation of three independent experiments. Mann-Whitney U test was used
to ascertain statistical differences. * denotes significant difference (p<0.05).
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The spatial distribution of lectin binding was revealed by confocal microscopy.
Because cells need to be fixed in this experiment, we first assessed the effect of PFA
fixation on lectin binding. Lectin binding on postfixed cells (staining before fixation)
was compared with that on prefixed cells (staining after fixation). In general, the staining
patterns under two different experimental conditions were close except that prefixation
resulted in loss of LFA binding to all three cell lines (data not shown). In fact, It was
documented that fixation can change lectin binding patterns of cells. Unfavorable
combinations of fixatives and buffers can cause a loss of more than 90% bound lectin 231.
For example, a loss of lectin mistletoe lectin-1 binding was observed during lectin
cytochemistry analysis of fixed colon cancer HT 29 cells

. Based on these findings,

postfixation of cells is more effective and we applied it for all coverslip staining.
Under confocal microscopy, similar subcellular staining patterns were observed
across three cell lines for all lectins (Fig. 15). Binding was typically seen along the cell
membranes, with long or short cell surface projections. In very few cells, granular uptake
of the glycoconjugate complexes into the cytoplasm could be visualized as a granular
fluorescence. WGA and ConA displayed the brightest fluorescence over the entire cell
membrane, while SNA and MAL exhibited moderate signals. The binding sites for
lectins LFA, AAA, and HP A, which showed low fluorescent intensities in flow analysis,
were also evident during microscopic evaluation except LFA, which gave a totally
negative binding to ML2. Due to the variations in capture conditions, we didn't
quantitate the staining intensity across cell lines. But above results confirmed that lectin
binding sites were almost exclusively on the cell surface.
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Figure 15 Cell surface carbohydrate expression analyzed by lectin cytochemistry.
PC3, N2, and ML2 cells were cultured on coverslips in 6-well plates. They were
stained with seven lectins with different carbohydrate specificities under the optimal
experiment conditions, fixed, and examined by cofocal microscopy.
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3.4 Discussion
In this aim we presented a study using a panel of lectins to characterize carbohydrate
expression patterns on PC3 and its metastatic variants. Our approach was first to
delineate the types and levels of carbohydrates using flow cytometry, and second to
localize specific carbohydrate residues with respect to the subcellular regions. Because
several factors such as blocking buffer, cell confluence, and specificity of lectin are
important considerations, an optimized protocol and suitable controls were included to
verify accurate data interpretation. For flow cytometry, counterstaining with an
impermeable nuclear stain, propidium iodide, and analyzing the fluorescence signals of
intact cells ensure that lectin binding is localized to the cell surface rather than
intracellular sites. For microscopic analysis, fixation performed after lectin binding
avoids the interference by various artifacts. By adopting these strategies, we have
evaluated the carbohydrate profiles on PCa cells and identified the specific carbohydrates
associated with PCa cell metastatic potentials.
Flow cytometry assessment of lectin binding revealed that cell surface carbohydrate
of PC3 and its variants is composed mainly of glycoconjugates containing a-mannose/aglucose, GlcNAc, and sialic acid as terminal saccharides, based on the high fluorescence
intensity values obtained from SNA, MAL, ConA, and WGA. These results were not
surprising since a-mannose/a-glucose and GlcNAc are present in all N-linked glycans,
and sialic acid is capped on both O- and N-linked glycans. Few residues of fucose (a-1, 6
linkage) and GalNAc were detected by flow cytometry, suggesting that these
carbohydrates were minor. But another possibility is that these sugars are present on the
core structure of glycans and masked by the terminal sialic acid

. In this case,
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neuraminidase treatment in combination of lectin flow cytometry can uncover more
binding sites and reveal their real abundance. It is noteworthy that lectin LFA
recognizing the same broad carbohydrate group as SNA, MAL, and WGA, however,
provided the very low fluorescent intensity. This apparent conflict in carbohydrate
identification can result from several factors affecting binding site access, which include
subtle differences in binding specificity within carbohydrate groups, as well as steric
configurations of lectins 225. In addition, the differences in fluorescence conjugated to
each lectin also influence lectin performance. Therefore, a diversity of glycoconjugates
containing unique sugar structures or sequences may be present on PCa cell surface, and
a wider spectrum of reliable lectins is necessary to properly characterize glycan
composition.
The most remarkable difference in cell surface glycan composition among three cell
lines was observed for a2-6 linked sialic acid. SNA binding was greatly decreased in
metastatic ML2 cells compared to non-metastatic N2 cells, suggesting a possible negative
role for the expression of a2, 6-linked sialic acid in metastasis. Sialic acids are ninecarbon monosaccharide typically terminating the out ends of cell surface glycan chains.
They are greatly diversified and more than 50 structural variations exist in nature m ' 2 3 4 .
Increases in cell surface sialylation are often linked to transformation and metastatic
phenotype. For instance, Yogeeswaran et al. reported the positive correlation between
the quantity of cell surface total sialic acid and metastatic ability of murine tumor cells
l i e

m

. Similarly, Sata et al. demonstrated an increased a2,6-sialylation on human colon
cancer cell membranes using the lectin SNA

. A high level of SNA reactivity was

found to be an independent parameter for poor prognosis in colorectal carcinoma 237.
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However, the opposite evidence was also documented. In a comparison of cell surface
glycoconjugates between a highly metastatic murine melanoma cell line B16-BL6 and its
positive sialidase transfectants, which showed markedly decreased metastasis in vivo and
invasiveness in vitro, lectin flow cytometry and lectin blotting didn't revealed significant
differences using either sialic acid- recognizing lectins or anti-sialyl Lex antibody 238. In
addition, Takano et al. described a WGA-resistant mutant of MDAY-D2 cell line (W16)
which showed a small increase in total sialic acid, but accompanied by slower growing
subcutaneous tumors and less liver metastasis 239. Therefore, some researcher pointed out
that metastatic ability does not correlate with the overall sialic acid content but only with
specific molecules such as pi integrin

'

. In another direction, there are observations

that specific sialic acid linkage correlated with the metastatic growth of cancer cells. For
example, analysis of B16 melanoma metastatic variants showed no difference in the total
levels of sialic acid, but the highly metastatic subline contained more oc2-3 sialylation in
SAoc2-3Gal|31-4GlcNAc oligosaccharides whereas low metastatic variants exhibited
i n

higher oc2-6 sialylation in SAa2-6Gaipi-4GlcNAc chains

. These results provide

supporting for our finding. Alternations in the distribution of sialic acid on cell surface
glycoconjugates in cancers might lead to changes in cell-cell adhesion by the exposing of
sub-terminal glycans, and/or inappropriate exposure of peptides. These changes may be
important in the process of cancer cell dissemination and may influence the ability of
cancer cells to adhere to endothelia at distant sites for the formation of metastasis 8 '

4

.

In summary, the study in Aim I showed that cell surface glycoconjugates of PC3 and
its variants are extensively sialylated and contain residues of a-mannose/a-glucose,
GlcNAc, fucose, and GalNAc in variable amounts. The differences in metastatic abilities
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of PC3 variants did correlate with the relative levels of a2-6 sialic acid on their surfaces.
Characterization of carbohydrate residues related to PCa metastasis represents the first
step in our investigation. Studies would move forward to specifically isolate and identify
the metastasis-associated cell surface sialoglycoproteins.
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CHAPTER IV
AIM II: TARGETED IDENTIFICATION OF METASTASIS-ASSOCIATED CELL
SURFACE SIALOGLYCOPROTEINS IN PROSTATE CANCER

4.1 Introduction
Altered cell surface glycosylation is a hallmark of cancer86. Specific glycan
structures have been identified on tumors and serve as diagnostic indicators of the
malignant and metastatic phenotype 86 ' 96 . Sialic acid (SA) residues are located on the
nonreducing terminus of the glycans on many cell surface glycoproteins where they play
a pivotal role in viral infection, leukocyte-endothelial cell adhesion, neuronal
development, immune cell activation, cancer metastasis, and many other normal and
pathological processes

41

. Our previous data from lectin staining demonstrated changes

of cell surface sialylation in a syngeneic prostate cancer cell model. Evidence from both
patient histochemical analysis and experimental tumor models also indicate that altered
sialylation of tumor cell surfaces is associated with a metastatic tumor phenotype " ' m .
As we described earlier, the surface sialylation changes have been reported reflecting the
amount, type, distribution, and bonding of sialic acids to adjacent molecules. For
instance, a positive correlation can be reported between the levels of cell surface
sialylation and metastatic ability of various experimental tumors 110'242. In addition, the
distribution of sialic acid on specific N- or O-linked oligosaccharides has been
demonstrated to alter the metastatic potential of cancer cell lines 113. In some cases tumor
development has been associated with overexpression of P1-6 branching that results in
increased number of Gaipi-4GlcNAc structures available for sialylation

117243

.

Therefore, exploring cell surface sialylation changes during tumor development and
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disease progression likely affords excellent opportunities to identify sensitive and specific
cancer biomarkers.
Elucidation of structural details of cell surface glycosylation by mass spectrometry
is hampered by the limited relative abundance of surface proteins compared to cytosolic
components, the complex and microheterogeneous nature of glycans, and the inherent
complexities of deciphering low energy carbohydrate fragmentation ions versus higher
energy peptide fragments in complex mixtures l 4. The type of mass spectrometer and
ionization energies to be used, and the complexity of the sample, are critical parameters
1 84.

for successful glycoprotein analysis

. In recent years, lectin- and antibody-based

affinity selection has been used with some success to purify glycoproteins/glycopeptides
with specific structures 169'170'244"246. Other approaches for glycopeptide characterization
arise from the exploitation of glycan physical and chemical reactivity. Larsen et al. took
advantage of the high affinity of titanium dioxide microcolumns toward SA residues to
isolate SA-containing peptides from serum under highly acidic conditions

. Two

similar approaches, involving hydrazide and boronic acid chemistry, capitalize on the cisdiols present in monosaccharides. Zhang et al. described the use of hydrazide chemistry
for the purification by directly coupling of glycoproteins to a solid support173'174.
Similarly, Sparbier et al. used boronic acid-functionalized beads to covalently capture
1 89

glycoproteins followed by elution with acid

. Although these methods are effective at

the enrichment and identification of broad classes of glycoproteins/glycopeptides, they
still lack the specificity and selectivity required for analysis of specific cell surface
glycoproteins that could serve as potential cancer biomarkers.
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In recent years, a growing area of chemical biology strives to probe glycans in living
systems by using bioorthogonal chemical reactions 248. These strategies, first described
by Bertozzi's group, modulate cell surface glycan structures by biosynthetic introduction
of unnatural sugars containing bioorthogonal chemical reporters, namely, functional
groups that possess unique reactivity orthogonal to those of natural biomolecules. The
process entails two steps. First, cells (or organisms) are incubated with a metabolic
monosaccharide precursor adorned with a unique functional group-the chemical reporter.
Once the chemical reporter is incorporated into the target glycans, it is treated in a second
step with a probe molecule bearing complementary bioorthogonal functionality

249 250

'

. In

principle, a chemical handle such as a ketone, azide, or thiol carried by unnatural
monosaccharides, can be metabolically incorporated into glycoproteins of cells or in
1 79

living organisms

. Azide has proven the most useful analogs owing to the small size,

metabolic stability, selective reactivity profile, and lack of reactivity with natural
179 94R

biofunctional structures

'

. In sialic acid biosynthesis, as shown in Figure 16, the

first committed step is the conversion of UDP-JV-acetylglucosamine (UDP-GlcNAc) to Nacetylmannosamine (ManNAc). Six subsequent steps, including five enzymatic
transformations and one transport step, produce a sialic acid residue appended to a
glycoprotein or glycolipid destined for cell surface or secretion 251. Interception of the
pathway with N-azidoacetyl-D-mannosamine (ManNAz), an unnatural analog of
ManNAc which competes with ManNAc in the sialic acid pathway, results in the cell
surface presentation of the azide-labeled glycans (Fig. 17A). The azide can be
•

chemically probed with phosphine via the Staudinger ligation

9 ^ 9 9^"3

'

, linear alkynes via

the Cu-catalyzed azide-alkyne cycloaddition (CuAAC) 254 , and with a variety of
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Figure 16 Schematic representation of sialic acid biosynthetic pathway in human
cells. Cytosolic glucose is converted in several steps into UDP-GlcNAc, which serves
as substrate for the bifunctional, rate-limiting, committed enzyme of sialic acid
biosynthesis, UDP-GlcNAc 2-epimerase (GNE) (a). The GNE catalytic activity
epimerizes UDP-GlcNAc to ManNAc, followed by the phosphorylation of ManNAc
to ManNAc-6-phosphate (MaNAc-6-P) by ManNAc 6-kinase (b). ManNAc-6-P is
then further converted into NeuAc (sialic acid) by the sequential action of sialic acid
9-phosphate synthase (c) and sialic acid 9-phosphatase (d). NeuAc is activated into
cytidine monophosphate-sialic acid (CMP-NeuAc) by CMP-sialic acid synthetase (e)
in the nucleus. Cytosolic CMP-NeuAc displays strong feedback inhibition (dotted
line) of GNE enzymatic activity by binding to its allosteric site, thereby contributing
to the tight regulation of intracellular sialic acid biosynthesis. CMP-NeuAc can
subsequently be transported into the Golgi complex (f) as a substrate for the
biosynthesis of sialyl-oligosaccharides by sialyltransferases (g). Adapted from
Yarema, K.J. etal. Nat Biotechnol 19, 553 (2001).
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Figure 17 Bioorthogonal chemical reactions for sialic acid. The process entails two
steps: metabolic labeling (A) and click chemistry (B). (A) Cells are fed with
peracetylated Af-azidoacetylmannosamine (Ac4ManNAz), an unnatural analog of JVacetylmannosamine (ManNAc). Ac4ManNAz penetrates the cell-surface membrane
easily due to the hydrophobic nature of the modified sugar. In the cytosol, it is
enzymatically deacetylated and then metabolically converted to the corresponding Nazidoacetyl sialic acid (SiaNAz), which is subsequently incorporated into
sialoglycoconjugates. (B) Glycoproteins selectively labeled with azide can be
detected with a fluorescent or biotinylated alkynes via the Cu-catalyzed azide-alkyne
cycloaddition or "click chemistry". In this reaction, an azide and a terminal alkyne
form a very stable triazole conjugate with the help of Cu (I) catalysis. Adapted from
Invitrogen website (www.invitrogen.com).
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cyclooctynes via the strain-promoted azide-alkyne cycloaddition 255. As a result, the
reporting sugars have been coupled with a plethora of tags such as FLAG peptides,
biotin, fluorescent or fluorogenic molecules, with the potential for visualization and
isolation. Each chemicalselective reaction has its own advantages and disadvantages.
The Staudinger ligation, which forms an amide bond between the azide and an esterderivatized phosphine, suffers from slow reaction kinetics and competing oxidation of the
phosphine reagents 249. By contrast, CuAAC, often referred to classical click chemistry,
offers high-sensitivity and fast rate by forming a triazole from an azide and a terminal
alkyne with the help of Cu (I) catalysis (Fig. 17B). But it may hurt live cells by Cu
cytotoxicity249. The successful application of bioorthogonal chemical reactions to label
and detect several types of cell surface glycans, such as sialiac acid

'

'

and mucin-

type O-linked glycans (GalNAC) 258>259, or cytosolic O-GlcNAcylated glycans (GlcNAc)
, has been reported by some groups. However, their application for proteomics is
limited to only O-GlcNAc modified cytosolic glycoproteins based on the Staudinger
ligation reaction 261 ' 262 .
In this study, we described a novel glycoproteomic identification strategy for the
selective detection, isolation and identification of cell surface sialoglycoproteins from
cultured cell lines. The method utilizes the sialic acid biosynthetic pathway for the
incorporation of monosaccarides bearing bioorthogonal functional handles
(tetraacetylated N-azidoacetyl-D-mannosamine, AC4ManNAz) into cellular sialic acid.
This reagent has primarily been used to label and visualize cell surface sialyl
glycoconjugates by Staudinger ligation

'

. We extended its application to detect cell

surface azide-modified sialoglycoproteins by click chemistry. To illustrate the potential
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of using this cell labeling procedure in biomarker discovery, we combined it with an MSbased proteomics approach as applied to our syngeneic metastatic PCa cell line model.

4.2 Materials and Methods
Materials — Complete™ protease inhibitors were purchased from Roche Applied
Sciences (Indianapolis, IN, USA), sequencing grade trypsin was from Promega (Madison,
WI, USA), and Immobilon-FL PDVF membrane was from Millipore (Billerica, MA,
USA). Protein-free blocking buffer and high capacity streptavidin agarose resin was
from Thermo Scientific (Rockford, IL, USA). Dulbecco's modified Eagle media
(DMEM), fetal bovine serum (FBS), antibiotics-antimycotic, Click-iT™ ManNAz
metabolic glycoprotein reagent, Click-iT™ Biotin Protein Analysis Detection Kit,
propidium iodide, fluorescein conjugated streptavidin (streptavidin-FITC), 4-12%
NuPAGE® Bis-Tris gels, and lithium dodecyl sulfate (LDS) buffer were from Invitrogen
(Carlsbad, CA, USA). 2 x Laemmli buffer, 7.5% Criterion® Tris-HCl Gel, and Bio-Safe
coomassie blue were from Bio-Rad (Hercules, CA, USA). The anti-P-actin mAb were
provided by BD PharMingen (San Diego, CA, USA). The streptavidin-IR 800 and goat
anti-mouse antibody conjugated to IR 800 were from Li-COR Bioscences (Lincoln, PA,
USA).

Cell Culture and Metabolic Labeling—PC3-N2 and PC3-ML2, as described in Aim I,
were cultured in DMEM medium supplemented with 10% FBS and 1% antibiotics at 37
°C with 5% CO2. For metabolic labeling, growth medium was replaced at 70% cell
confluence with complete DMEM medium containing various concentrations of an azido-
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modified sugar, tetraacetylated N-azidoacetyl-D- mannosamine (AC4ManNAz), or a
control sugar, N-acetyl-D-mannosamine (ManNAc), and cells were incubated for 1-3
days. Cells then were dissociated from the plastic surface by non-enzyme dissociation
buffer.

Flow Cytometric Analysis of Cell surface Sialic Acid Labeling—After metabolic
labeling, N2 and ML2 cells were harvested, washed with 0.1% FBS/PBS, and
resuspended (106 cells) in 100 ul click reaction solution with the indicated amount of
each component. The reaction was incubated at room temperature for 30 min, and then
cells were washed three times with 0.1% FBS/PBS. Cells were subsequently stained with
streptavidin-FITC (1 ug/sample in 100 ul 2% FBS/PBS) for 30 min at 4°C, and washed
with 2% FBS/PBS three times. Before subjecting to flow cytometric analysis, cells
incubated with 1 ug/ml propidium iodide in 500 ul 2% FBS/PBS at 4°C for 20 min. Data
was acquired by FACScalibur and analyzed by Flowjo software.

Confocal Microscopy Analysis of Cell surface Sialic Acid Labeling—N2 and ML2 cells
were seeded onto 6-well plates containing glass coverslips and cultured in 10%
FBS/DMEM. Growth medium was supplemented with 40 uM AC4ManNAz or ManNAc
for 3 days. Cells were washed with ice-cold PBS, fixed with 2% paraformaldehyde, and
then subjected to click reaction solution (25 ul biotin-alkyne, 2.5 ul CuS04, 2.5 ul and 5
ul for component D and E, 65 ul PBS). Subsequently, the fixed and labeled cells were
washed with PBS and stained with streptavidin-FITC (same as above) or streptavidin
Alexa fluor 488. To visualize intracellular sialylation, permeabilization with 0.5% Triton

X-100 was performed after fixation and before click reaction. PI or TO-PR03 was used
to stain nuclei. Finally coverslips were mounted to the slides with VectorShield medium,
and sealed with nail polish. Fluorescent images were examined and captured under a
confocal microscope.

Cell surface Sialoglycoprotein Labeling and Detection in Cell Extracts — N2 and ML2
cells were seeded in 15-cm dishes and treated with the optimized labeling conditions for
AC4ManNAz and ManNAc (20 uM for 1 day) in growth medium. After cells were
harvested with non-enzyme dissociation buffer, 5x10 cells were collected and washed
with 0.1% FBS/PBS. Subsequently, cells were subjected to click reaction solution as
described above. Upon conjugation, cell pellets were washed with ice-cold PBS twice to
remove unreacted reagents and then lysed in lysis buffer 1(1% NP-40, 150 mM NaCl,
protease inhibitor, 100 mM sodium phosphate, pH7.5) using a Dounce homogeniser.
The total cell lysate were further cleared by methanol-chloroform precipitation and
resolved in lysis buffer II (1% SDS, protease inhibitor, 50 mM Tris-HCl, pH 8.0).
Protein concentrations were measured using the BCA protein assay (Pierce). To detect
biotin-labeled sialoglycoproteins in cell extracts, 20 ag of labeled protein lysate was
resolved by SDS-PAGE. Electrophoresed proteins were transferred onto PVDF
membrane, blocked with Odyssey Blocking Buffer (Rockland Immunochemicals,
Gilbertsville, PA, USA), probed with streptavidin-IR 800, and visualized and quantified
using an Odyssey infrared imaging system.
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Sialoglycoprotein Capture — Streptavidin (SAv) beads were pretreated with protein-free
blocking buffer overnight at 4°C and washed five times with PBS. Cell lysate (2 mg) was
incubated with 100 ul beads in 0.3% NP-40/ PBS overnight at 4°C with a rotating shaker.
The captured glycoproteins were washed intensively with modified RIP A buffer (150
mM NaCl, 2% SDS, 1% NP-40, 1% Na Deoxycholate, 50 mM Tris-HCl, pH 7.5). Bound
material was eluted by boiling for 10 min in 100 ul 2 x Laemmli sample buffer. For
assessment of capture efficiency, 10 ul of the eluent, along with the input and flowthrough fractions were separated by SDS-PAGE and visualized with streptavidin-IR 800
as stated above.

ID Gel Electrophoresis andln-gel Digestion — Captured glycoproteins (45 ul) were
separated through on 1.0 mm 7.5% Tris-HCl polyacrylamide gels. Gels were stained
with Coomassie blue and imaged on a Typhoon 9410 (GE Healthcare, Piscataway, NJ,
USA). Twenty-seven equally-spaced gel pieces were excised from each lane, spanning
the full height of the gel (40-300 kDa). Individual gel pieces were destained with 25 mM
NH4HCO3 in 50% acetonitrile (ACN), reduced with 20 mM dithiothreitol in 25 mM
NH4HCO3 for 45 min at 56°C, and alkylated with 55 mM iodoacetamide in 25 mM
NH4HCO3 in the dark for 1 hr at room temperature. After washing, the gel pieces were
dehydrated with ACN and dried using a speed vac. Trypsin (12.5 ng/ul in 25 mM
NH4HCO3, pH 8.0) was added to each gel piece, and the gel pieces were allowed to swell
on ice for 1 hr. Excess trypsin was removed, replaced with 25 mM NH4HCO3, 10%
ACN, pH 8.0, and the mixture was incubated overnight at 37°C. The digest was collected
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and peptides were extracted with 50% ACN/5% formic acid twice. The combined
extracts were then dried using a Speed-Vac for subsequent LC-MS/MS analysis.

Whole Cell Extract and In-solution Digestion— For N2 and ML2 cell lysate experiments,
both cell lines were cultured in complete growth medium to 80% confluence. Cells were
then washed with PBS and the pellet resuspended in 160 ul dissolution buffer containing
100 mM NH4HCO3 and TFE (1:1 v/v). The samples were sonicated for 20 seconds three
times and incubated at 60°C for 1 h. The lysates were centrifuged to remove cell debris
and unbroken cells and the supernatant was collected. The protein concentration of the
samples was determined by BCA assay and normalized for each sample and before
reduction and alkylation with TCEP and iodoacetamide respectively. The concentration
of TFE was reduced to 5% by the addition of 1.4 ml 100 mM NH4HCO3. Trypsin was
added at a ratio of 1:50 protease to protein and the digestion proceeded at 37°C for 18 hrs
with constant mixing. After digestion the sample was dried down in a Speed-Vac,
desalted and lyophilized before LC-MS/MS analysis.

LC-MS/MS analysis — Digests were resuspended in 20 ul Buffer A (5% ACN, 0.1%
Formic Acid, 0.005% heptafluorobutyric acid) and 15 ul loaded onto a 12-cm x 0.075
mm fused silica capillary column packed with 5 uM diameter C-18 beads (The Nest
Group, Southboro, MA) using a programmed automatic injection. Peptides were eluted
over 80 minutes, by applying a 0-80% linear gradient of Buffer B (95% Acetonitrile,
0.1% Formic Acid, 0.005% HFBA) at a flow rate of 200 ul/min with a pre-column flow
splitter resulting in a final flow rate of -300 nl/min directly into the source. In some
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cases, the gradient was extended to 150 minutes to acquire more MS/MS spectra. A
LTQ™ Linear Ion Trap (ThermoFinnigan, San Jose, CA, USA) was run in an automated
collection mode with an instrument method composed of a single segment and five datadependent scan events with a full MS scan followed by four MS/MS scans of the highest
intensity ions. Normalized collision energy was set at 35, activation Q was 0.250 with
minimum full scan signal intensity at 1 x 10 with no minimum MS intensity specified.
Dynamic exclusion was turned on utilizing a three-minute repeat count of 2 with the mass
width set at 1.0 m/z. Sequence analysis was performed with MASCOT (Matrix Sciences,
London GB) using the SwissProt 57.1 database with a human taxonomy filter enabled.
The database searches were performed with fixed modification as carbamidomethy (Cys)
and variable modifications as oxidation (Met) and deamidation (Asn, Gin). Enzyme
specificity was selected to typsin. The spectra from 27 LTQ runs in each gel lane were
combined to search SwissProt. All the MS/MS spectra were manually inspected to verify
the validity of the database search results. False discovery rates were estimated to be
0.25% on the protein level by searching a decoy version of the SwissProt protein
database. The relative abundance of peptides was estimated by spectral counting.

Bioinformatic Analysis — Initial basic information on the structure of the identified
proteins was obtained through literature reports.

The ProteinID Finder (Proteome

Solutions) program was employed to extract such available information from the UniProt
database. Due to the limited annotation of protein glycosylation for most human proteins
and the shortage of subcellular location information for hypothetical proteins and
functionally uncharacterized proteins, we also subjected each identified protein to
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prediction algorithms based on protein sequence analysis. For protein glycosylation we
used NetNGlyc (http://www.cbs.dtu.dk/services/NetNGlyc/) to predict the possible
presence of the consensus NXS/T glycosylation motif. For subcellular location, all
identified proteins were analyzed with two transmembrane prediction algorithms SOSUI
(http://bp.nuap.nagoya-u.ac.ip/sosui/sosui)

and

TMHMM

(http://www.cbs.dtu.dk/services/TMHMM-2.Of) indicating hydrophobic protein sequence
regions. As a group, the total identified proteins were analyzed by Ingenuity Pathways
Analysis (IPA) software to determine their molecular function and interacting networks.
To generate the lists of cell surface glycoproteins uniquely expressed in N2 or ML2
cells, identified proteins were required to meet the following 3 criteria: (a) identified from
one cell line; (b) unique peptide > 1, and NXS/T motif > 1 or UniProt indicated N-linked
or O-linked glycosylation; and (c) transmembrane region > 1, or UniProt membrane
subcellular location.

4.3 Results

4.3.1 Methodology Overview.
Our strategy for interrogation of cell surface sialoglycoproteins using selective
chemical tagging followed by high-affinity enrichment and GeLC-MS/MS analysis is
summarized in Figure 18. The method consists of several steps: 1) metabolic labeling of
N2 and ML2 cells with the azide-containing mannose analogue, AC4ManNAz; 2)
chemoselective conjugation of azide sugars with a biotinylated alkyne capture reagent via
Cu (I) catalyzed click chemistry in live cells; 3) affinity enrichment of the labeled cell
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Figure 18 Outline of Aim II experimental work-flow. (1) metabolic labeling cells with
an unnatural mannose analogue, peracetylated azido-mannose (AC4ManNAz); (2)
chemoselective conjugation of azido sugars with a biotinylated alkyne capture reagent
via Cu (I) catalyzed click chemistry on live cells; (3) cell lysis; (4) streptavidin (SAv)
affinity purification; (5) sialoglycoproteins elution; (6) SDS-PAGE for protein
separation; (7) gel slice digestion and peptide release; (8) peptide analysis by LCMS/MS; (9) database search and protein identification; (10) bioinformatic analysis.
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surface sialylated proteins by streptavidin (SAv) capture; and 4) separation by ID gel
electrophoresis and identification by LC-MS/MS. When compared with other published
approaches, the theoretical advantage of our approach is the targeted selectivity for sialyl
glycosylated proteins on the cell surface.

4.3.2 Efficient Cell Surface Expression of AC4ManAz-Sialoglycoproteins.
A critical parameter in the proposed strategy is the efficient labeling and surface
expression of the azide-containing sialoglycoproteins. In order to evaluate the efficiency
of surface expression of azide-containing sialoglycoproteins, N2 and ML2 cells were
subjected to metabolic incorporation of AC4ManNAz, conjugated with biotin with the
click reaction, and subsequently stained with streptavidin-FITC to visualize the glycans
harboring the azide group. We conducted fluorescence-assisted flow cytometric analysis
of non-permeabilized cells for determining the efficiency of streptavidin-FITC labeling.
As quantified by flow cytometry (Fig. 19A), the AC4ManNAz-treated N2 and ML2 cells
displayed 80-100 fold greater FITC-specific fluorescence intensity than the control
ManNAc-treated and untreated cells. This result demonstrates that the azide moieties
were efficiently incorporated into cellular glycans. We next conducted confocal
microscopy analysis of streptavidin labeled cells to specifically assess the cellular
location of the azide-modified glycans. As seen in Figure 19B, prominent FITC staining
primarily at the cell membrane was observed when the cells were subjected to metabolic
incorporation of ManNAz. Consistent with flow cytometric data, confocal microscopic
analysis of cells treated with control ManNAc displayed much reduced staining,
confirming the labeling via azide-containing glycans is specific. Furthermore, there was

99

A
SOO

190

$0

S3

i
40

40

20

10"

B

10'

Str«>iavi*!»-rrrc

Str«p1**t«lin-FITC

Figure 19 Efficient and selective labeling of sialoglycoproteins on the cell surface. (A)
Flow cytometry analysis of N2 and ML2 cells treated with AC4ManNAz or ManNAc.
Nonpermeablized cells were biotin-tagged through click reaction, and stained with
streptavidin-FITC. PI negative gated FACS histogram showing three populations of
cells: control cells (red), cells treated with ManNAc (gray filled), and cells treated with
AC4ManNAz (green). (B) Confocal imaging of N2 and ML2 cells for visualization of
the tagged cell-surface sialoglycoproteins. Cells were treated with AC4ManNAz or
ManNAc, labeled with biotin-alkyne via click reaction and stained with streptavidinFITC (green) and PI (red) after fixation. Left panel: AC4ManNAz -treated cells; right
panel: ManNAc-treated control cells.

no evidence of cell surface labeling for the control groups.

4.3.3 Visualization of sialylated glycoconjugated inside the cell.
The biosynthesis of cell surface sialoglycoconjugates involves a lot of intracellular
processes (Fig. 16). After confirming that azide-modified sialyl glycans resided on the
cell surface, we were curious how the metabolism of AC4ManNAz looked inside the
cells. To this end, we changed cell staining protocol by permeabilizing cells before
performing click reaction. As demonstrated in Figure 20, treatment with ManNAz
resulted in membranous staining as well as a strong juxtanuclear pattern inside the cells
after clicking on the biotin-alkyne and staining with Alexa 488-conjugated streptavidin.
This pattern seems typical for the Glogi apparatus, but need verification in future study.
In contrast, cells incubating with natural ManNAc and following the same staining
procedures showed minimal fluorescence. These data documented that metabolic
labeling in combination with click reaction is an option to study intracellular sialyl
residues, likely those trafficking through the secretory pathway.

4.3.4 Optimization of metabolic labeling and click reaction.
We further optimized the azide labeling and click reaction to maximize cell
viability/vigor (Fig. 21). The first concern was whether exogenous sugar analogs
affected cell growth since cell toxicity may lead to global protein expression changes.
We measured cell proliferation with WST-1 reagent after cells were treated with
AC4ManNAz. As shown in Figure 21 A, the addition of 200 uM ManNAz greatly

Figure 20 Fluorescent imaging of intracellular sialylation. N2 and ML2 cells were
treated with AC4ManNAz or ManNAc, fixed and permeabilized. Then cells were
conjugated with biotin-alkyne via click reaction and stained with streptavidin Alexa
Fluor 488 (green) and TO-PR03 (blue). Fluorescent images were captured by cofocal
microscopy. Left panel: AC4ManNAz -treated cells; right panel: ManNAc-treated
control cells.
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Figure 21 Optimization of azide labeling and click reaction. (A) N2 cells were grown
in a 96-well plate with different doses of AC4ManNAz (0-200 uM) for up to 3 days.
Cell viability and proliferation was determined using WST-1 reagent. Each point was
tested in 6 replicates. (B) Dose-dependency of click reaction. ML2 cells were treated
with 40 uM AC4ManNAz for 3 days, probed with different volumes of click reagents,
and stained with streptavidin-FITC. The fluorescent intensity was monitored by flow
cytometry. (C) Dose curve of ManNAz labeling. ML2 cells were treated with 0-80
|aM AC4ManNAz for 3 days, probed with 25 \i\ biotin-alkyne. (D) Time course of
siaNAz glycoconjugate labeling. The optimized conditions of 20 uM AC4ManNAz
and reaction with 25 jal biotin-alkyne were used in a time course of incorporation and
detection in ML2 cells.
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inhibited cell growth up to 90% at day 1-3. However, ManNAz up to 50 uM had no or
minimal toxicity on cells. We next optimized the click reaction with the emphasis on the
dose of biotin-alkyne and copper. Both showed a dose-dependent increase of fluorescent
signal on the cell surface (Fig. 21B). Considering the potential toxicity of Cu (I), we
choose 25 ul of biotin-alkyne with 2.5 ul CUSO4 for future experiment because this
amount of reagents is enough to provide strong azide-alkyne reaction (50 fold greater
than control). Dose-curve of ManNAz labeling (Fig. 21C) showed a dose-dependent
increase of fluorescent signal up to 20 uM. After that the MFI decreased gradually.
However, the MFI of ManNAz treated cells was still with 24-fold at 80 uM greater than
control ManNAc. Time-course experiments (Fig. 2ID) revealed the saturation of
ManNAz incorporation within one day of incubation. Surprisingly, two-day incubation
led to a decrease of azide-bearing sialyl glycans on the cell surface whereas the level of
labeled glycans on day 3 restored to 55% level of day 1. This result might reflect turnover
status of cell surface sialyl glycans. Base on these cumulative results, the optimal
concentration and time of ManNAz for labeling sialyl glycans fall between 20-40 uM for
1 day and 25 ul of biotin-alkyne reagent.

4.3.5 Targeted Isolation of Cell surface Sialoglycoproteins.
Having demonstrated efficient labeling of cell surface glycoconjugates, we
continued with a general characterization of whole cell lysates of Biotin-labeled
glycoconjugates via SDS-PAGE separation and visualization by reaction with
streptavidin-IR800. Expression of P-actin was used for normalization. Overall
sialylation, as judged by streptavidin staining, was restricted to extracts from the
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ManNAz labeled cells (Fig. 22). In addition, there appeared to be greater sialylated
glycoproteins in the ML2 cell line when compared to the N2 cell line. We also observed
a major protein band that migrated just under 150 kDa and reacted with streptavidin.
These observations were consistent with the prior fluorescence imaging analyses in
demonstrating a specific uptake and labeling of the ManNAz treated cells.
We next examined the efficiency of our system for the enrichment of biotin-labeled
sialoglycoproteins. The streptavidin-derivatized beads were used to isolate targeted
proteins from N2 and ML2 cell lysates. The effect of various parameters on the binding
of non-glycoproteins versus glycoproteins to the streptavidin beads was evaluated by IDPAGE and streptavidin-FITC reaction to develop an optimized enrichment (Fig. 23). For
example, a variety of protein/streptavidin bead ratios were investigated for efficient
capture of the targeted glycoproteins (Fig. 24). The capture efficiency was analyzed by
ID-PAGE followed by silver staining as well as in-blot streptavidin-FITC detection.
Compared to the control groups, the number of bands and band intensity observed on
silver-staining gels and streptavidin-FITC blot for treated groups were increased
dramatically when the ratio of sample loading/SAv beads increased. 500 (a.g cell lysate
on 20 ul bead slurry resulted in the maximum isolation. Using the similar criteria, we
optimized other parameters including S Av beads preblocking buffer, binding buffer,
washing buffer, and elution buffers. We found that targeted glycoprotein binding to SAv
beads was optimal when the beads were preblocked with protein-free blocking buffer and
binding was performed at 4°C with a detergent (0.3% NP-40) present in the binding
buffer. Increasing detergent concentration to 4% in RIPA wash buffer significantly
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Figure 22 Detection of azide-tagged sialoglycoproteins in cell lysates. After N2 and
ML2 cells were metabolically labeled with ManNAc analogs and conjugated with
biotin-alkyne under the optimized conditions, the cells were lysed and total protein
was extracted as stated in Experimental procedures. Top panel: 20 ug of labeled
protein was resolved in 4-12% gel by SDS-PAGE and visualized by incubation with
streptavidin-IR 800. Reactive bands indicate sialylated glycoproteins. The same blot
was probed with |3-actin to verify equal protein loading. Bottom panel: the numbers
showed relative expression of sialylated glycoproteins after normalization with the
P-actin.
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Figure 23 Schematic representation of streptavidin (SAv) pull down assays. SAv
beads were pretreated with protein-free blocking buffer and washed with PBS. Then
they were incubated with cell lysate in 0.3% NP-40/ PBS. The bound proteins were
washed intensively with modified RIPA buffer to reduce nonspecific protein
binding. Precipitated proteins were eluted from SAv beads with Laemmli buffer by
boiling. The optimized steps such as SAv beads preblocking, protein/beads ratio,
binding buffer, wash buffer, and elution buffer, were highlighted in blue.
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Figure 24 The effect of different protein/beads ratios in S Av pull down assays. (A
and B) ML2 cells were metabolically labeled with ManNAc or its analogs (ManNAz),
conjugated with biotin-alkyne, and lysed. Different amounts of lysate (25-200 ug)
were subjected to SAv pull down assays by incubating with 20 ul SAv beads slurry.
The eluted proteins were resolved in 4-12% gel by SDS-PAGE and visualized by
silver staining. (C) Blot staining was performed on the same set of samples with
streptavidin-FITC to confirm the specific enrichment. The blot was scanned by
typhoon imager.
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reduced nonspecific protein binding. Efficient elution of bound glycoproteins was
achieved by boiling samples in 2 x laemmli buffer.
With the optimized streptavidin binding protocol, we added 2 mg whole cell lysates
to 100 ul bead slurry and performed pull down assay as described. The eluted
sialoglycoproteins were subjected to in-blot streptavidin-IR 800 detection. In both cell
types we observed a dramatic enrichment for biotin-conjugated proteins in the bound and
eluted fractions from the ManNAz-treated cells (Fig. 25). In contrast there was
dramatically reduced overall staining of biotin-labeled protein in the ManNAc-labeled
control cells. We again observed an intense signal at sub-150 kDa in eluted fractions
from cells treated with ManNAz, and absent or minimal signal in flow-through fractions
and eluents from the control group. These results demonstrate efficient capture and
enrichment of the azide-labeled proteins.

4.3.6 Identification of Surface Glycoproteins by Mass Spectrometry.
Since we were able to establish both efficient cell surface labeling and effective
isolation of sialoglycoproteins, we next performed a proof-of-principle experiment for the
application of this approach to the identification of sialoglycoproteins differentially
expressed between metastatic (ML2) and non-metastatic (N2) prostate cancer cell lines.
The cells were processed for metabolic labeling as described above, the tagged proteins
were enriched with SAv resins, and the eluted proteins were separated by SDS-PAGE
(Fig. 26) and analyzed by LC-MS/MS. In total, 536 non-redundant proteins were
identified (Fig. 27). This total derived from 324 proteins from the N2 line and 372
proteins from the ML2 line when metabolically labeled with ManNAz. In contrast the
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Figure 25 Efficient capture and enrichment of azide-tagged sialoglycoproteins.
Azide-tagged and biotin-conjugated sialoglycoproteins from the total lysate of N2
and ML2 cells were captured by streptavidin beads, separated in 7.5% gel and
visualized by streptavidin-IR 800. Shown are the results from 20 (j,g of post-click
lysate (N for neat), 5% of the flow through material that did not bind to the beads
(FT for flow through), and 5% of material captured from 2 mg of protein that bound
to beads (E for eluent).

Figure 26 Separation of proteins enriched by SAv pull down assays. Azide-tagged
and biotin-conjugated sialoglycoproteins from 2 mg total lysate of N2 and ML2
cells were enriched by streptavidin beads. The eluents were separated in 7.5% gel
and visualized by Coommassie blue staining. Twenty-seven equally-spaced gel
pieces spanning the full height of the gel (40-300 kD) were excised from each
lane, in-gel digested by trypsin, and analyzed by LC-MS/MS.
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Figure 27 Number of proteins identified in PC3 variants by LC-MS/MS. Venn
diagrams showed the overlap of proteins identified in N2_ManNAz group,
ML2_ManNAz group, and ManNAc_pool group which combined N2_ManNAc and
ML2_ManNAc groups. Proteins identified with significant peptide scores (p<0.05)
and expect scores (p<0.5), and at least one unique peptide were included in the
analysis.
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control cells lacking ManNAz yielded 132 proteins from the N2 line and 75 proteins from
the ML2 line. The total number of proteins identified using a sliding scale for unique
peptides is shown in Table 5. Approximately 60% of proteins identified contained two
or more unique peptide hits. Another purpose of setting up control groups was to
evaluate the extent of nonspecific interaction between the SAv resin and proteins in the
N2 and ML2 cell lystes. Although a pre-blocking step and high detergent resin wash was
carried out, a number of proteins were still identified in the control groups. Most of
these proteins were high abundant house-keeping proteins, such as actin, tubulins,
plectin-1, pyruvate carboxylase, pyruvate kinase and heat shock proteins. These proteins
were subtracted from the list of total proteins identified in the treated groups, further
narrowing the pool of proteins identified as cell surface molecules (216 proteins for N2
and 245 for ML2 group).
The enrichment efficiency for sialoglycoproteins is a key factor in characterization
of the utility of this methodology. As shown in Figure 25, the presence of
sialoglycoproteins was significantly enhanced after affinity chromatography by SAv
beads when compared to raw cell lysate or processed control extracts (ManNAc). The
specific enrichment of glycoproteins was further examined using the results from the
mass spectrometry characterization. As an initial analysis we determined the top 10 most
abundant glycoproteins from each cell line. The expression of these abundant proteins
were estimated and ranked by spectral counts and unique peptides as shown in Table 6A
and Table 6B. We then compared the relative abundance of these top 10 glycoproteins,
as derived from the sialoglycoprotein-targeted enrichment/isolation, between the
ManNAz and ManNAc labeled cells. Based upon this comparison, the top most
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Table 5 Total number of proteins identified for each experimental group
No. ofUniqpep

N2_ManNAz N2_ManNAc

ML2_ManNAz

ML2_ManNAc

1

128

64

153

44

2

62

24

72

10

3

29

13

47

6

4

23

11

22

8

>5

82

20

78

7

Total

324

132

372

75
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Table 6 Top 10 abundant glycoproteins identified in N2 and ML2 cells ranked by
unique peptides
A. N2 cells
N2_ManNAz
Spect_ Uniq_
counts
pep

N2_ManNAc
Spect_ Uniq
counts j e p

Acc#

Protdesc

1

075694

Nuclear pore complex protein Nupl55

21

17

4

3

2

P05556

Integrin beta-1

64

14

0

0

3

PI 4625

Endoplasmin

17

10

6

3

4

P26006

Integrin alpha-3

7

5

0

0

5

P17301

Integrin alpha-2

7

5

0

0

6

P15144

Aminopeptidase N

8

4

0

0

7

P02786

Transferrin receptor protein 1

6

4

3

2

8

P16144

Integrin beta-4

5

4

0

0

9

PI6070

CD44 antigen

6

3

0

0

Podocalyxin-like protein 1

6

3

0

0

No.

000592
10
* p=0.0015

B. ML2 cells
ML2_ManNAz
Spect_ Uniq_
counts
pep

ML2_ManNA
Spect_ Uniq
counts _pep

Acc#

Protdesc

1

P05556

Integrin beta-1

75

14

0

0

2

P15144

Aminopeptidase N

21

14

0

0

3

075694

Nuclear pore complex protein Nupl55

20

11

2

2

4

P17301

Integrin alpha-2

17

10

0

0

5

P16144

Integrin beta-4

10

8

0

0

6

P14625

Endoplasmin

16

7

2

1

7

P02786

Transferrin receptor protein 1

10

7

1

1

8

Q02413

Desmoglein-2

7

5

0

0

9

P35613

Basigin

11

4

0

0

Integrin alpha-3

9

4

0

0

No.

P26006
10
*P<0.0001
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abundant glycoproteins were present in far higher incidence from the ManNAz-treated
group. We observed a similar enrichment by the ManNAz group when we employed
emPIA score to rank the glycoproteins (Table 7A and Table 7B). These results clearly
demonstrate a substantial increase in the selective capture of the most abundant known
cellular glycoproteins via this methodology.
As a final assessment of the extent of enrichment of glycoproteins on the cell surface
and in the extracellular compartment, we compared our targeted method to a nonselective global proteomic analysis of whole cell lysates of the same cell model. Whole
cell lysates were prepared from N2 and ML2 cells, directly digested by trypsin and
subjected to LC-MS/MS as described in materials and methods. Three nano-LC-MS/MS
runs of tryptic digests showed that a significant number of total proteins (310 for N2 and
280 for ML2) could be detected utilizing this simple non-fractionation approach.
When analyzed for protein content, we found that 3.8% of the N2 proteome and 2.9% of
the ML2 proteome identified from this global approach were annotated as glycoproteins
using the UniProt database. In comparison, our targeted approach yielded 9.3% and
13.5% respectively (Fig. 28). Although the use of the UniProt database to determine if a
protein is glycosylated is notoriously under-representative, a four-fold enrichment was
revealed. Most striking was that 10 of 12 internal glycoproteins, found to be abundant
and identified in the targeted approach, were not identified in the whole cell proteome
approach.
We next conducted a comparative analysis of the two approaches with specific
emphasis on which cellular compartment the proteins were derived. Figure 29 displays
the UniProt-designated subcellular distribution of proteins identified from the whole cell
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Table 7 Top 10 abundant glycoproteins identified in N2 and ML2 cells ranked by
emPIA scores
A. N2 cells
Acc#

prot_desc

N2_ManNAz

N2_ManNAc

1

P05556

Integrin beta-1

2.71

0

2

P14625

Endoplasmin

1.01

0.22

3

075694

Nuclear pore complex protein Nupl55

0.75

0.13

4

P02786

Transferrin receptor protein 1

0.31

0.18

5

000592

Podocalyxin-like protein 1

0.28

0

6

P26006

Integrin alpha-3

0.26

0

7

PI6070

CD44 antigen

0.25

0

g

Q8TCT9

Minor histocompatibility antigen HI3

0.25

0

9

P17301

Integrin alpha-2

0.24

0

Aminopeptidase N

0.23

0

10 P15144
* p :=0.0319

B.] V1L2 cells
Acc#

prot_desc

ML2 ManNAz

ML2_ManNAc

1

P05556

Integrin beta-1

3.54

0

2

P35613

Basigin

0.91

0

3

P15144

Aminopeptidase N

0.88

0

4

P14625

Endoplasmin

0.73

0.1

5

075694

Nuclear pore complex protein Nupl55

0.51

0.06

6

P02786

Transferrin receptor protein 1

0.46

0.06

7

PI 6070

CD44 antigen

0.33

0

8

P27797

Calreticulin

0.33

0

9

Q9UNF1

Melanoma-associated antigen D2

0.24

0

10

Q13740

CD 166 antigen

0.23

0

P=0.00207
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Figure 28 Improved capture of known glycoproteins. Identified proteins were crossreferenced to the UniProt Knowledgebase for known glycoproteins. The percent of
total proteins that were matched to known glycoproteins is shown, in comparison to
that typically determined by global proteomic approaches.
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Figure 29 Subcellular location of identified proteins. The cellular location was
determined by cross-referencing the annotations from UniProtKB. Each protein was
designated with only one subcellular location. The protein classes are shown as
percent of total protein on the x axis. This analysis was conducted for both the
surface glycoprotein and global methodologies.
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proteome and the cell surface glycoproteome. We observed that about 13.2% of proteins
from the whole cell analysis of N2 and ML2 were classified as being extracellular and
membrane-bound. This result is consistent with studies using whole cell proteome
approaches to examine breast cancer cell and ovarian cancer cell proteome 263 ' 264 . In
contrast, our cell surface glycoprotein approach resulted in a proteome for N2 and ML2
with 25.9% and 29.8% of proteins being secreted or cell surface proteins, respectively.
These cell surface proteins include CD markers, cell surface receptors, membrane
transport, and cell adhesion proteins, such as CD44, CD 166, integrins, anexins, calnexin,
etc. In contrast, a small portion of proteins identified using our targeted approach was
classified as having ER/golgi location (~2%). A large portion of proteins were classified
as intracellular (>50%), either cytoplasm or nucleus, whereas 18 proteins for N2 and 13
proteins for ML2 remain unclassified. Sardana et al. conducted a cellular secretome
analysis in which the conditioned medium of three prostate cancer cell lines (including
PC3) were examined to identify just over 2000 proteins of which 12% were classified as
known extracellular proteins

. We observed 32 proteins that were in common with the

"secretome" study and that 85% of these were classified as membrane proteins (Fig. 30).
These findings underscore the value of our targeted strategy to capture and isolate cell
surface glycoproteins.

4.3.7 Selective Identification of Differentially Expressed Cell surface
Sialoglycoproteins
Currently less than 5% of proteins are annotated as glycoproteins in the UniProt
database

. This is a striking number when current estimates suggest that more than

Figure 30 Overlap of our cell surface proteins with prostate cancer secretome.
Venn diagram shows the overlap between cell surface proteins identified by our
targeted glycoproteomic approach and prostate cancer secretome reported by
Diamandis' group (Sardana, Ref.32). Since subcellular location classification in
prostate cancer secretome is redundant, the combination of 329 extracellular and
504 membraneous proteins results in total 730 proteins.
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50% of eukaryotic proteins are glycosylated. Therefore, we assembled the identified
proteins that could be attributed to membrane-bound and extracellular compartments by
UniProt database or predicted to contain transmembrane domains (SOSUI, TMHMM).
These were further analyzed for the prediction of sites for N-linked glycosylation
(NetNGlyc). Using these criteria, we compared the surface sialoglycoprotein expression
profiles of the metastatic variants. Ultimately, 36 and 44 cell surface glycoproteins were
uniquely identified in N2 and ML2 respectively. A list of these proteins, their UniProt
accession number, and molecular function is presented in Tables 8 and 9. Known
functions of these proteins include cell-cell or cell-matrix adhesion, protein transporter,
signaling in response to cytokines and growth factors, induction of coagulation, and
proteolysis.

5.3.8 Functional Mapping of Differential Expressed Sialoglycoproteins
Among those 36 differentially expressed cell surface glycoproteins in non-metastatic
N2 cells (Table 8), many proteins, such as, complement decay-accelerating factor
(CD55), Catenin beta-1 (CTNNB1), focal adhesion kinase 1 (PTK2), Myosin-VI
(MY06), A kinase anchor protein 1 (AKAP1) and symplekin (SYMPK), can positively
or negatively regulate apoptosis pathway (Fig. 31). The several proteins, including
catenin beta-1, catenin delta-l(CTNNDl), disks large homolog 5 (DLG5) and symplekin,
are involved in regulation of cell adhesion. The protein transports, Secl6A, Sec23B and
Sec24C are involved in transport from the endoplasmic reticulum to the Golgi apparatus.
Whereas coatomer subunit gamma (COPG) reversibly associates with Golgi non-clathrincoated vesicles and protein YIPF5 can assist transport between endoplasmic reticulum
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Table 8 Cell surface N-linked glycoproteins differentially expressed in N2 Cells
Spect_ Uniq
counts _pep

Acc#

Gene
Name

Protein Name

Predicted
MW (Da)

Observed
MW (Da)

Functions

4

4

P28290

SSFA2

Sperm-specific antigen
2

139,554

170,000

Actin binding

1

1

Q92667

AKAP1

98,250

120,000

Protein binding

1

1

Q00341

HDLBP

A kinase anchor
protein 1,
mitochondrial
Vigilin

141,995

140,000

Sterol metabolism

1

1

Q8NFJ5

GPRC5A

Retinoic acid-induced
protein 3

40,624

300,000

Signal transduction

4

3

Q9Y678

COPG

Coatomer subunit
gamma

98,967

90,000

ER-Golgi vesicle
transport

1

1

P50416

CPT1A

88,995

300,000

Lipid metabolism

2

2

P35222

CTNNB1

Carnitine Opalmitoyltransferase 1,
liver isoform
Catenin beta-1

86,069

90,000

Cell adhesion;
signal transduction

1

1

060716

CTNND1

Catenin delta-1

108,674

100,000

Cell adhesion;
signal transduction

1

1

P08174

CD55

Complement decayaccelerating factor

42,400

75,000

Complement
activation

3

3

Q7L2E3

DHX30

Putative ATPdependent RNA
helicase DHX30

134,938

130,000

ATP binding; ATPdependent helicase
activity

1

1

060610

DIAPH1

Protein diaphanous
homolog 1

141,942

140,000

Receptor binding

1

1

Q8TDM6

DLG5

Disks large homolog 5

215,446

240,000

Cell adhesion;
signal transduction

3

2

P50570

DNM2

Dynamin-2

98,345

95,000

Vesicular trafficking

1

1

Q9BW60

ELOVL1

Elongation of very
long chain fatty acids
protein 1

32,755

300,000

Fatty acid
biosynthesis

1

1

095864

FADS2

Fatty acid desaturase 2

52,340

300,000

Lipid metabolism

1

1

Q05397

PTK2

Focal adhesion kinase
1

119,956

120,000

Integrin-mediated
signaling pathways

11

Q92616

GCN1L1

Translational activator
GCN1

294,953

300,000

Translation activator

2

Q8TCT9

HM13

Minor
histocompatibility
antigen H13

41,747

300,000

Proteolysis; protein
binding
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Table 8 continued
Q86YT6

MIB1

E3 ubiquitin-protein
ligase MIB1

112,461

110,000

1

Q9UM54

MY06

Myosin-VI

150,965

150,000

4

Q5SRE5

NUP188

NucleoporinNUP188
homolog

198,369

220,000

1

075781

PALM

Paralemmin

42,221

60,000

Component of the
nuclear pore
complex (NPC)
Cell shape

1

000408

PDE2A

cGMP-dependent 3',5'cyclic
phosphodiesterase

107,360

50,000

Signal transduction

1

P13796

LCP1

Plastin-2

70,815

70,000

2

1

Q8TEM1

NUP210

Nuclear pore
membrane
glycoprotein 210

205,895

300,000

T-cell activation;
intracellular protein
transport
Protein transport

6

3

075400

PRPF40A

Pre-mRNA-processing
factor 40 homolog A

109,022

120,000

mRNA processing

1

1

Q63HN8

RNF213

RING finger protein
213

378,474

300,000

4

3

015027

SEC16A

Protein transport
protein Secl6A

234,855

250,000

Nucleosidetriphosphatase
activity
ER-Golgi transport

1

1

Q15437

SEC23B

Protein transport
protein Sec23B

87,393

80,000

ER-Golgi transport

2

2

P53992

SEC24C

Protein transport
protein Sec24C

119,779

1

1

P46977

STT3A

Dolichyldiphosphooligosacchar
ide~protein
glycosyltransferase
subunit STT3A

81,104

300,000

N-linked
glycosylation

1

1

Q92797

SYMPK

Symplekin

141,915

140,000

4

3

Q9NXF1

TEX 10

Testis-expressed
sequence 10 protein

106,349

90,000

Cell adhesion;
mRNA processing
Unknown

1

1

094901

UNC84A

Protein unc-84
homolog A

90,806

300,000

1

1

Q9H1C4

UNC93B1

Protein unc-93
homolog Bl

66,930

300,000

1

1

Q969M3

YIPF5

Protein YIPF5

28,370

40,000

2

120,000

Notch signal
pathway,
ubiquitination
regulation
Protein transport;
endocytosis

ER-Golgi transport

Protein binding;
cytoskeletal
anchoring
Immunity;
intracellular protein
transport
ER-Golgi transport
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Table 9 Cell surface N-linked glycoproteins differentially expressed in ML2 Cells
Spect Unk
Acc#
counts pep
1
P08195
1

SLC3A2

4F2 cell-surface
antigen heavy chain
(CD98)

1

1

P49748

ACADVL

3

2

095573

ACSL3

3

2

Q5T9A4

ATAD3B

11

4

P35613

5

3

1

Predicted
MW(Da)
58,023

Observed
MW(Da)
80,000

Very long-chain
specific acyl-CoA
dehydrogenase
Long-chain-fattyacid~CoA ligase 3

70,745

70,000

Cell growth; aminoacid transport;
carbohydrate
metabolism
Fatty acid metabolism

81,338

85,000

Fatty acid metabolism

73,098

70,000

ATP binding

BSG

ATPase family AAA
domain-containing
protein 3B
Basigin

42,573

Cell surface receptor

P27797

CALR

Calreticulin

48,283

50,00070,000
60,000

1

Q01518

CAP1

Adenylyl cyclaseassociated protein 1

52,222

60,000

1

1

Q96A33

CCDC47

Coiled-coil domaincontaining protein 47

56,123

65,000

4

2

Q9H5V8 CDCP1

CUB domaincontaining protein 1

94,241

130,000

2

2

P12109

COL6A1

Collagen alpha-1 (VI)
chain

109,602

130,000

Cell adhesion; tumor
progression and
metastasis
Cell adhesion

A8TX70

COL29A1

Collagen alpha-5(VI)
chain

291,796

120,000

Cell adhesion

Q15046

KARS

Lysyl-tRNA
synthetase

68,461

70,000

Protein biosynthesis

75,826

75,000

Protein transport;
mRNA transport

36,410

300,000

Lipid/steroid
biosynthesis
Cell adhesion

2

Gene Name

Q9BW27 NUP85

Protein Name

Functions

Molecular calcium
binding chaperone
Cell polarity
maintenance; signal
trasduction
Protein binding

Q9NZ01

TECR

Nuclear pore
complex protein
Nup85
Synaptic glycoprotein

Q02413

DSG1

Desmoglein-1

114,670

70,000

P06744

GPI

Glucose-6-phosphate
isomerase

63,335

65,000

Angiogenesis;
gluconeogenesis

A6NKF9 GPR89C

Putative protein
GPR89C

36,760

300,000

Unknown

P43304

Glycerol-3 -phosphate
dehydrogenase

81,296

80,000

Calcium ion binding

GPD2
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Tab!le 9 continued
2

1

A1L0T0

ILVBL

Acetolactate
synthase-like protein

68,452

70,000

1

1

Q14721

KCNB1

96,672

60,000

1

1

Q8TF66

LRRC15

Potassium voltagegated channel
subfamily B member
Leucine-rich repeatcontaining protein 15

Transferase activity;
magnesium ion
binding
Ion transport

65,268

75,000

Protein binding

1

1

P29966

MARCKS

Myristoylated
alanine-rich C-kinase
substrate

31,707

80,000

Substrate for protein
kinase C; binds
calmodulin, actin, and
synapsin

2

1

Q7Z434

MAVS

57,063

75,000

Innate immune
defense against viruses

1

1

Q8NHP6 M0SPD2

60,051

60,000

Unknown

1

1

Q6PIF6

MY07B

Mitochondrial
antiviral-signaling
protein
Motile sperm
domain-containing
protein 2
Myosin-Vllb

243,612

250,000

2

1

015118

NPC1

Niemann-Pick CI
protein

144,868

250,000

7

4

Q9UKX7 NUP50

Nucleoporin 50 kDa

50,512

60,000

Actin binding; motor
activity
Intracellular
trafficking of
cholesterol
Protein transport;
mRNA transport

1

1

Q6V1P9 DCHS2

Protocadherin-23

323,744

55,000

Cell adhesion

1

1

Q9H307 PNN

Pinin

81,679

130,000

8

6

P14923

JUP

Junction plakoglobin

82,434

85,000

Cell adhesion; mRNA
processmg
Junctional plaque
formation

1

1

Q15063

POSTN

Periostin

93,883

70,000

Cell adhesion.

4

3

PI 8031

PTPN1

50,505

55,000

Regulation of insulin
signal pathways

8

7

P46060

RANGAP1

Tyrosine-protein
phosphatase nonreceptor type 1
Ran GTPaseactivating protein 1

63,958

80,000

Signal transduction

1

1

Q9GZS1

POLR1E

54,441

55,000

rRNA transcription

3

3

P04843

RPN1

68,641

70,000

N-linked glycosylation

DNA-directed RNA
polymerase I subunit
RPA49
Dolichyldiphosphooligosacch
aride-protein
glycosyltransferase
subunit 1
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Table 9 continued
1

1

Q9Y265

1

1

Q96QD8 SLC38A2

1

1

Q9Y512

SAMM50

3

2

P35498

SCN1A

2

1

015269

SPTLC1

1

1

000186

STXBP3

7

4

094826

TOMM70A

3

1

Q15849

SLC14A2

1

1

P38606

ATP6V1A

RUVBL1

RuvB-like 1

50,538

60,000

Sodium-coupled
neutral amino acid
transporter 2
Sorting and assembly
machinery
component 50
Sodium channel
protein type 1 subunit
alpha
Serine
palmitoyltransferase

56,332

300,000

52,342

60,000

230,876

300,000

Mitochondrial outer
membrane translocase
complex assembly
Ion transport

53,281

50,000

Lipid metabolism

68,633

70,000

Vesicle docking in
exocytosis

68,096

75,000

102,213

70,000

Receptor for protein
import into
mitochondria
Urea transporter.

68,660

70,000

1

Syntaxin-binding
protein 3
Mitochondrial import
receptor subunit
TOM70
Urea transporter,
kidney
V-type proton
ATPase catalytic
subunit A

Cell cycle; cell
division; growth
regulation
Amino-acid transport

ATP synthesis coupled
proton transport
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Figure 31 Functional pathway analysis of glycoproteins unique to N2 cells. Ingenuity
Pathway Analysis (IPA) was employed to functionally map the cell-surface
glycoproteins unique to N2 cells. The network diagram shows the biological functions
that these glycoproteins are associated with, in the context of disease. Apoptosis
involved in tumor development has been listed as the top function, as reflected by the
number of glycoproteins (highlighted in blue) connected with it.

j

and Golgi. Other candidates are involved in different functions, such as T cell activation
(Plastin-2), N-oligosaccharyl transferase (dolichyl-diphosphooligosaccharide—protein
glycosyltransferase subunit STT3 A), mRNA and protein transporter (nucleoporin
NUP188 homolog and nuclear pore membrane glycoprotein 210), fatty acid betaoxidation (carnitine O-palmitoyltransferase 1, liver form), fatty acid biosynthetic process
(elongation of very long chain fatty acids protein 1), unsaturated fatty acid biosynthetic
process (fatty acid desaturase 2), and RNA splicing, mRNA processing (pre-mRNAprocessing factor 40 homolog A), etc.
Among those 44 differentially expressed cell surface glycoproteins in metastatic
ML2 cells (Table 9), a large number of proteins are involved in cell movement, cell-cell
signaling and interaction, and cellular growth and proliferation. There are 11 proteins
involved in cell movement (Fig. 32). Notably, 6 proteins, Basigin (BSG), Periostin
(POSTN) and Glucose-6-phosphate isomerase (GPI), Calreticulin (CALR), Leucine-rich
repeat-containing protein 15 (LRRC15), Myristoylated alanine-rich C-kinase substrate
(MARCKS), are involved in the invasion of tumor cell lines. Other 5 proteins, Junction
plakoglobin (JUP), Tyrosine-protein phosphatase non-receptor type 1 (PTPN1),
Niemann-Pick CI protein (NPC1), Sodium-coupled neutral amino acid transporter 2
(SLC38A2) and Adenylyl cyclase-associated protein 1 (CAP1), are involved in migration
or movement of eukaryotic cells, embryonic cells or cancer cells. Of above proteins,
SLC38A2, JUP, PTPN1, POSTN, CALR, BSG, and Pinin (PNN), CUB domaincontaining protein 1 (CDCP1), DNA-directed RNA polymerase I subunit RPA49
(POLR1E), Collagen alpha-1 (VI) chain (COL6A1), are involved in growth, colony
formation of eukaryotic cells, leukocyte, fibroblast or cancer cell lines. Other
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Figure 32 Functional pathway analysis of glycoproteins unique to ML2 cells.
Ingenuity Pathway Analysis (IPA) was employed to functionally map the cell-surface
glycoproteins unique to ML2 cells. The network diagram shows the biological
functions that these glycoproteins are associated with, in the context of disease. Cell
movement, invasion and migration have been listed as the top functions, as reflected
by the number of glycoproteins (highlighted in blue) connected with them.

glycoproteins differentially expressed in ML2 are associated with cell signaling
(Syntaxin-binding protein 3), cell assembly (Ran GTPase-activating protein 1), nuclear
protein export (Nucleoporin 50 kDa), innate immune defense against viruses
(Mitochondrial antiviral-signaling protein), et al. Interestingly, several proteins, Very
long-chain specific acyl-CoA dehydrogenase (ACADVL), Long-chain-fatty-acid—CoA
ligase 3 (ACSL3), Synaptic glycoprotein (TECR), Serine palmitoyltransferase 1
(SPTLC1) and Niemann-Pick CI protein, are involved in unique lipid/steroid
metabolism.

4.4 Discussion
Metastatic spread of cancer involves tumor cell extravasation and subsequent
invasion of surrounding tissue, all processes that are tightly regulated by cell surface
mechanisms 123'140. The identification of surface-accessible glycoproteins, which are
altered in the metastatic process, will reveal the underlying biological events that support
cancer metastasis, may facilitate the discovery of new biomarkers for cancer diagnosis,
prognosis, and help define new therapeutic targets. In this study, a novel surface
glycoprotein targeted strategy, based on metabolic labeling and click chemistry, was
developed for purification and characterization of sialoglycoproteins. Metabolic labeling
of glycans with sugar analogues and subsequent probe capture via Click chemistry have
been applied to cellular microscopy

. However, to our knowledge, our data is the first

to demonstrate its application to targeted proteomics.
Click chemistry specifically refers to a bioorthogonal ligation event between azide
and alkyne

. The position of azide-alkyne pair can be exchanged, that is, the same
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reaction can be carried out using the alkyne as the chemical reporter. Wong and
coworkers reversed the polarity of the reagents, using an alkynyl ManNAc derivative for
metabolic labeling of cultured cells and CuAAC-mediated reaction with an azidefunctionalized probe for imaging of sialylated glycoproteins

. The primary advantage

of Click chemistry over the Staudinger ligation is its faster rate, high-sensitivity, and
high-selectivity

. Our flow cytometry results and confocal images confirmed the high

selectivity/specificity of click chemistry for labeling cell surface sialoglycoconjugates. In
conjunction with LC-MS/MS, we applied this method to comparatively analyze the cell
surface sialoglycoproteome of non-metastatic (N2) and metastatic (ML2) prostate cancer
cell lines. Our findings reveal substantial changes in the abundance of proteins that have
previously been associated with metastatic spread of cancer and the discovery of some
new cell surface sialoglycoprotein with potential roles in metastasis. The enrichment for
surface glycoproteins demonstrated by this method provides proof of concept of the
utility of this approach in the discovery of sialic acid-containing glycoproteins of disease
significance.
Although many cellular proteins are glycosylated, they are rarely identified by
global proteomics approaches. Targeted labeling and enrichment of specific groups of
glycoproteins simplifies the complexity of a cellular proteome and serves to reduce the
dynamic range of protein expression. We demonstrate that the application of the
described method is effective for cell surface glycoprotein identification. A substantial
enrichment of cell surface glycoproteins of low abundance (based on spectral counts) was
observed. These included adhesion proteins implicated in cancer development such as
proocadherin-23 and CUB-domain containing protein 1, protein binding and signal
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transduction molecules such as leucine-rich repeat-containing protein 15 and focal
adhesion kinase 1.
Our approach resulted in a proteome that was enriched to approximately 29% for
cell surface or excreted proteins. This compares favorably with other proteomic
approaches using cell surface biotinylation and MudPIT analysis 264'268, in which cell
surface protein enrichment of ~30% was reported for human HT-1080 fibrosarcoma cell
line and human CaOV3, OVCAR3, and ES2 ovarian cancer cell lines. More recently, onbead tryptic digestion followed by the specific release of N-linked glycosylated peptides
via peptide-N-glycosidase F (PNGase F) and LC-MS/MS has been reported to
17^ 178 180

successfully identify N-linked glycopeptides

'

'

. Because the authors assumed

that all proteins identified by the approach were glycoproteins there was no report of
target efficiency. Aebersold and co-workers combined this system with the periodate
oxidation/hydrazide method for the specific analysis of the cell surface membrane
glycoproteome

. Although successful, this technology is still challenging due to a

potential for false positive identification that arises from the dependence on single
peptide analysis, 1 Da glycan shift and competition with natural Asn to Asp conversion.
To eliminate the false positive identification of the N-linked peptides, MS data
acquisition from more intense isotopic peaks and manual inspection of mass spectra are
required. Because N-linked glycosylation predominates in secreted and cell surface
proteins, we would suggest that combining a selective click chemistry approach as we
have described with this gel-free system for the analysis of the cell surface
glycoproteome would be a successful alternative strategy.
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The significant number of proteins annotated as nuclear or cytoplasmic that were
present among our cell surface sialoglycoproteome is noteworthy. To some extent,
occurrence of these predominantly intracellular proteins may be due to their high
abundance. Despite our efforts to optimize the labeling protocol and increase wash
stringency, some proteins classified as intracellular were still precipitated by the SAv
resin. High-salt (1.5M NaCl) and high-pH (0.1M Na2C03) buffers have been reported to
reduce such contamination and may reduce this background

'

. Another possible

reason for the contamination is limited cell death during the click reaction. Click reaction
requires copper as a catalyst, which is toxic to the cell

. Mammalian cells can survive

low concentrations (below 500 urn) of copper(I) for 1 hour 249. However, certain cell
death was still observed under our optimized click conditions. Fortunately, a new
generation click chemistry, called stain-promoted cycloaddition, has been developed and
has been shown to maximally preserve cell viability through bypassing the requirement
of copper 255 ' 271 . Bertozzi's group applied copper-free click chemistry for dynamic in
vivo imaging, claiming comparable kinetics to the copper-catalyzed reaction and speed
with no apparent toxicity 272. We have similarly observed identical labeling performance
and selectivity with much less cytotoxicity when cells were labeled with these copperfree reagents (data not shown). Improving cell viability could improve proteome
selectivity and would also allow for kinetic experiments post-reaction via click. Finally,
one must consider existing evidence for the occurrence of cytoplasmic proteins bound to
the extracellular membrane or exposed on the cell surface, particularly in aggressive
cancer cells

" . Thus, a portion of these "cytoplasmic" proteins may be glycosylated

and surface bound.

The cell surface glycoproteomics approach we describe can also be expanded to
other types of glycoprotein targets. For instance, in addition to increased sialylation,
other types of cancer-related glycosylation changes have been reported, such as increased
cell surface fucosylation, the addition of polygalactosamine units, higher-ordered
branching of N-linked glycans and mucin-type O-linked glycosylation. Currently, in
addition to tetraacelated N-azidoacetyl-D-mannosamine for sialic acid, several click pair
labeled molecules targeted for these cancer-related glycosylation alterations are
commercially available 250. For example, tetraacetyl fucose alkyne for fucosylate
proteins, tetraacelated N-azidoacetylgalactosamine for O-linked glycoproteins and
tetraacelated N-azidoacetylgluctosamine for O-GlcNAC-modified proteins are readily
available. In addition to cancer, this method is clearly also valuable for analysis of
glycosylation changes in immune deficiencies, hereditary disorders, and
neurodegenerative diseases.
In summary, we report a new glycoproteomic strategy for the analysis of specific
subclasses of cell surface glycoproteins. The approach combines selective metabolic
labeling of cell surface glycans, affinity purification of sialylated proteins, SDS-PAGE
separation, and subsequent LC-MS/MS for protein identification. A total of 80 proteins
differentally expressed between cell lines were uniquely identified, including many
integral plasma membrane glycoproteins that were not reported by previous proteomic
analyses. Given the importance of the cell surface glycoproteins for drug design,
biomarker discovery, and the regulation of cellular behaviors, the described protocol
would help expedite the discovery of new cancer biomarker and therapeutic targets in
diseases and delineation of signal transduction pathways.

CHAPTER V
Aim III: VERIFICATION OF EXPRESSION OF CELL-BASED BIOMARKERS IN
CLINICSAL SAMPLES

5.1 Introduction
Biomarker development is a multistep process entailing several essential
components: discovery, qualification, verification, research assay optimization, clinical
validation and commercialization

. With the application of high throughput genomic

and proteomic technologies to biological samples, a large number of biomarker
candidates with apparent differential expression have been reported as candidates for
novel cancer detection assays. However, few biomarkers have been validated and
successfully translated into clinical tests. This is in large part due to the incredible
mismatch between the large numbers of biomarker candidates and the paucity of reliable
assays, the cost, and the methods for validation studies

. Therefore, the critical step in

biomarker development lies in screening candidate lists to find those few with
performance characteristics that merit the effort and expense of full validation.
Biomarker prioritization is often performed on the basis of case biological knowledge,
the candidate's performance in discovery datasets, and reagent availability
Depending on the stringency of the discovery process and the number of candidates
identified, verification may be undertaken on only a subset of qualified candidates. In
verification, independent methods should be employed to provide better quantification of
candidates than is typical for discovery. In addition, verification, like validation, should
be performed on clinical samples that closely represent the population in which a final
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clinical test would be deployed

. The expected output of prioritization and verification

is a small number of highly credentialed candidates suitable for validation studies.
Having identified a panel of differentially expressed cell surface sialoglycoproteins
on a syngeneic metastatic PCa model by our targeted glycoproteomic approach in Aim II
study, we further prioritized and verified these metastasis-associated candidates for
additional rationales. Previously, we used an in vitro cell culture model system.
Cultured PCa cell lines are valuable tools to replicate the progression of the disease,
especially for complex metastatic events which are difficult to analyze in clinical
specimens. They are typically easy to establish, maintain and manipulate. However, cell
line model systems lack the biological complexity and variability that is inherent in real
patient samples

'

. In addition, the bottom-up strategy employed in our previous

study has the inherent weakness of unambiguously reassembling the peptide sequence
into their precursor proteins

. Therefore, it is necessary to verify their expression and

determine their clinical utility to warrant further investment in clinical validation studies.
Specifically, our prioritization was based on the following criteria: (1) candidates are
significantly differentially expressed in PCa metastatic variants; (2) bioinformatics
analysis indicates the cell surface location and potential function in cancer invasion and
metastasis; (3) literature mining shows an inferred role in cancer progression; (4) specific
antibodies are available since the immunoassays remain the gold standard for ultimate
clinical application of validated biomarkers. Using this criteria, we selected two
glycoprotein candidates from our list, CUB domain containing protein 1 (CDCP1) and
basigin, for downstream experiments (Fig. 33). Here we present the important findings
for CDCP1 glycoprotein.

Candidate biomarkers

Clinical samples:

Cell models:

r
Western blot
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Figure 33 The work-flow of verification of cell-based biomarkers. After candidate
glycoproteins are identified, we prioritize them and confirm the differential expression
in our cell line models using immunoassays. We also evaluate their expression in
clinical samples including PCa tissues and Expression Prostate Secretion (EPS) urines
with different aggressiveness.

CDCP1 is one of the candidates that were preferentially expressed by the highly
metastatic ML2 cells. CDCP1 is a type I single transmembrane protein also known as
substractive immunization associated 135 kDa (SIMA135) 280, gpl40 281, and
989

transmembrane and associated with Src kinases (Trask)

, and has been assigned the

cluster of differentiation (CD) designation CD318 283. Physiologically, CDCP1 is
expressed by stem or progenitor cells in the hematopoietic, mesenchymal, and neural
984. 98S

tissues

'

98fi

. It is also overexpressed in a number of solid tumors including breast

987 988

colon

'

980

, kidney

•

, pancreatic

900

,

901

, and lung cancers

. To date, its biological

function has not been well defined. Some experimental data support the role of CDCP1
909 90^

in cancer progression

'

9QH

, ECM degradation

, anchorage-independent signaling in

epithelial cells 294, and cancer cell resistance to anoikis 292, a form of apoptosis triggered
by the loss of cell survival signals generated from the interaction of cells with the
extracellular matrix. In PCa, although the potential of CDCP1 as a therapeutic target as
cancer treatment has been evaluated by an anti-CDCPl monoclonal antibody generated
90S

from a phage display combinatorial antibody library

, its expression and potential

clinical significance have not been systematically studied.
In Aim III, we comprehensively examined CDCP1 protein expression in a battery of
prostate cancer cell lines and clinical samples by applying multiple immuno-based
methods. We also characterized the glycosylation status of CDCP1 by employing a
series of glycosidases and glycosylation inhibitors. Importantly, we evaluated the
potential clinical significance of CDCP1 expression in PCa patient samples, including
surgical PCa tissues and Expressed Prostatic Secretion (EPS) urine fluids. Overall, our
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studies suggest that CDCP1 is dysregulated in prostate cancer and it might be a useful
diagnostic marker and therapeutic target for PCa patients.

5.2 Materials and Methods
Antibodies and Reagents — The following CDCP1 -specific antibodies were used in the
study: mAb 41-2, generated by subtractive immunization with a nonmetastatic population
versus metastatic population of epidermoid HEp-3 carcinoma

, and kindly provided by

Dr James P. Quigley (The Scripps Research Institute, CA, USA); rabbit antibody
CS4115, generated against the COOH-terminal peptide of CDCP1 (Cell Signaling,
Danvers, MA, USA); and goat antibody AF2666 recognizing the extracellular domain of
CDCP1 (R&D Systems, Minneapolis, MN, USA). Murine anti-P-actin (#612656) and
anti-mAb (#610524) were provided by BD PharMingen (San Diego, CA, USA). Murine
anti-Golgi 58 kD protein (ab27043) was purchased from Abeam (Cambridge, MA, USA).
IRDye 700 or IRDye 800 conjugated secondary reagents and Alexa Fluor 488 or Alexa
Fluor 594 conjugated secondary reagents were from Li-COR Bioscences (Lincoln, PA,
USA) and Invitrogen (Carlsbad, CA, USA), respectively. Control immunoglobulins
(IgGs) were from Vector lab (Burlingame, CA, USA). Complete™ protease inhibitor
cocktail and Halt™ protease inhibitor cocktail were from Roche Applied Sciences
(Indianapolis, IN, USA) and Pierce (Rockford, IL, USA). PNGase F, Neuraminidase,
and Endoglycosidase H were from New England Biolabs (Beverly, MA, USA). High
capacity streptavidin agarose resin and protein A/G PLUS-agarose were from Thermo
Scientific (Rockford, IL, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Dulbecco's modified Eagle media (DMEM) and fetal bovine serum (FBS) were from

Invitrogen. Antibiotics-antimycotic, Click-iT

ManNAz metabolic glycoprotein

reagent, Click-iT™ Biotin Protein Analysis Detection Kit, propidium iodide, TO-PR03,
4-12% NuPAGE® Bis-Tris gels, and lithium dodecyl sulfate (LDS) buffer were from
Invitrogen. 2 x Laemmli buffer, 7.5% Criterion® Tris-HCl Gel, Precision protein
standards, and Bio-Safe coomassie blue were from Bio-Rad (Hercules, CA, USA). All
other chemicals were from Sigma (St. Louis, MO, USA).

Cell Lines — Human prostate bone metastasis PC3, prostate carcinoma lymph node
metastasis LNCaP, prostate carcinoma brain metastasis DU145, and prostate carcinoma
xenograft 22Rvl cell lines were obtained from the American Type Culture Collection
(ATCC). PC3 two sublines denoted PC3-N2 (non-metastatic) and PC3-ML2 (highly
metastatic) were selected based on differential invasiveness and ability to form metastatic
tumors in SCID mice as described

and kindly provided to us by Dr. Stearns' group at

Drexel University. The lineage-related LNCaP sublines C4, C4-2 and C4-2B were
resulted from passage and hormone manipulation of LNCaP cells in vivo. They mimic
the progression of PCa from androgen sensitive (LNCaP and C4) to androgen refractory
(C4-2 and C4-2B), as well as the increasingly malignant phenotype from primary tumor
(C4-2) to bone metastases (C4-2B) in a nude mouse host. These cells were developed by
9QA 9Q7

Dr. Chung's group

'

and provided to us via ViroMed Labs. HPV-18 immortalized

prostate epithelial cell line RWPE-1 retains some "normal" cell attributes such as
responsive to growth factors and androgen. The cells were exposed to mutagen and
sublines WPE1-NB14 and WPE1-NB26 were derived with variable phenotype. The
WPE1-NB14 and NB26 lines are both anchorage independent but differ in their
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invasiveness. The WPE1-NB14 is moderatlye invasive in vitro wheras NK26 has a high
invasive ability. These sublines were developed by Dr.Williams' group at the University
of Michigan

and purchased from ATCC. Another prostate carcinoma lymph node

metastasis PacMetUTl cell line 2 " was obtained from the University of Texas Health
Science Center at San Antonio. All of the cells were cultured in the growth medium and
passaged according to the developer's and manufacturer's instructions.

Expressed Prostatic Secretion (EPS) Urine Sample Preparation— EPS Urine samples
were collected from men reporting to the clinic for a prostate biopsy procedure at the
Urology of Virginia, Sentara Medical Group and Eastern Virginia Medical School
between 2007 and 2009, under the informed consent and Institutional Review Board
approved protocols as described 30°. Briefly, following a gentle prostate massage during
a digital rectal examination (DRE), the first voided urine (10-20 ml) containing the EPS
was obtained from each individual. Then, they were centrifuged to remove the cell
pellet/sediment, and the supernatant was aliquoted and stored at -80°C. In this study,
individual EPS urine sample pools representative of non-cancer (n=15), low-grade PCa
(n=16), and high-grade PCa (n=14) conditions were compiled. Non-cancer cases were
defined as being biopsy negative for cancer, low-grade PCa samples were exclusively a
Gleason grade of 6 (3+3), and high-grade PCa samples were with a Gleason score of 8
and above, predominantly 9 or 10. Each pool was concentrated to ~200 fold using an
Amicon Ultra spin filter (10 kDa and 3 kDa cutoff; Millipore) and the aliquots were
stored at -80°C. Protein concentration was measured by Bradford assay.
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Flow Cytometry Analysis — Confluent cultures of N2 and ML2 cells were harvested
from the culture dishes by non-enzyme dissociation buffer, washed with 2% FBS in PBS,
and incubated with mouse-anti-CDCPl mAb 41-2 antibody (6 jag/ml) for 1 h at 4°C.
After two washes, cells were incubated with Alexa Fluor 488-conjugated goat-anti-mouse
antibody (2 (J-g/ml) for 30 min at 4°C. Before subjected to flow cytometry analysis, cells
were treated with propidium iodide (1 ug/ml) in 500 ul 2% FBS in PBS for 20 min at
4°C. Cells stained without the primary antibody were used as negative controls. Data
was acquired by FACScalibur and analyzed by Flowjo software.

Immunofluorescence Staining of Cultured Cell Lines — Cells were seeded onto 6-well
plates containing glass coverslips and cultured in growth medium to 80% confluence.
They were washed with ice-cold PBS and fixed in 4% paraformaldehyde for 15 min at
room temperature. For intracellular staining, the cells were permeabilized with 0.5%
Triton X-100 in PBS for 10 min at room temperature or ice-cold 100% methanol for 10
min at -20°C. Cells were subsequently washed twice with PBS, blocked with 3% BSA in
PBS for 1 h at room temperature. The cells were then incubated with mouse anti-CDCPl
mAb 41-2 (6 ug/ml) or rabbit-anti-CDCPl CS4115 (1:100 dilution) polycolonal
antibodies in the blocking buffer overnight at 4°C. After three washes, the cells were
incubated with Alexa Fluor 488 or 594-conjugated secondary antibodies (2 ug/ml, goat
anti-mouse or goat anti-rabbit IgG, respectively) in the blocking buffer for 1 h at room
temperature. Nuclei were stained with TO-PR03. For double staining with click
labeling, cells were grown in medium supplemented with 20 uM AC4ManNAz or
ManNAc for 2 days, fixed as above, subjected to click reaction solution (25 ul biotin-
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alkyne, 5 ul CuS04, 5 ul and 10 ul for component D and E, 65 ul PBS, total 100 fal) for
30 min at room temperature. Cells were then permeablized and incubated with antiCDCP1 antibodies as above. The next day, cells were stained with Alexa Fluor 488conjugated streptavidin (2 ug/ml) and Alexa Fluor 594-conjugated CDCP1 secondary
antibody for 1 h at room temperature. For double staining with the ER and Golgi
markers, cells were fixed and permeabilized as above, incubated with mouse-anticalnexin (2.5 ug/ml) or anti-Golgi 58kDa protein (5 |ag/ml) antibodies, and rabbit-antiCDCP1 CS4115 (1:100 dilution) overnight at 4°C. The following day, cells were stained
with Alexa Fluor 488 or 594-conjugated secondary antibodies as above. The cells were
finally washed twice, mounted to the slides with VectorShield medium (Vector Labs,
Burlingame, CA, USA), and sealed with nail polish. Cells treated in a similar way but in
the absence of primary antibodies were included as negative controls. Labeled cells were
visualized and photographed using a Zeiss LSM510 META confocal imaging system at
the appropriate excitation/emission wavelengths (Carl Zeiss, Thornwood, NY, USA).

Tissue Samples and Immunofluorescence Staining — O.C.T.-embedded frozen PCa
tissues from patients who underwent radical prostatectomy were obtained from our
Virginia Prostate Center. Cryosectioning was done on a Microm HM 505E cryostat at
-20°C. A serial cryosection (6 urn) was stained with Hematoxylin and Eosin (H&E) as a
guide and analyzed by a pathologist to determine tissue morphology. Two additional
serial sections were mounted on Superfrost microscope slides and used for
immunofluorecence staining. Tissue sections were fixed immediately after cutting in 4%
paraformaldehyde in PBS for 15 min, and permeabilized with 0.5% Triton X-100 in PBS
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for 10 min. They were then blocked with 3% BSA in PBS for 1 h and incubated with
mouse-anti-CDCPl mAb 41-2 antibody (6 ug/ml) overnight at 4°C. After three washes,
the cells were incubated with Alexa Fluor 488-conjugated secondary goat-anti-mouse
antibody (2 fig/ml) in the blocking buffer for 1 h at room temperature. Nuclei were
stained with propidium iodide (PI) (0.1 |J.g/ml) for 3 min before mounting and sealing.
An adjacent section treated similarly but in the absence of primary antibody was used as
the negative control. Slides were viewed and imaged by an Olympus BX51 fluorescent
microscope fitted with a DP70 digital camera and a Zeiss LSM510 META confocal
imaging system.

Deglycosylation Assays — To elucidate glycan components of CDCP1, enzymatic
deglycosylation experiments were performed. Before PNGase F and Endo H treatment,
cell lysates (20 ag) from PC3, N2, and ML2 cells were denatured and reduced for 10 min
at 100°C in 0.5% SDS and 1% 2-mercaptoethanol. For PNGase F digestions, samples
were adjusted to 1 % Nonidet P 40 and 50 mM sodium phosphate, pH 7.5, and then
incubated with PNGase F (1,000 NEB units) overnight at 37°C. For Endo H digestions,
samples were adjusted to 50 mM sodium citrate, pH 5.5. After addition of Endo H (1,000
NEB units), the mixtures were incubated overnight at 37°C. Neuraminidase reactions
were incubated overnight at 37°C in 50 mM sodium acetate, pH 6.0 and contained 50
NEB units neuraminidase per 20 ug of protein. Fetuin was used as the positive controls
for PNFase F, Endo H, and neuraminidase deglycosylation. For drug treatment, nearconfluent cells were washed twice with PBS and cultivated for 23 h in fresh culture
media in the absence or presence of 5 ug/ml tunicamycin or 1 ug/ml swainsonine. Cells
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were then washed twice before addition of M-PER lysis buffer containing lx complete
protease inhibitor. The cell lysates were collected with a rubber scraper, passed through
26-gauge needles, and sonicated by 3 times for 10 seconds. The whole cell lysates were
centrifuged at 14,000g for 15 min to remove cell debris and unbroken cells. The
supernatant was saved and protein concentration was tested by the BCA protein assay kit.

Western blot analysis — Whole cell lysates were collected in the M-PER lysis buffer
containing lx protease inhibitor cocktail. Protein concentrations were measured by the
BCA protein assay. Cell lysates, streptavidin pull down fractions, and serum-free
conditioned media were separated by electrophoresis through 4-12% or 7.5% SDS-PAGE
and then transferred to Immobilon-FL PDVF membranes (Millipore, Billerica, MA,
USA). Membranes were blocked in LiCor blocking buffer (Rockland Immunochemicals,
Gilbertsville, PA, USA) diluted with PBS (1:1) and then incubated with anti-CDCPl
primary antibodies (CS4115, 1:1000; AF2666, 0.2 ug/ml) overnight at 4°C. Following
extensive washing, membranes were incubated with species-specific IRDye700 or 800conjugated secondary antibodies (goat anti-rabbit, 1:15,000; donkey anti-goat, 1:15,000)
for 1 h at room temperature, and visualized with a LiCor Odyssey infrared imager (LiCor,
Lincoln, NE, USA). Consistent protein loading was determined by reprobing membranes
stripped in Restore Western blot stripping buffer with anti-actin antibody (0.05 ug/ml).

5.3 Results
5.3.1 Identification of CDCP1 in ML2 Cell surface Sialoglycoprotein Enriched
Fraction

Having combined metabolic labeling and click chemistry with LC-MS/MS, we
successfully identified a panel of cell surface sialoglycoproteins whose expression was
differential between metastatic (ML2) and nonmetastatic (N2) human prostate cancer
cells. CDCP1 is one of the candidates that were identified only from metastatic ML2
cells. Here we present the details about how CDCP1 was confidently identified by this
technique. After using the streptavidin pull down assay in Aim II, we saw an intense
signal at sub-150 kDa in eluted fractions from cells treated with ManNAz, which was
absent in flow-through fractions and eluents from the control group (Fig. 25).
Specifically, in-blot streptavidin IR-800 detected a higher intensity of this area in the
ML2 eluent than that of the N2 eluent (Fig. 34A, SAvB). The corresponding bands from
a Coomassie stained gel (Fig. 34A, CB) were excised and analyzed by LC-MS/MS.
Three unique peptides from the 135-kDa band of ML2 eluent were determined by mass
spectrometry to be the recently identified membrane protein CDCP1 (Fig. 34A). The
positions of these peptides in the sequence of CDCP1 were designated in Figure 34B.
They spanned the amino acids within intracellular carboxy terminus (peptide 3:700-718),
extracellular CUB1 (peptide 1:280-297) and CUB3 domains (peptide 2: 582-593).
Figure 34C showed the fragmentation pattern of nanoelectrospray ionization MS/MS of
the doubly charged (m/z 910.3) tryptic peptide, which corresponded to the C-terminal
tryptic fragment of human CDCP1. There was no CDCP1 identified in N2 or the control
fractions, although the overall protein pattern and content was indistinguishable for N2
and ML2 eluents (Fig. 34A, CB).

147

CB

SAvB
N2

ML2

N2

ML2

250 Peptide 1: R.VEYYIPGSTTNPEVFK.L
Peptide 2: R.OQVACLTFFKE
Peptide 3: K.GPAVGIYNGNINTEMPR.Q

s-ga&as

m

B
"N'^WN

Signal
Peptide
(1-29)

""N I " • N " " * " *

CUB1
(221-348)
Peptkk-1
(280-297)

""N

«"NS»N

CUB2
(417-544)

"'N «»N

CUm TM CytoplwnicDoiMln
(345-660)
(687-836)
Peptide-2
(382-393)

Peptide^
(700-718)

Figure 34A-B Identification of CDCP1 in ML2 cell surface sialoglycoprotein enriched
fraction. (A) N2 and ML2 cells were metabolically treated with AC^ManNAz and
conjugated with biotin-alkyne on live cells via click reaction. The total cell lysate was
extracted and pulled down with streptavidin resins. Aliquots of the purified
sialoglycoproteins were examined by in-blot streptavidin-IR 800 (SAvB) detection,
and the remaining samples were stained with Bio-Safe coomassie blue (CB). Three
tryptic peptide fragments determined by LC-MS/MS (peptides 1 to 3) were indentified
within the sequence of CDCP1. (B) Schematic representation of human CDCP1
structural features including N-terminal signal peptide, 3 extracellular CUB-like
domains, 14 potential N-glycosylation sites, transmembrane domain, and intracellular
cytoplasmic domain. Dark boxes indicate the positions of tryptic peptides identified by
LC-MS/MS.
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Figure 34C Identification of CDCP1 in ML2 cell-surface sialoglycoprotein enriched
fraction. (C) Representative mass spectra of tryptic CDCP1 digestion. Top panel: MS
spectrum of the CDCP1 tryptic peptides; arrow indicates ion at m/z= 910.31 (2+)
selected for MS/MS. Low panel: MS/MS spectrum of the peptide
K.GPAVGIYNGNINTEMPR.Q, annotated using the y-ions series.
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5.3.2 CDCP1 Structural Features
The schematic representation of human CDCP1 structure features was included in
Figure 34B. Consistent with a predicted cell surface protein, CDCP1 contains a signal
peptide at position 1-29, an extracellular domain at 30-665, a transmembrane domain at
666-686, and cytoplasmic domains at 687-836. It was reported that the extracelluar
domain harbors three regions with low homology to complement protein subcomponents
Clr/Cls, urchin embryonic growth factor, and bone morphogenetic protein 1 (CUB)
domains, which could be involved in proteinrprotein and protein:carbohydrate
interactions

. Importantly, there are 14 consensus N-glycosylation sites predicted in

the extracellular part, as well as a palmitylation motif and five tyrosine residues present
in the intracelluar domain, indicating the potential function of CDCP1 in outside-in signal
transduction 283. The predicted mass for full length CDCP1 is 92.9 kDa and 90.1 kDa for
mature CDCP1 after signal peptide cleavage. However, the apparent molecular weight in
Western blot is 135-140 kDa indicating extensive glycosylation 280. UniProtKB database
suggests that CDCP1 may have two truncated isoforms: CDCP2 (73 kDa) which is
missing 187 amino acids from its N-terminal and CDCP3 (34 kDa) that lacks 502 amino
acids from its C-terminal and is a secreted form. To date, there has been no evidence
about the presence of these two isoforms.

5.3.3 CDCP1 Expression in Prostate Cell Lines
To verify our proteomic results, we compared CDCP1 levels in cell surface
glycoprotein enriched fractions and whole cell lysates by Western blot. N2 and ML2
cells were metabolically labeled, conjugated with biotin-alkyne, and lysed as described
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above. An equal volume of streptavidin pull down eluents was resolved by SDS-PAGE
and detected by a rabbit polyclonal antibody generated against peptides near the Cterminus. Consistent with the observed LC-MS/MS differential of CDCP1 between PC3
variants, Western blot analysis of the cell surface glycoprotein pool demonstrated that
CDCP1 levels were ~3.4-fold greater on the surface of ML2 compared with N2 cells
(Fig. 35A). The level of CDCP1 (135 kDa) in ML2 total cell lysate was also higher (1.5fold) than N2 lysate, albeit not as dramatically as in the surface fraction (Fig. 35B).
Besides 135 kDa full-length CDCP1, N2 and ML2 cells also manifested another
truncated (70 kDa) species, a proteolysis product of 135-kDa species, as recently reported
. Although LMW-CDCP1 presented marginal levels in both N2 and ML2 streptavidin
pull down fractions (Fig. 35A), we could not identify this species by our targeted
glycoproteomic approach, mostly like because its levels were beyond MS detection
threshold. Interestingly, LMW-CDCP1 displayed a lower level (1.7-fold) in ML2 lysate
than N2 lysate. Therefore, the ratio of HMW-CDCP1 to LMW-CDCP1 seemed to be
correlated with metastatic ability of prostate cancer cells. There was a slight difference in
the apparent molecular weight of this protein between N2 and ML2 cells, possibly
reflecting different glycosylation status of CDCP1 in metastatic cells.
Since increased levels of CDCP1 were observed in some aggressive epithelial tumor
cells

, we set out to investigate the expression of CDCP1 in a panel of prostate cell

lines. As shown in Figure 36, CDCP1 protein was detected in all 13 prostate cell lines
examined but with various expression levels: 10 clearly expressed both forms of CDCP1:
PC3 and its two sublines, LNCaP and its three sublines, RWPEl's two sublines, and
DU145 prostate cancer cells; 3 expressed only HMW-CDCP1: immortalized RWPE-1,

151

J*

¥ $' /

& *

B

&

/

150

f

*

t

150 _,>

.HMWCDCP1

IHMW.CDCPI
100

100 _1

75

1

•»•=•-_•

- ,i,

£ » 4LMWCDCP1

4LMW-CPCP1
• U S A v submit

.•1' w .

42 - i

•^p-actin

Figure 35 Verification of CDCP1 expression in N2 and ML2 cells. (A) N2 and ML2
cells were metabolic labeled with AC4ManNAz, and conjugated with biotin-alkyne
via click chemistry. Then total cell lysates were extracted and subjected to
streptavidin pull-down assays as described previously. The eluted fractions were
analyzed by Western blot with CDCP1 antibody (pAb4115). Cells treated with
natural ManNAc were used as controls by following the same experimental
procedures. (B) Western blot analysis of total cell lysates of RWPE1, PC3, N2, and
ML2 with CDCP1 antibody. P-actin was included as a loading control.
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Figure 36. Verification of CDCP1 expression in prostate cell lines. Whole cell
lysates were prepared from different prostate cell lines and their sublines. Western
blot analysis was performed with primary antibody specific to CDCP1 (pAb4115).
P-actin was included as a loading control. PC3 & Sublines: PC3 (androgenindependent), developed from a skeletal metastasis; N2 and ML2, selected from PC3
cell line; N2 is non-metastatic while ML2 is metastatic. LNCaP & Sublines: LNCaP
(androgen-dependent), isolated from the lymphnode of a confirmed metastatic PCa
patient; C4, C4-2 and C4-2B, developed from LNCaP; C4-2, androgen-independent
and tumorigenic; C4-2B, androgen-refractory and bone metastatic. RWPE-1 &
Sublines: RWPE-1, HPV-18 immortalized prostate epithelial cell line response to
growth factors and androgen; WPE-NB-14, tumorigenic and moderately invasive;
WPE-NB-26, tumorigenic and highly invasive. DU145 (androgen-independent),
isolated from a brain lesion of a metastatic PCa patient. PacMetUTl, isolated from a
lymph node of PCa patient.
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PacMetUTl, and 22Rvl prostate cells. Among these cells, the highest CDCP1
expression was found in androgen-independent prostate cancer cell lines of the PC3
lineage followed by DU145 cells. Lower CDCP1 expression was found in androgen
dependent LNCaP cells, its androgen refractory C4-2 and C4-2B sublines, as well as
RWPE1 subline cells. In LNCaP and RWPE1 prostate cancer progression models, the
correlation of ratio of HMW-CDCP1 to LMW-CDCP1 with invasive activity appeared
not strong in panels of tumor cell line from same origins but with more aggressive
phenotypes.

5.3.4 Characterization of CDCP1 Glycosylation
CDCP1 was identified in our cell surface sialoglycoprotein enriched fractions. The
apparent molecular mass of CDCP1 in SDS-PAGE (135 kDa, Fig. 35A) exceeded that
predicted by primary sequence analysis (90 kDa). Moreover, there are 14 potential Nlinked glycoprotein sites in the extracellular part of human CDCP1 (Fig. 35B). All of
these observations highlight the possibility of CDCP1 glycosylation. However to date,
no study about the carbohydrate structure of CDCP1 has been reported.
To address CDCP1 glycosylation, we first employed three glycosidases with
different specificities to enzymatically digest CDCP1 in vitro. Whole cell extracts were
treated with N-glycosidase F (PNGase F) that cuts off entire N-linked glycans,
neuraminidase which hydrolyzes terminal sialic acid units, or Endoglycosidase H (Endo
H) that preferentially cleaves high mannose-containing and hybrid oligosaccharides (Fig.
37A). Then proteins were separated by SDS-PAGE, and subjected to Western blot
analysis. As shown in Figure 37B, PNGase F treatment resulted in the disappearance
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Figure 37 Characterization of CDCP1 glycosylation in vitro. (A) Schematic
representation of cleavage sites for the three highly specific glycosidases, PNGase F,
Endo H, and neuraminidase, respectively on a complex type of N-linked
oligosaccharide. (B-D) Western blot analysis of untreated and PNGase F (B)
neuraminidase (C), and Endo H (D) hydrolyzed lysates from PC3, N2, and ML2
cells. The blots were probed with specific CDCP1 antibody (pAb4115). P-actin was
included as a loading control.

155
of 135 kDa and 70 kDa bands and generation of lower molecular weight bands of
approximately 90 kDa and 60 kDa, respectively, the former corresponding to the mass of
deglycosylated HMW-CDCP1 form. After digestion with neuraminidase, the size of the
HMW band decreased slightly, whereas the changes of LMW band were not detectable
(Fig. 37C). These results indicated higher sialic acid content in N-glycans of the HMWCDCP1 than the LMW species, which was consistent with the previous cell surface
glycoproteomic data. In that experiment, we could only detect the marginal levels of
LMW-CDCP1 expression compared to the significantly high levels of HMW-CDCPlin
the cell surface sialoglycoprotein enriched fractions (Fig. 35A). Deglycosylation with
Endo H led to a mass shift of 25 kDa for HMW-CDCP1 (Fig. 37D), less than what would
be expected for the full cleavage of N-glycans (45 kDa). This result demonstrated that
high-mannose or hybrid oligosaccharide chains only contributed to a portion of the Nglycans present on HMW-CDCP1. In contrast, Endo H treatment of LMW-CDCP1
produced several broad bands closer to or even lower than that after N-glycan removal
(Fig. 37D), suggesting the presence of different glycoforms of LMW-CDCP1 containing
a higher extent of mannose or hybrid glycosylation, and implying occurrence of Oglycans on this CDCP1 species.
To further study the glycosylation status of CDCP1 in vivo, we treated cells with a
N-linked glycosylation inhibitor tunicamycin (TM) or a mannosidase inhibitor II
swainsonine (SW) under conditions optimal for drug activity but minimal for
cytotoxicity. Whole cell extracts were then obtained and examined by Western blot
analysis. Addition of TM, a nucleoside antibiotic which prevents the formation of the
dolichol intermediate necessary for oligosaccharide addition of the nascent polypeptide
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chain caused a significant decrease in cellular HMV-CDCP1, which was similar to the
results produced with the PNGase F treatment (Fig. 38A). Surprisingly, TM did not
affect the migration of LMW-CDCP1 in gel. Addition of SW, which blocks converting
N-glycans from hybrid-type to complex-type during mannose processing in Golgi,
slightly decreased the masses of HMW-CDCP1, but had no effect on LMW-CDCP 1
levels (Fig. 38B). This result reflected the addition of complex glycosylation to HMWCDCP1 but not LMW-CDCP 1, consistent with results from the Endo H treatment.
Like sialylation, fucosylation is another form of glycosylation commonly present on
cell surface glycoproteins. Altered fucosylation has been also associated with cancer
progression and metastasis

. To determine whether CDCP1 is a carrier of cell surface

fucosylation, we applied our targeted glycoproteomic strategy for cell surface fucosylated
glycoproteins. N2 and ML2 cells were metabolically labeled with alkyne fucose and
probed with biotin-azide via click chemistry. Then, total cell lysates were subjected to a
streptavidin pull-down assay and the eluted fractions were analyzed by Western blot with
CDCP1 antibody. As shown in Figure 39, the same levels of HMW-CDCP1 were
detected in N2 and ML2 treated fractions (fucalkyne), but absent in control groups (fuc),
indicating fucosylation of HMW-CDCP1 to the same degree in N2 and ML2 cells.
Conversely, there was no detectable fucosylation on LMW-CDCP 1.
Taking together, the above data suggested that although both CDCP1 species
contained heavy N-linked glycans and were modified by fucose, the type and extent of
carbohydrate moieties attached were different; the carbohydrate present on the HMWCDCP1 harbored three types of N-glycosylation and was terminated by a significant
amount of sialic acid residues. In contrast, high-mannose/hybrid-type N-glycans and
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Figure 38 Characterization of CDCP1 glycosylation in vivo. (A-B) PC3, N2, and
ML2 cells were treated with or without tunicamycin (5 |ag/ml, A) or swainsonine (1
l-ig/ml, B) for 23 h. The total cell lysate was extracted and analyzed by Western blot
with CDCP1 antibody (pAb4115). P-actin was included as a loading control.
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Figure 39 Fucosylation of CDCP1 in N2 and ML2 cells. N2 and ML2 cells were
metabolic labeled with alkynl fucose (fuc_alkyne) and probed with biotin-azide
via click chemistry. Then total cell lysates were extracted and subjected to
streptavidin pull down assays. The eluted fractions were analyzed by Western blot
with CDCP1 antibody. Cells treated with natural fucose (fuc) were used as
controls by following the same experimental procedures.
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probably O-glycans were primarily present on LMW-CDCP1.

5.3.5 Cellular Expression of CDCP1 in N2 and ML2 Cells
CDCP1 expression in N2 and ML2 cells was further substantiated by analysis of
CDCP1 protein expression on the cell surface by flow cytometry (Fig. 40A) with a
mouse monoclonal antibody (mAb 41-2) generated in subtractive immunization 280. Both
living N2 and ML2 cells showed high levels of cell surface CDCP1, but ML2 cells (Mean
fluoresence intensity, MFI, 377) seemed to have more CDCP1 on the cell surface than N2
cells (MFI, 290). Immunofluorescence staining of permeabilized N2 and ML2 cells,
using the same antibody, showed a clear plasma membrane localization of CDCP1 (Fig.
40B). Surprisingly, some intracellular juxtanuclear staining was also found in both N2
and ML2 cells. No positive immunostaining of N2 and ML2 cells was observed in the
absence of the primary antibody indicating the specificity of the antibody for human
CDCP1. A similar finding was observed staining using another antibody CS4115 (data
not shown).
Since the glycosylation processing and transport pathway of a cell surface
glycoprotein usually go via the ER and Golgi apparatus, we further examined the
subcellular location of CDCP1 in N2 and ML2 cells by co-localization studies. First, we
wanted to confirm the plasma membrane localization of CDCP1. As expected,
simultaneously applying glycan chemical labeling and immunoflurecence staining with
CDCP1 antibody revealed complete cell surface co-localization (Fig. 41, yellow
coloring), consistent with the initial technique used to identify CDCP1. We next
investigated which particular intracellular compartments CDCP1 was located, using

Figure 40 Cellular expression of CDCP1 in N2 and ML2 cells. (A) Flow cytometry
analysis of CDCP1 expression in N2 and ML2 cells. N2 and ML2 cells dissociated
from the flasks were incubated with CDCP1 antibody mAb 41-2 (closed histograms)
or blocking buffer (open histograms) and then with goat anti-mouse IgG conjugated
with Alexa 488. PI staining was used to gate living cells. Data was acquired by
FACScalibur and analyzed by Flowjo software. (B) Immunofluorescence analysis of
CDCP1 expression in N2 and ML2 cells. N2 and ML2 cells growing on coverslips
were fixed with 4% paraformaldehyde and permeabilized with ice-cold 100%
methanol. They were incubated with CDCP1 antibody mAb 41-2 (top panel) or
blocking buffer (bottom panel), stained with goat anti-mouse IgG conjugated with
Alexa Fluor 488 (green). The nuclei were stained with TO-PR03 (blue). Fluorescent
images were captured by Zeiss confocal microscopy.

Figure 41 Analysis of CDCP1 subcellular location by colocalization. N2 cells
were treated with AC4ManNAz for 2 days, fixed with 4% paraformaldehyde,
and conjugated with biotin-alkyne via click reaction. Cells were then
permeabilized with 0.5% Triton X-100, and stained with streptavidin-Alexa
Fluor 488 (green) and anti-CDCPl antibody (pAb 4115), Alexa Fluor 594conjugated secondary reagents (red). The nuclei were stained with TO-PR03
(blue). Fluorescent images were captured by Zeiss confocal microscopy.
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double immunostaining of CDCP1 and an ER-resident marker calnexin or a Golgi
complex marker 58 kDa protein in N2 cells. As shown in Figures 42 and 43, cells
expressing endogenous CDCP1 displayed a perinuclear and associated reticular staining
typical of the ER (Fig. 42) along with a juxtanuclear pattern typical of the Golgi
apparatus (Fig. 43). Merging images with CDCP1 signal resulted in considerable
punctuate overlapping patterns, indicating CDCP1 was localized and processed in ER and
Golgi complex. Taking together, immunofluorescent and co-localization data indicated
that CDCP1 went along with the secretory pathway and mainly localized on the plasma
membrane in prostate cancer cells.

5.3.6 CDCP1 Expression in Prostate Cancer Tissues
The expression pattern of CDCP1 protein in four frozen sections of human prostate
cancer tissues was examined by immunofluorescence with the use of mAb 41-2 (Fig. 44).
CDCP1 was present on normal prostate epithelial cells as well as on malignant cells.
However, the staining intensity and subcellular staining pattern were significantly
different between malignant and adjacent normal epithelial cells. In contrast to a
previous report

that found the staining of malignant glands was generally less

prevalent and less intensive than benign glands, we observed that human prostate
epithelial cancer cells had overall higher reactivity than the matched normal ones (Fig.
44A, b-c), although CDCP1 expression levels varied among tumor cells in the same case.
Malignant epithelial cells expressing CDCP1 protein usually belonged to a single acinus
or to a few adjacent acini (Fig. 44A, h-i). Staining was predominantly localized on the
plasma membrane in cancerous epithelial cells as shown by the confocal images (Fig.

Figure 42 Analysis of CDCP1 ER subcellular location by Immunolocalization.
N2 cells growing on coverslips were fixed with 4% paraformaldehyde, and
permeabilized with ice-cold 100% methanol, and stained with anti-CDCPl
antibody (pAb 4115), Alexa Fluor 488-conjugated secondary reagents (green),
and anti-calnexin antibody, Alexa Fluor 594-conjugated secondary reagents
(red). The nuclei were stained with TO-PR03 (blue). Fluorescent images were
captured by Zeiss confocal microscopy. Arrow indicated the punctuate
colocalization patterns of CDCP1 and calnexin.
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Figure 43 Analysis of CDCP1 Golgi subcellular location by Immunolocalization.
N2 cells growing on coverslips were fixed and permeabilized with 0.5% Triton
X-100, and stained with anti-CDCPl antibody (pAb 4115), Alexa Fluor 488conjugated secondary reagents (green) and anti-Goldi 58 kD protein antibody,
Alexa Fluor 594-conjugated secondary reagents (red). The nuclei were stained
with TO-PR03 (blue). Fluorescent images were captured by Zeiss confocal
microscopy. Arrow indicated the punctuate colocalization patterns of CDCP1 and
Golgi58 kD protein.
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44C, d-f). The basal surface contained more concentrated CDCP1 than the apical and
lateral membranes. In contrast, in adjacent normal cells the majority of the CDCP1
targeted was in a discrete juxtanuclear compartment, close to basal side. The staining on
the plasma membrane appeared to a much lesser degree than in cancer cells (Fig. 44C, ac). The proportion and intensity of cancerous cells expressing CDCP1 protein in a given
tissue section were heterogeneous, but it seemed to increase with the high Gleason score
(Fig. 44D). Other cell types including blood cells, endothelium, vascular smooth muscle,
neuroendocrine cells, and prostatic stoma fibroblasts, were negative. Control sections
that were incubated with the secondary, but not the primary antibody, were free of
staining (Fig. 44B). In summary, the expression of CDCP1 proteins in prostate cancer
tissues was altered as it presented extensively on the plasma membrane of malignant
epithelial cells with elevated level of expression.

5.3.7 Shedding of CDCP1 Ectodomain from Conditioned Media and EPS Samples
A number of integral cell surface proteins, such as c-met and CD44 are also
produced as soluble molecules 303 ' 304 . Western blot analysis, probing with an antibody
generated against the CDCP1 extracellular domain (AF2666), was employed to examine
whether PCa cells produce a soluble form of CDCP1. The concentrated serum-free
conditioned media (SFCM) from DU145 cells was used as a positive control because a 65
kDa CDCP1 ectodomain was recently reported in DU145 SFCM 302 . As shown in
Figure 45A, the antibody detected several immunoreactive bands (55 kDa, 42 kDa, 33
kDa, and 28 kDa) in EPS urine, possibly the ectodomain shedding of CDCP 1. After
normalization of total protein loading, as shown in Figure 45B, band at 55 kDa was
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Figure 44A-B Expression of CDCP1 in prostate patient tissues. (A)
Immunofiuorescent analysis of CDCP1 expression in matched normal (N) and
cancerous (T) prostate tissues from a PCa patient (Gleason score = 3+4). Successive
sections (6 um) were stained with H&E (a, d, g) or anti-CDCPl antibody (mAb412) and Alexa Fluor 488-conjugated secondary reagents (green, b-c, e-f, h-i). Nuclei
were stained with PI (red, b, e, h). d-f and g-i showed high magnification (x400) of
the normal glands (N) and tumor glands (T) marked in the top panels (white box),
respectively. Images were captured by Olympus fluorescent microscopy.
Magnification for top panel xlOO, for middle and low panels x400. (B) Negative
control for CDCP1 staining. Slides stained in the absence of primary CDCP1
antibody were used as negative controls
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Figure 44C Expression of CDCP1 in prostate patient tissues. (C) Immunofluorescent
analysis of CDCP1 subcellular location in matched normal and cancerous prostate
tissues from a PCa patient (Gleason score = 3+4). PCa sections were stained with
anti-CDCPl antibody (mAb41-2, green) and/or PI (red) and representative images
for normal glands (a-c) and tumor glands (d-e) were demonstrated, b-c and e-f
showed high magnification of the normal glands and tumor glands marked in the left
panels (white box), respectively. Images were captured by Zeiss cofocal microscopy.
Magnification xlOO (a, d), x880 (b, c), x!040 (e, f).
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Figure 44D Expression of CDCP1 in prostate patient tissues. (D) Three more PCa
tissues were analyzed for CDCP1 expression. Top panels, tissue specimens were
stained with H&E and examined by the pathologist. Bottom panels,
immunofluorescent staining of CDCP1 in the circled tumor areas of H&E sections.
Middle panels, immunofluorescent staining of CDCP1 in matched normal areas.
Red fluorescence showed PI staining for nuclei. Representative PCa Gleason scores
are indicated.

Figure 45 Shedding of CDCP1 ectodomain into the extracellular compartment. (A)
Detection of CDCP1 ectodomain in the conditioned media and expressed prostatic
secretion (EPS) samples. Western blot analysis of conditioned media from DU145
cell lines and EPS samples from non-cancer, non-aggressive PCa, and aggressive PCa
were performed with a goat antibody generated against the extracellular domain of
CDCP1 (AF2666). The detected low molecular weight signals (55 kDa, 42 kDa, 33
kDa, and 28 kDa) in EPS urine may indicate the ectodomain shedding forms of
CDCP1. (B) Sypro Ruby stained gel of samples shown in the left panel indicating the
total protein loading.
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present at a higher level in the aggressive PCa EPS urine pool than in the non-aggressive
PCa and non-cancer pools.

5.4 Discussion
PCa is the most common occurring malignancies in men and advanced metastatic
PCa is currently incurable. Identifying the mediators that drive metastasis may offer
insights into how to monitor or prevent PCa progression. By utilizing a novel cell surface
glycoproteomic approach and a PCa metastatic cell model derived from PC3 cells, we
uniquely identified CDCP1 protein in the metastatic ML2 cells, indicating a potential role
of CDCP1 in PCa progression. The function of CDCP1 in cancer progression is also
highlighted in other independent studies to identify CDCP1 by employing several
different biased genetic and protein based approaches. Using cDNA chip hybridization
techniques to search for genes preferentially expressed in solid tumors relative to normal
tissues, Scherl-Mostageer et al. identified CDCP1 as a novel human tumor-associated
gene in 2001, which is highly transcribed in lung and colon cancer derived cell lines
Two years later, Hooper et al. first isolated the complete CDCP1 protein sequence using
subtractive immunization intended to generate antibodies towards cell surface epitopes
preferentially expressed by highly metastatic relative to non-metastatic carcinomas 280. In
2005, aiming at searching for cell-cycle phase-specific mediators of activated Src family
kinases (SFKs), Bhatt et al. identified CDCP1 as a mitotic substrate of SFKs in human
MDA-MB-468 breast cancer cells. They also showed that overexpression of CDCP1 led
to cell loss of adhesion phenotype

. Subsequently, Uekita et al. also identified CDCP1

•

as a SFK interacting protein in human A459 lung adenocarcinoma cells

9Q9

. In these
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cells, phosphorylated CDCP1 was required to overcome anoikis and permit in vitro
anchorage-independent growth. In addition, CDCP1 was identified as a molecule
associated with important signaling proteins such as protein kinase C8 (PKC8) 305 .
Supporting the role of CDCP1 in cancer progression, upregulated CDCP1 expression has
9&fi

been observed in breast

, colon

987 9R&

'

9RQ

, kidney

900

, pancreatic

9Q1

, and lung cancer

patients and a number of epithelial cancer cell lines 280 ' 282 ' 292 ' 293 ' 306 .
Further characterization of CDCP1 in this study showed that there are two forms of
CDCP1 protein in most PCa cell lines, the 135 kDa full-length and a shorter 70 kDa
species. Similar sized CDCP1 species have been observed in many other human
epithelial cell lines such as breast cancer MDA-453 and MDA-468 cells, pancreatic
cancer BxpC3 cells, esophageal cancer TE7 cells, and several lung and colon cancer cell
'i Of.

lines

. As reported, the LMW-CDCP1 can be expressed endogenously or induced
9 H1

through the action of exogenous serine proteases such as trypsin

"X 0 9

'

9 R1

, plasmin

and

989 "^09

matriptase

'

. Currently the endogenous mechanisms and functional relevance of this

cleavage is not clear. Here our data showed that the ratio of HMW-CDCP1 to LMWCDCP1 is highly relevant to the metastatic potential of PCa cells. Supporting this
proposal, we observed a trend that membranous expression of CDCP1 was more intense
in high-grade aggressive PCa tissues than low-grade PCa (Fig. 44D). Other data coming
from in vitro experiments and animal models also strengthened the involvement of
HMW-CDCP1 in cancer progression. In another congenical metastatic epidermoid
carcinoma cell model, the expression levels of 135 kDa CDCP1 were much higher in the
highly metastatic variant of Hep3 over non-metastatic variants 280. Also overexpression
of CDCP1 in HeLa cells conferred these relatively non-aggressive cells with higher
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efficiency in experimental metastasis in mice 307. Moreover, Uekita et al. demonstrated
that reduction of 135 kDa CDCP1 by siRNA significantly inhibited the metastasis of
A549 lung adenocarcinoma cells in vivo, but had no effect on primary tumor growth in
9Q9

mice

. Recently, this group showed that HMW-CDCP1 promoted migration, invasion,

and anchorage independence of highly invasive gastric cancer cell lines in vitro as well as
enhanced the peritoneal dissemination in mice of these cells

. Taking advantage of the

function-blocking mAb 41-2 which mainly targets HMW-CDCP1, and chick embryo
metastasis model, Quigley's group elegantly showed that CDCP1 functions as an antiapoptotic molecule and facilitates tumor cell survival at the late stages of the metastatic
cascade, likely during or soon after extravasation307. Unlike HMW-CDCP1, there is
little accumulative data for the function of LMW-CDCP1 in cancer progression. In our
cell model system, we found that the expression levels of LMW-CDCP1 are negatively
associated with the malignant abilities of PCa cells. Some studies showed that LMWCDCP1 was tyrosine phosphorylated under several cellular events including proteolysis
302

and cell adhesion

94

. The phosphorylation promoted the formation of the

CDCP1 :Src:PKC8 multiprotein complex 302, suggesting a role of LMW-CDCP1 in
signaling transduction. However, the contribution of such phosphorylation for disease
progression, especially for cancer metastasis, remains undefined. Therefore, further
exploration of the essential roles of two CDCP1 forms in cancer progression should be of
high priority.
For other lineage-related PCa cell pairs, the trend seemed not as pronounced, as only
low levels of HMW-CDCP1 were detected in the invasive cell lines. This can be
explained because the different cell models reflect the distinct properties of PCa
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progression, for example, the LNCaP derivative sublines mainly mimic the progression
of PCa hormone independent, whereas RWPE-land its sublines represent the early stages
of tumorigenesis and invasiveness. Thus it is not surprising to see the weak trend in these
models. Additional congenically matched pairs of high and low metastatic tumor cell
lines as well as accurate in vivo animal models will have to be examined to establish
whether a clear link exists between two species of CDCP1 expression and the extent of
malignant progression.
The existence of 14 consensus N-glycosylation sites in the extracellular domain and
5 tyrosine residues in the intracellular COOH terminus of CDCP1 suggests functional
involvement of CDCP1 in outside-in signal transduction. Compared to extensive studies
of CDCP1 phosphorylation, the glycosylation status and its roles are not yet understood.
The work reported here for the first time characterizes the glycosylation of CDCP1.
Deglycosylation of CDCP1 with PNGase F and Endoglycosidase H showed that both
CDCP1 forms contain N-glycans of high-mannose or hybrid types. Despite these
common glycosylation features, the CDCP1 forms differ in extent and type of certain
glycosylation modifications. We previously identified HMW-CDCP1 by virtue of it
being predominant in the cell surface sialoglycoprotein enriched fraction of metastatic
ML2 cells, indicating sialylation of CDCP1. Neuraminidase treatment confirmed the
presence of sialic acid. Therefore, these two independent experiments both indicated that
HMW-CDCP1 carries more sialic acid in its N-glycans than LMW-CDCP1. In another
one of our recent projects aimed at the identification of cell surface fucosylated
glycoproteins, HMW-CDCP1 rather than LMW-CDCP1 was also identified in cell
surface fucosylated glycoprotein enriched fractions of N2 and ML2 cells, suggesting the
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existence of core-fucosylated N-glycans on HMW-CDCP1. More interestingly, we
observed that the extent of sialylation of HMW-CDCP1 also correlated with the
metastatic potentials of PCa cells consistent with the increasing evidence that
hypersialylation is one of the most common changes of N-glycosylation during malignant
transformation and progression 98 '' 10 . Our data raises the possibility that glycosylation
signatures, especially sialylation, affect roles of two CDCP1 species in cancer
progression. It is well known that glycosylation is critical in determining a protein's
stability, conformation, folding, and binding affinity for other molecules 85. In addition,
glycans per se are adhesion molecules directly involved in cell recognition

. The

negative charge and the terminal position of sialic acid can determine the ability of a
protein to interact with other molecules and even cells. As reported, CDCP1 interacted
with a number of adhesion and matrix proteins including cadherins and syndecans
Actually, CDCP1 overexpression stabilizes a detached cellular phenotype and has a poor
ability to spread plastic, which was ascribed to the intracellular constitutive
9SO 0Q4.

phosphorylation by SFKs

'

. Therefore, it is attractive to think that the glycosylation

of CDCP1 is the extracellular signal. Together with intracellular phosphorylation, it may
modulate cell adhesion as well as epithelial tumor attributes such as anchorageindependent growth, anoikis resistance, and metastasis. Current detailed N-glycan
profiling of two CDCP1 forms as well as elucidation of the possible roles of sialylation of
CDCP1 in relation to cancer progression are being pursued in our laboratory.
Another interesting finding from this study is the dysregulated expression of
CDCP1 in primary PCa tissues. By using sensitive immunofluorecent staining instead of
routine immunohistochemistry, we observed significant alterations in expression levels
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and subcelluar locations of this protein in PCa tissues compared to adjacent normal
tissues. Moreover, although only a small number of patient samples were examined, it
appeared that the expression pattern of CDCP1 was more obvious in high-grade
aggressive PCa. Our result is opposite of a previous report in which Siva et al. found
lower CDCP1 mRNA and protein expression in cancerous PCa cells than normal ones 295.
Since CDCP1 is a protein that is processed by multiple post-translational modifications
including glycosylation, phosphorylation, and proteolysis, mRNA levels can not
accurately reflect the amount of functional protein. The difference in protein staining
levels may mainly result from the usage of two distinct antibodies. Here we used a
murine monoclonal antibody mAb 41-2, which was generated by subtractive
immunization 280 and demonstrated functional blocking of experimental and spontaneous
metastasis of Hela-CDCPl and PC3-hi/diss cells in mice and chicken embryo model
systems

. In contrast, Siva et al. made the mouse-anti-CDCPl antibody 25 A11 by

whole cell panning and subtraction with red blood cells

. This antibody decreased PC3

cells migration and invasion in vitro and exhibited inhibitory effects on primary tumor
growth and metastasis of PC3 cells in a mouse xenograft model, when coupled to the
cytotoxin saporin, either directly or via a secondary antibody 295. The mechanistic
differences between these two antibodies are unclear and await further exploration.
Other variations such as prostate tissues, and staining technology (immunofluorescence
vs immunohistochemistry) could also contribute to the difference. However, consistent
with our results, dysreglulated CDCP1 expression has been also observed in a number of
TOO

cancers and is reported to have important clinical utility

. In 2008, Awakura et al.

analyzed CDCP1 expression by immunohistochemistry in 230 renal cell carcinomas and
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showed that 33.5% patients had high levels of CDCP1 expression which inversely
correlated with the disease-specific and recurrent-free survival

. In another study,

Ikeda et al. performed the similar examination in 200 lung adenocacinoma patient
samples and demonstrated that 30.0% cases were classified as expressing moderate to
high levels of CDCP1. High CDCP1 expression is associated with the occurrence of
lymph node metastasis, high relapse rate, and poor prognosis

. Recently Miyazawa et

al. evaluated 145 pancreatic cancer samples and indicated the elevated expression of
CDCP1 was significantly correlated with decreased overall survival of these patients 290.
Taken together, these clinicopathological studies and cell-based investigations strongly
supported that CDCP1 can be used as a cancer prognostic marker and could potentially
be targeted to disrupt epithelial cancer progression. Indeed the murine anti-CDCPl
antibodies, exhibiting function-blocking activity of metastasis as mentioned above, have
underscored the potential of CDCP1 as a therapeutic target as cancer treatment. More
recently, the human antibody specifically against CDCP, obtained from human single
chain Fv (scFv) phage displayed libraries by subtractive panning, was shown to
effectively inhibit in vivo metastasis and in vitro colony formation of human carcinoma
cells without toxin conjugation309. The properties of immuno-tolerance and efficiency of
anti-metastasis make the human anti-CDCPl antibody a promising candidate for further
therapeutic development. Although significant for several epithelial cancers, the clinical
relevance of CDCP 1 expression in PCa has not been reported as of now and a large-scale
analysis of CDCP 1 expression in PCa samples will warrant future investigation.
The detection of CDCP 1 fragments in PCa patient EPS urine samples is a significant
finding. Proximal fluids, including EPS urine, are found adjacent to a given tissue or
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organ and represent a repertoire of secreted proteins and shed cells reflective of the
physiological and pathological states of that tissue 30°. Thus, they are potential sources of
proteins and genetic biomarkers for cancer. In this study, EPS urine was collected in the
clinic by forced (or expressed) ejection of prostatic fluids into the urethra following
prostate massage. The presence in vivo of a 55 kDa CDCP1 ectodomain shed from cell
surface, and the relatively higher levels of CDCP1 fragment in aggressive PCa EPS
urines, indicates that CDCP1 has the potential as a diagnostic maker for prostate cancer.
Hooper et al. detected a membrane-shed moiety of CDCP1 of approximately 110 kDa in
the serum-free conditioned medium of human epidermoid carcinoma cell line, which
would be predicted to contain most of the extracellular domain

. They also described

strong immunohistochemical staining in the goblet cells of normal colon crypts, the
lumen of glands and in the glandular mucus of colon carcinoma, suggesting the
production of a soluble form of CDCP1. Bhatt et al. and He et al. reported that CDCP1
undergoes proteolytic digestion by the serine proteases after amino acids R368 or K369
and this cleavage is linked to intracellular signaling pathways

'

. The presence of

CDCP1 ectodomain in clinical samples prioritizes CDCP1 as a diagnostic marker worth
future validation.
In summary, most PCa cell lines expressed the 135 kDa full-length and a truncated
70 kDa species of CDCP 1 protein. Both CDCP1 forms contain heavy N-linked
oligosaccharides rich in high-mannose or hybrid-type chains and terminated by sialic acid
residues. However, the ratio of high to low molecular weight CDCP1, as well as the
glycosylation levels of 135 kDa CDCP1 correlated to the metastatic status of variant PC3
cell lines. Flow cytometry and immunocytochemistry data confirmed elevated levels of

178
CDCP1 in metastatic ML2 cells, and also demonstrated that this protein is processed by
ER/Golgi network and concentrated on the plasma membrane. Immunofluorescent
staining of human PCa tissues indicated that CDCP1 exhibited increased intensity and
extensive cell surface staining in malignant epithelial cells. In contrast, CDCP1 was
targeted to a discrete juxtanuclear compartment and the plasma membrane staining in
matched normal cells appeared much weaker. Shedding of CDCP1 ectodomain was
detected by Western blot at elevated levels in aggressive PCa patient EPS urine samples.
Our data indicate that expression of CDCP1 protein is dysregulated in PCa and it has the
potential utility as a therapeutic target and a diagnostic marker for PCa progression.

CHAPTER VI
CONCLUSIONS AND FUTURE DIRECTIONS
6.1 AIM I (Chapter III): Characterization of cell-surface lectin-binding patterns
associated with metastasis in human prostate cancer cells.
A. Our optimization of lectin staining protocols determined that the use of nonenzymatic dissociation buffer for cell suspension preparation provides the best balance of
dissociation efficiency, cell viability, and cell-surface carbohydrate retention.
Additionally, our results show that blocking buffer, staining buffer, cell confluence, and
the concentrations of lectin are potential sources of variation affecting successful lectin
flow cytometry analysis. Lectin staining of unfixed cells is superior to fixed cells for
cytohistochemistry analysis for representation of the true surface binding patterns.
B. Lectin flow cytometry and microscopy revealed that the cell-surface
glycoconjugates of PC3 and its variants contain a diversity of carbohydrate groups and
are extensively sialylated.
C. Total cell-surface carbohydrate profiling by lectin binding showed that the
metastatic potential of PC3 variants is inversely correlated with the level of cell-surface
a2-6 linked sialic acid.

6.2 Future Directions of Aim I
In Aim I, the predominant carbohydrate detected by lectin flow cytometry for PC3
and its variants was sialic acid while other residues showed relatively weaker signals,
initially suggesting that these carbohydrates were low contents on the PCa cells.
However, terminal sialic acid can mask other lectin binding sites and the extent of
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masking effect is various m . One aspect of future studies will use a neuraminidase for
enzymatic removal of sialic acid to reveal the real abundance of underlined sugars.
Besides sialylation, fucosylation, and N-acetylgalactosamine (GalNAc) studied in
this Aim, well-characterized lectins for other types of aberrant cancer-related
glycosylation are also available. For example, lectin L-PHA recognizes pi-6 branching
of N-linked oligosaccharides, a common feature of most cancers 86. Lectins AHA and
ECA react with two different linkages of T antigen, Gal beta l-3GalNac, and Gal beta 14GlcNac, respectively. The expression of these carbohydrates was reported to correlate
with metastatic sites of prostate cancer

. Therefore, the future employment of a wider

spectrum of and linkage-specific lectins will be useful to intensively characterize cellsurface glycosylation patterns associated with PCa metastasis.
Our data reported the use of flow cytometry as an effective technique for detecting
differences in cell-surface lectin binding in fresh cultured cells. To make more clinical
relevant conclusions, in the future we can extend it to spilled cells from fresh prostate
cancer tissues or fine-needle aspirates, and compare lectin binding patterns of primary
PCa tumor to metastases from other sites such as the lymph nodes.

6.3 AIM II (Chapter IV): Targeted identification of metastasis-associated cellsurface sialoglycoproteins in prostate cancer.
A. We have developed a robust MS-based glycoproteomic methodology for the
selective identification of specific subclasses of cell-surface glycoproteins. The approach
combined metabolic labeling of cell-surface sialyl glycans, chemical probing of the

labeled sugar with biotin-alkyne via click reaction, affinity purification of sialylated
proteins, SDS-PAGE separation, and subsequent LC-MS/MS for protein identification.
B. Azide-modified sialic acid metabolic precursor (ManNAc) was efficiently and
specifically incorporated into cell-surface sialylated glycans in PCa cancer cells, as
demonstrated by flow cytometry and confocal microscopic analysis. Click-activated
conjugation of the biotin tag following metabolic labeling allows visualization of cellsurface glycoproteins as well as, observation of intracellular localization of sialylated
glycoconjugates.
C. Our optimization of metabolic labeling and click reaction experiments
determined that ManNAz treatment with 20-40 uM for 1 day and click reaction with 25
ul of biotin-alkyne with 2.5 ul CuS04 can provide maximum cell viability/vigor.
D. Specific azide-modified sialoglycoprotein signals were detected by streptavidinIR 800 in post-click cell extracts treated with ManNAz, demonstrating the feasibility of
labeling individual glycoproteins by using this probing system. In addition, there
appeared to be a major protein band (under 150 kDa) that reacted with streptavidin and
greater sialylated glycoproteins in the ML2 cell line when compared to the N2 cell line.
E. The bound and eluted fractions from streptavidin beads produced strong distinct
glycoprotein patterns visualized by in-blot streptavidin-IR 800 detection and ID-PAGE
analysis, indicating efficient capture and enrichment of the azide-labeled proteins.
F. Application of the described targeted glycoproteomic approach to our syngeneic
PCa cell line model allowed for the identification of total 536 non-redundant proteins.
Using conservative criteria, 64 proteins (26%) from N2 and 72 proteins (29%) from ML2
were classified as extracellular or membrane-associated glycoproteins. A selective
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enrichment of sialoglycoproteins was observed at the affinity chromatography step.
When compared to global proteomic analysis of the same cells, the proportion of
identified glycoprotein and cell-surface proteins were on average 3-fold higher in the
AC4ManNAz labeled cells. Functional clustering of differentially expressed proteins by
Ingenuity Pathway Analysis demonstrated that the vast majority of the glycoproteins
over-expressed in the metastatic ML2 subline were involved in cell motility, migration,
and invasion.
G. A total of 80 cell-surface glycoproteins differentially expressed between cell lines
were uniquely identified and proposed as PCa biomarkers specific to metastatic
competence.

6.4 Future Directions of Aim II
In Aim II, our targeted glycoproteomic approach coupled glycan labeling with
traditional gel-based liquid chromatography tandem mass spectrometry (GeLC-MS/MS)
technology for glycoprotein identification. GeLC-MS/MS offers a number of benefits for
protein identification such as increasing the depth of analysis by spreading out the
complex protein mixture over 20-30 gel slices, removing low molecular weight
impurities which are often detrimental for MS sequencing, and providing observed mass
of proteins which is very useful to predict post-translational modifications
Alternatively, MS-based shotgun technology which directly analyzes complex protein
mixtures using multidimensional high-pressure liquid chromatography (LC/LC) in
conjunction with tandem mass spectrometry (MS/MS), has advantages in speed,
sensitivity, and automation312. In the future, we would combine glycan labeling

technology with shotgun proteomic platform for the analysis of the cell-surface
glycoproteome. Specifically, glycoproteins enriched by streptavidin beads as we have
described will be serially digested with Lys-C and trypsin, yielding a first peptide pool
representing all of the bound proteins. The peptide pool will be subjected to shotgun
proteomic analysis and the resulting proteins will be searched against the UniprotKB
human protein database for glycoprotein assignment. The remaining tagged N-linked
glycopeptides bound to streptavidin beads will be released via peptide-N-glycosidase F
(PNGase F), yielding a secondary glycopeptide pool. The glycopeptide pool will be
analyzed by LC-MS/MS and glycoprotein identification will be read directly from the
conversion of Asn residues to Asp. Such strategies will offer two extra advantages: an
increase in sequence coverage of the glycoproteins by crossing-referencing between the
two pools; and the determination of N-linked glycosylation sites. This would be of
particular interest in studies where changes of glycosylation occupancy are suspected to
link with the disease states.
One possible reason for the significant number of proteins annotated as nuclear or
cytoplasmic that was present among our cell-surface sialoglycoproteome is copper
cytotoxity during the click reaction. Fortunately, a new generation of copper-free click
chemistry can resolve this problem

. Improving cell viability could allow for

subcellular fractionation to increase membrane glycoprotein identification. With
collaboration with Dr. Binghe Wang at Georgia State University, the development of
copper-free click chemistry-based glycoproteomic methodology is currently underway.
The main accomplishment of Aim II was the identification of 80 cell-surface
glycoproteins differentially expressed between cell lines by our targeted glycoproteomic
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approach. Here "differentially expressed glycoproteins" refer to glycoproteins which
were uniquely identified in one cell line. Some glycoproteins identified in both cell lines
but possibly with differential levels were lost. To overcome such limitations, quantitative
proteomic techniques are necessary to be incorporated into our glycoproteomic approach.
In the past decade, several quantitative proteomics techniques have been widely
employed by the whole proteomics community, including stable isotopic or isobaric
labeling using chemical reactions (e.g. ICAT and iTRAQ) 313-3145 metabolic incorporation
(e.g. SILAC)

, and enzymatic reactions (e.g. O labeling)

, as well as less

quantitatively accurate label-free approaches 3I7 . These techniques are readily adapted
into our glycoproteomic analysis at different stages. For example, the SILAC technique
can incorporate stable isotope labeled amino acids into proteins during the cell culturing
process while the iTRAQ technique can introduce isobaric tags after tryptic digestion of
1 R

glycoproteins.

O can be incorporated into the N-glycopeptides during enzymatic

reactions, such as tryptic digestion (incorporation of two 18 0 into the peptide carboxyl
•

1 R

terminal) and PNGase F-mediated hydrolysis (incorporation of one O into the
asparagine of N-glycosylation sites). Therefore, future attempts will be made to
incorporate these quantitative techniques into our targeted glycoproteomics to facilitate
glycoprotein isolation, identification, and quantification in one experiment.
6.5 AIM III (Chapter V): Verification of expression of cell-based biomarkers in
clinical samples.
A. CUB-domain-containing protein 1 (CDCP1) was successfully identified from the
prominently sialylated band (under 150 kDa) observed in Aim II by GeLC-MS/MS.
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B. Western blot analysis of the cell-surface glycoprotein enriched fractions as well
as whole cell lysates confirmed the proteomic data, demonstrating the over-expression of
CDCP1 in metastatic PCa cell line (ML2). Additionally, the 135 kDa full-length and a
truncated 70 kDa species of CDCP1 protein were found to be expressed in most PCa cell
lines.
B. Analysis of deglycosylation cell lysates indicated that both CDCP1 species
contains heavy N-linked glycans and are modified by sialylation and fucosylation, where
the type and extent of carbohydrate moieties attached are different. The carbohydrate
present on the HMW-CDCP1 harbors three types of N-glycosylation, and is terminated
by a significant amount of sialic acid residues. In contrast, high-mannose/hybrid-type Nglycans and probably O-glycans are primarily present on LMW-CDCP1 and they are less
sialylated.
C. Western blot analysis of our syngeneic PCa cell line model suggested that the
ratio of high to low molecular weight CDCP1, as well as glycosylation levels of the 135
kDa CDCP1 is correlated to the metastatic competence of PC3 variants.
D. Flow cytometry and immunocytochemistry data confirmed elevated levels of
CDCP1 in metastatic ML2 cells, and also demonstrated that this protein is processed by
the ER/Golgi network and concentrated on the plasma membrane.
E. Immunofluorescence microscopy of human PCa tissues revealed dysregulated
expression of CDCP1 proteins in prostate cancer tissues. CDCP1 exhibits an increased
intensity of cell surface presentation in malignant gland cells whereas it is confined to a
discrete perinuclear compartment with only weak plasma membrane staining in matched
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normal cells. Importantly, CDCP1 expression levels appeared to increase with increasing
Gleason score.
F. Shedding of putative CDCP1 ectodomains was detected by Western blot at
elevated levels in aggressive PCa post-DRE urine samples.

6.6 Future Directions of Aim III
The prioritization and verification of candidate biomarkers provides an important
bridge between discovery and validation. Traditionally, proteins of interest are verified
using immunoassays, as we did in Aim III, which require high-quality antibodies that
already exist. For many or most novel candidates, such antibodies will not be available.
The cost and time associated with the generation and optimization of a specific antibody
is considerable and makes this option both prohibitively expensive and inefficient for
high numbers of proteins. For panels of protein candidates, verification by multiple
reaction monitoring MS (MRM-MS) using a triple quadrupole mass spectrometer
presents a compelling alternative. MRM on the triple quadrupole mass analyzer is the
gold standard for developing MS-based quantitative methods. In the MRM mode, an ion
of interest (the precursor) is preselected with the first mass filter Ql, and induced to
fragment in Q2 by collisional excitation with a neutral gas in a pressurized collision cell.
The resulting 'product ions' (that is, the fragmentation products of the selected precursor)
are mass analyzed using the third quadrupole Q3 152. MRM-MS has much higher
throughput, accuracy, and sensitivity and allows for substantial multiplexing.
Importantly, addition of isotopically labeled internal standards allow for absolute
quantification

5

. By rapid and continuous monitoring exclusively for the specific ions
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of interest, MRM-MS enhances the lower detection limit for peptides by up to 100-fold.
Moreover, a moderate number of candidate proteins (30-100) can be simultaneously
targeted and measured in a single experiment, particularly when using scheduled MRM,
which incorporates prior knowledge of peptide elution times into the LC-MS/MS
1

program

M

. MRM-MS has been applied to estimate the levels of give minor

glycoproteins in human serum 155, to measure the levels of biomarker candidates in a
mouse model of breast cancer

, and to study the N-linked glycosylation reaction in

congenitial disorders of glycosylation type-I serum

. Thus, MRM-MS is an extremely

powerful for biomarker discovery and candidate validation. With panels of cell-surface
sialoglycoprotein candidates on hand and triple quadrupole mass spectrometry available
at our lab, we will be devoted to develop MRM-MS assays for our future candidate
biomarker verification.
CDCP1 is type I cell-surface protein with extensive glycosylation. Compared to
extensive studies of CDCP1 phosphorylation, the glycosylation status and its roles are not
yet understood. The work reported in Aim III for the first time characterizes the
glycosylation of CDCP1 by several glycosidases and glycosylation inhibitors. To
uncover the underlying mechanisms of CDCP1 glycosylation in PCa progression and
metastasis and discover potential glycan-based biomarkers, a survey of CDCP1 glycome
is necessary. The complete analysis of CDCP1 glycosylation includes mapping its
glycosylation sites, determination of sequence and linkage of glycans, and site-specific
carbohydrate characterization. We have multiple mass spectrometers including MALDITOF/TOF, ESI-LC-MS/MS, and triple quadrupole MS at our lab with the capabilities of
performing multiple levels of glycan analysis. For example, the monosaccharide

composition of CDCP1 can be analyzed by MALDI after the glycan is released from
purified CDCP1. Glycosylation sites of CDCP1 can be mapped by PNGase F treatment
in conjunction with LC-MS/MS analysis. Determination of the glycan sequence of
CDCP1 and site-specific glycan analysis can be performed by tandem MS experiments
by the use of the triple quadrupole MS. Therefore, detailed glycan profiling of two
CDCP1 forms as well as elucidation of the possible roles of glycosylation of CDCP1 in
relation to cancer progression will be an interesting project and it will be pursued in our
laboratory.
In a small set of PCa tissues, we observed that the expression of CDCP1 in PCa is
dysregulated and elevated membranous expression of CDCP1 appears to correlate with
PCa aggressiveness. To further determine the clinical significance of CDCP1 expression,
a larger cohort of samples will be used to examine CDCP1 expression in PCa tissues
using immunohistochemistry (IHC). We have a large bank of formalin-fixed paraffinembedded (FFPE) PCa tissue blocks representing all stages and grades. The analysis of
these archived samples with complete pathology and clinical outcome will allow us to
establish a clearer link between CDCP1 expression and the extent of malignant
progression. Currently, optimization of IHC conditions for FFPE PCa tissues is being
pursued at our laboratory.
The detection of CDCP1 fragments in PCa EPS urine samples patients is significant
since the finding indicated that the ectodomain shedding of CDCP1 can reach the body
fluids and serve as early sentinel for cancer detection. Future studies will confirm the
Western blot results by immunoprecipitation of CDCP1 from EPS with antibody
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targeting to the N-terminal portion of CDCP1 and analysis of the purified CDCP1
fragments by mass spectrometry.

6.7 Concluding Remarks
Altered glycosylation has been associated with tumor development and disease
progression. Given the growing evidence that glycans of cell-surface glycoproteins are
involved in each and every aspect of tumor progression, glycoproteins are becoming
important targets for the development of biomarkers for cancer diagnosis, prognosis, and
therapeutic response to drugs. With the guidance of cancer-related changes in
glycosylation, the marriage of efficient glycoprotein enrichment and sophisticated MS
technologies offers great opportunities for biomarker research. The studies described
herein provide an example of glycobiology-driven biomarker discovery. By selectively
tagging cancer-related cell-surface glycans, we have been able to exclusively target the
pool of cell surface-expressed glycoproteins for subsequent in-depth MS analysis. The
successful identification of membrane glycoprotein CDCP1 whose expression is
dysregulated in PCa provides strong proof-of-principal evidence for our developed
glycoproteomic approach. There are numerous roles of CDCP1 that may play in cancer
metastasis including inhibiting apoptosis and aiding in extravasations. Additional,
CDCP1 may have soluble/shed isoforms which could provide additional critical
information concerning PCa progression. Much work remains to be done to translate the
identified biomarkers to validation assays and subsequently in high-throughput clinical
assays.
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